P P D 
P P D 
P P D 
P P D 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642788] 2 0 1 9 
2( 1 3 3) P R O T O C O L S Y N O P SI S 
A P h ase III, R a n d o mise d, D o u ble Bli n d, Pl ace b o C o ntr olle d, M ultice ntre 
St u d y of M ai nte n a nce Ol a p ari b M o n ot her a p y i n P atie nts wit h g B R C A 
M u t ate d Met ast atic P a ncre atic C a ncer w h ose Dise a se H as N ot Pr o gresse d 
o n First Li ne Pl ati n u m B ase d C he m ot her a p y 
I nter n ati o n al C o -o r di n ati n g I n vesti g at or:  M D 
 M D 
St u d y ce ntre(s) a n d n u m ber of p atie nts pl a n ne d: A p pr o xi matel y 8 0 ce ntres w orl d wi de will 
be i nit iate d t o ra n d o mise a p pr o xi matel y  1 4 5 p ati e nts wi t h  ger mli ne B R C A 1/ 2 m ut ati o ns a n d 
metastati c a de n ocarci n o ma of t he pa ncreas ( hereafter referre d t o as pa ncreas ca ncer).  
A d dit i o nal c o u ntri es a n d ce ntres m a y  be a d de d de pe n de nt o n recr uit me nt  rates. 
St u d y peri o d P h ase of de vel o p me nt 
Esti mate d date of first patie nt e nr olle d Q [ADDRESS_642789] patie nt c o m plete d Q 1 2 0 2 1 
 
 
 
O bjecti ves 
Pri m ar y O bjecti ve: O utc o me Me as ure: 
T o deter mi ne t he efficac y o f Ola pari b 
mai nte na nce m o n ot hera p y  c o m pare d t o 
pl ace b o b y  pr o gressi o n  f ree s ur vi val 
( P F S) Pr o gressi o n Free S ur vi val ( P F S) b y BI C R 
usi n g m o difie d R E CI S T 1. [ADDRESS_642790] 2 0 1 9 
3( 1 3 3) Sec o n d ar y O bjecti ve: O utc o me Me as ure: 
T o deter mi ne t he efficac y o f Ola pari b 
mai nte na nce m o n ot hera p y  c o m pare d t o 
pl ace b o O verall S ur vi val ( o bser ve d a n d pre dicte d 
usi n g o bser ve d P F S a n d O S data) 
Ti me fr o m ra n d o misat i o n t o sec o n d 
pr o gressi o n ( P F S 2) 
Ti me fr o m ra n d o misat i o n t o first s u bse q ue nt 
t h era p y  or deat h ( T F S T) 
Ti me fr o m ra n d o misat i o n t o sec o n d 
s u bse q ue nt t hera p y  or deat h ( T S S T). 
Ti me fr o m ra n d o misat i o n t o st u d y  treat m e nt 
di sc o nti n uat i o n or deat h ( T D T) 
O bject i ve Res p o nse Rate b y BI C R usi n g 
m o difie d R E CI S T 1. 1 cri t eri a f or e val ua ble 
patie nts 
Di sease C o ntr ol  Rate at 1 6 wee ks b y  BI C R 
usi n g m o difie d R E CI S T 1. 1 criteria 
T o assess t he effect of Ola pari b o n t he 
Heal t h -relate d Q ualit y of  Life 
( H R Q o L) as meas ure d b y E O R T C 
Q L Q -C 3 0 gl o bal Q o L scale. A d j uste d m ea n c ha n ge fr o m baseli ne i n 
gl o bal  Q o L sc ore fr o m  t he E O R T C -Q L Q -
C 3 0 q uesti o n naire 
S afet y O bjecti ve: O utc o me Me as ure: 
T o assess t he safet y a n d t ol era bilit y of 
Ol a pari b mai nte na nce m o n ot hera p y A d verse e ve nt ( A E), p h y sical e xa mi nat i o n, 
vit al  si g ns i ncl u di n g bl o o d press ure ( B P), 
p ul se, el ectr ocar di o gra m  ( E C G) a n d 
la b orat or y  f i n di n gs i ncl u di n g cli nical 
c he mistr y  a n d hae mat ol o g y 
E x pl or at or y O bjecti ve: O utc o me Me as ure: 
  
   
 C CI C CI 
Re vise d Cli nic al St u d y Pr ot o c ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642791] 2 0 1 9 
4( 1 3 3)  
 
 
 
 
 
 
 
 
  
 
 
 
 

 
 
 
 
  
 
 
 
   
 
 
  
   

 
 
 C CI C CI 
C CI C CI 
C CI C CI 
C CI C CI 
C CI C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642792] 2 0 1 9 
5( 1 3 3)  
 
 
 
 
 
 
 
 
 
  
T he e x pl orat or y  a nal yses m a y n ot be re p orte d i n t he cli nical st u d y  re p ort ( C S R).  If n ot, t he y  
will be re p orte d se paratel y .C CI 
C CI C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642793] 2019
6(133)Study Flow Chart 

Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642794] 2 0 1 9 
7( 1 3 3) T ar get P atie nt p o p ul ati o n 
All patie nts ra n d o mise d i n t he st u d y  will  b e selecte d base d o n t he f oll o wi n g 2 pri nci ples: 
Ge netic selecti o n :  D oc u m e nte d ger mli ne m utati o n i n B R C A 1 or B R C A 2 t h at is 
pre di cte d t o be del eteri o us or s us pecte d deleteri o us ( k n o w n or pre dicte d t o be 
detri me ntal /lea d t o l oss of f u nct i o n).  Pati e nts wi t h g B R C A 1a n d/ or g B R C A 2m ut at i o ns 
t h at are c o nsi dere d t o be n o n detri me ntal (e g, “ Varia nts of u ncertai n c li nical 
si g nifica nce” or “ Varia nt of u n k n o w n si g nifica nce” or “ Varia nt, fa v or p ol y m or p his m” 
or “ be ni g n p o l y m or p his m,” etc) will n ot be eli gi ble f or t he st u d y. 
Tre at me nt setti n g: All eli gi ble pat ie nt s m ust ha ve metastatic g B R C A m pa ncreas 
ca ncer, m ust ha ve recei ve d a mi ni m u m o f [ADDRESS_642795] ha ve n o e vi de nce of pr o gressi o n base d o n i n vesti gat or’s o pi [INVESTIGATOR_9384] o n. St u d y  treat me nt 
will be starte d after ra n d o misat i o n as s o o n as p ossi ble b ut n o less t ha n [ADDRESS_642796] u d y  treat m e nt, a n d as cl ose as 
p ossi ble t o ra n d o misat i o n. F oll o w -u p assess me nts s h o ul d be perf or me d e ver y  8 wee ks 
( ± 1 wee k) f or 4 0 wee ks a n d t he n e ver y  1 2 wee ks ± [ADDRESS_642797] i ve disease pr o gressi o n as defi ne d b y  m o difie d R E CI S T 1. 1. 
 
 
 
After c o nfir mat i o n o f eli gi bilit y, pati e nts will  be ra n d o mise d ( usi n g a n I V R S) i n a 3: 2 rati o 
( Ol a pari b: place b o) t o t he treat me nts as s pecifie d bel o w: 
Ol a pari b ta blets p o. 3 0 0 m g t wice dail y 
Pl ace b o ta bl ets t wi ce dail y 
I n vesti g ati o n al pr o d uct , d os a ge a n d m o de of a d mi nistr ati o n 
Ol a pari b is a vaila ble as a gree n fil m - c oate d ta blet c o ntai ni n g [ADDRESS_642798] u d y  treat m e nt orall y  at a d ose of 3 0 0 m g t wi ce dail y  ( bi d). T he 
pl a n ne d d ose of [ADDRESS_642799] 2 0 1 9 
8( 1 3 3) C o m p ar at or, d os a ge a n d m o de of a d mi nistr ati o n 
Pl ace b o will  b e a vaila ble as gree n fil m -c oate d ta blets m atc hi n g t he Ol a pari b ta blets. T hese 
s h o ul d be ta ke n as per i nstr ucti o ns f or Ola pa ri b ta blets. 
D ur ati o n of tre at me nt 
P ati e nts s h o ul d c o nt i n ue t o recei ve st u d y treat me nt u ntil o bject i ve ra di o l o gi cal disease 
pr o gressi o n per m o difie d R E CI S T 1. [ADDRESS_642800] atistic al met h o ds 
A p pr o xi matel y  1 4 5 p ati e nts will be ra n d o mise d ( 3: 2 rati o of Ola pari b: place b o) a n d t he 
pri mar y  P F S a nal ysis will occ ur o nce a p pr o xi matel y  8 7 P F S e ve nts (c o nfir me d via a ce nt r al  
re vie w, D C O 1) ha ve occ urre d.  A si n gle i nteri m P F S a nal ysis f or f ut ilit y will  b e perf or m e d 
w he n 5 0 % of t he fi nal n u m ber of pr o gressi o n e ve nt s nee de d f or t he pri m ar y P F S a n al ysis 
has bee n reac he d (a p pr o xi matel y 4 4 P F S e ve nts).  T he i nteri m a nal ysis wi ll be perf or m e d b y 
a n I n de pe n de nt Data Ma na ge me nt C o m mittee (I D M C) a n d f ull details will be pr o vi de d i n t he 
I D M C c harter.  
T he st u d y  i s size d ass u mi n g a tr ue treat me nt effect is a P F S Hazar d Rati o ( H R) of 0. 5 4, 
ass u mi n g 8 0 % p o wer a n d 2. 5 % al p ha ( 1 -si de d), wit h 3: 2 ra n d o misat i o n ( Ol a pari b: place b o). 
Ass u mi n g P F S is e x p o ne nt ia ll y distri b ute d, a P F S H R of 0. [ADDRESS_642801] patie nt e nter s t he trial. 
P ati e nts are t o be f o ll o we d f or t he fi nal a nal ysis of O S ( w he n a p pr o xi matel y  1 0 6 deat h e ve nts 
ha ve occ urre d, D C O 2).  Wit h [ADDRESS_642802] u d y  has 8 0 % p o wer t o s h o w a statist icall y 
si g nifica nt differe nce i n O S at t he 2. 5 % le vel ( 1 -si de d) if t h e ass u me d tr ue treat m e nt effect is a C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642803] 2 0 1 9 
9( 1 3 3) H R 0. 5 7; t hi s tra nslates t o a n a p pr o xi mate [ADDRESS_642804] ical a nal ysis of t he efficac y o f Ol a pari b will i ncl u de all ra n d o mise d patie nts 
( F ull A nal ysis Set; F A S) a n d will c o m p are t he treat me nt gr o u ps o n t he basis of ra n d o mise d 
treat m e nt, re gar dl ess o f t h e treat me nt act uall y recei ve d. I n a d dit i o n, ke y  se nsi ti vit y a nal yses of 
efficac y  e n d p oi nts will be perf or me d i n t he s u b gr o u p of pat ie nt s i n t he F A S t hat ha ve a 
gB R C A m ut ati o n c o nfir me d b y  t he M yria d test. W he n assessi n g safet y a n d t ol era bilit y, 
s u m mar ies will be pr o d uce d base d o n t he Safet y A nal ysis Set.  T his will i ncl u de all patie nts 
w h o recei ve at least o ne d ose of ra n d o mise d treat me nt ( Ola pari b or place b o).  T he safet y data 
will be s u m marise d descri pt i vel y a n d will n ot be f or mall y a nal yse d. 
P F S will be a nal yse d usi n g a l o g ra n k test .  T he H R t o get her wit h its 9 5 % c o nfi de nce 
i nt er val  ( CI) a n d p -val ue will be prese nte d (a H R less t ha n 1 will fa v o ur Ola pari b).  T he 
pri mar y  a nal ysis will be base d o n a bli n de d i n de pe n de nt ce ntral re vie w ( BI C R) of dis ease 
pr o gressi o n b y  m o difie d R E CI S T 1. 1; h o we ver, a se nsit i vit y a nal ysis will be perf or me d usi n g 
t h e i n vest i gat or -rec or de d assess me nt. 
S u b gr o u p a nal yses will be c o n d ucte d t o assess c o nsiste nc y of treat me nt effect acr oss p ote ntial 
pr o g n osti c f act ors (see Secti o n 8. 8. 2 f o r all pre defi ne d s u b gr o u ps). A n a nal ysis will n ot be 
perf or m e d if t here are t o o fe w e ve nts a vaila ble f or a mea ni n gf ul a nal ysis o f a parti c ular 
s u b gr o u p (ie, if t here are less t ha n 2 0 e ve nts i n a s u b gr o u p). 
O S a nal yses will be perf or me d at t he sa me ti me as t he pri m ar y a nal ysis o f P F S a n d will use 
t h e sa m e met h o d ol o g y  a n d m o d el  as P F S.  A fi nal  f or m al a nal ysis o f O S will  b e perf or m e d 
w he n a p pr o xi matel y  1 0 6 deat h e ve nts ha ve occ urre d ( D C O 2) a n d a m ult i plicit y a dj ust me nt 
will be ma de t o acc o u nt f or t he differe nt a nal yses.  
At  t he ti me of t he P F S a nal ysis ( D C O 1),  
 at t he fi nal a nal ysis will be deri ve d usi n g a wei g h te d s u m  of  t he 
o bser ve d O S data a n d t he pre dicte d O S val ue usi n g pri mar y P F S data a vaila ble at D C O 1. 
 
 C CI C CI 
C CI C C 
I
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642805] 2 0 1 9 
1 0( 1 3 3) P F S 2 a nal yses will be perf or me d at t he sa me t i me as t he pri mar y a nal ysis o f P F S, at t he ti me 
of  t he fi nal O S a nal ysis, P F S 2 will be a nal yse d usi n g t he sa me met h o d ol o g y a n d m o del as 
P F S. 
I n or der t o descri be t he nat ure of t he be nefits o f Ola pari b mai nte na nce treat me nt, P F S, P F S 2 
a n d O S will be teste d at a 1 -si d e d si g nifica nce l e vel  of  2. 5 %. H o we ver, i n or der t o str o n gl y 
c o ntr ol  t h e t y pe I err or, a m ult i ple testi n g pr oce d ure will als o be e m pl o ye d w here P F S is teste d 
fi rst usi n g t he f ull test mass a n d O S will be teste d if t he n ull h y p ot hesis f or P F S is rejecte d. 
Sec o n dar y  a nal yses of ti me t o treat me nt di sc o nt i n uati o n, ti me t o first s u bse q ue nt t hera p y or 
deat h, a n d ti me t o sec o n d s u bse q ue nt t hera p y  or deat h will be pr o vi de d, usi n g t he sa me 
met h o d ol o g y  as s pecifie d f or t he pri mar y a nal yses of P F S; h o we ver n o m ult i plicit y 
a dj ust m e nt will  b e a p plie d as t hese are vie we d as s u p p orti ve e n d p o i nt s. 
O bject i ve t u m o ur res p o nse rates a n d disease c o ntr ol rates ( base d o n ce ntral re vie w) will be 
s u m marise d f or t he t w o treat me nt ar ms.  I n a d dit i o n, t he i n vest i gat or re p orte d res p o nse rates 
will als o be s u m marise d. 
 
 
 
 
 
 
 
 
 
 
 
 
 C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642806] 2 0 1 9 
1 1( 1 3 3)  
 
 
 
 C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642807] 2019
12(133)TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................ [ADDRESS_642808] OF ABBREVIATION S AND DEFINITION OF TERMS .......................................... 19
1. INTRODUCTION ............................................................................................ 24
1.1 Background and rationale for conducting this study .......................................... 24
1.1.1 Pancreas cancer and its treatment ...................................................................... 24
1.1.2 Chem otherapy  use in advanced pancreas cancer ................................................ 25
1.1.3 PARP inhibit ion as a target for BRCA mutation posi tive cancer ........................ 26
1.1.4 Pre-clinical experience ...................................................................................... 26
1.1.5 Toxicology  and safet y pharm acology summary ................................................. 26
1.1.6 Clinical experience wit h Olaparib ..................................................................... 27
[IP_ADDRESS] Olaparib mo notherapy  studi es in pancreas cancer patients ................................. 27
1.2 Research hypothesis .......................................................................................... 27
1.3 Rationale for study  design, doses and control group .......................................... 28
1.3.1 Rationale for using Myriad Genet ics................................................................. 29
1.4 Benefit/risk and ethical assessment ................................................................... 29
1.4.1 Important potenti al risks ................................................................................... 30
[IP_ADDRESS] Myel odysplast ic syndro me/acute myelo id leukaemia ........................................ 30
[IP_ADDRESS] Pneumo nitis...................................................................................................... 31
[IP_ADDRESS] New Pr imary Malignancies ............................................................................... [ADDRESS_642809] 2 0 1 9 
1 3( 1 3 3) 3. 7. [ADDRESS_642810] u d y ................................ ...................................... 4 7 
3. 8 Restricti o ns ................................ ................................ ....................................... 4 8 
3. 8. 1 C o ntrace pti o n ................................ ................................ ................................... 4 8 
3. 8. 2 Ol a pari b a n d C Y P 3 A 4/ [ADDRESS_642811] u d y ................................ ............................................. 5 1 
4. S T U D Y P L A N A N D TI MI N G O F P R O C E D U R E S ......................................... 5 1 
4. 1 E nr ol me nt/scree ni n g peri o d ................................ .............................................. [ADDRESS_642812] u d y  treat m e nt (f ol l o w- u p visit) ................ [ADDRESS_642813] fi nal a nal ysis ............................................................. 6 4 
5. S T U D Y A S S E S S M E N T S ................................ ................................................. 6 5 
5. 1 Efficac y assess me nts ................................ ......................................................... 6 5 
5. 1. 1 C T a n d M RI sca ns T u m o ur assess me nts ( M o difie d R E CI S T 1. 1) ...................... [ADDRESS_642814] 2 0 1 9 
1 4( 1 3 3) 5. [ADDRESS_642815] i o n of a d verse e ve nts ..................................................... 8 1 
6. 3. 1. 1 A d verse e ve nts after t he 3 0 da y  f ol l o w u p peri o d .............................................. 8 2 
6. 3. 2 F o ll o w- u p of  u nres o l ve d a d verse e ve nts ............................................................ 8 2 
6. 3. 3 V ari a bles ................................ ................................ .......................................... 8 2 
6. 3. 4 Ca usalit y c o llecti o n ................................ ........................................................... 8 4 
6. 3. 5 A d verse e ve nts base d o n si g ns a n d s y m pt o ms ................................................... 8 4 
6. 3. 6 A d verse e ve nts base d o n e xa mi nat i o ns a n d tests ............................................... 8 4 
6. 3. 7 H y’s La w ................................ ................................ .......................................... [ADDRESS_642816] 2019
15(133)[IP_ADDRESS] Management of neutropenia, leukopenia and thrombocytopenia ........................ 91
Management of prolonged haematological toxicit ies while on study  treatm ent.................... 91
6.7.2 Management of non -haematol ogical  toxicity Olaparib ...................................... 92
[IP_ADDRESS] Management of new or worsening pulmo nary symptom s.................................. 92
[IP_ADDRESS] Management of nausea and vo miting................................................................ 92
[IP_ADDRESS] Interrupti ons for intercurrent non -toxicity related events ................................... [ADDRESS_642817](s) ................................................................. 94
7.2 Dose and treatment regimens ............................................................................ 95
7.3 Labelling .......................................................................................................... 95
7.4 Storage ............................................................................................................. 96
7.5 Com pliance ....................................................................................................... 96
7.6 Accountabilit y.................................................................................................. 96
7.7 Concomitant and other treatments ..................................................................... 97
7.7.1 Medicat ions that may NOT be administered ...................................................... 97
7.7.2 CYP3A4/5 restrictions ...................................................................................... 97
7.7.3 Other concomitant treatment ............................................................................. 98
7.7.4 Anti-emet ics/ Anti- diarrhoeals .......................................................................... 98
7.7.5 Anticoagulant Therapy ...................................................................................... 98
7.7.6 Administrati on of  other ant i-cancer agents ........................................................ 98
7.7.7 Subsequent therapi[INVESTIGATOR_72911] ........................................................................ 99
8. STATISTICAL ANALYSIS AND SAMPLE SIZE DET ERMINATION BY 
[CONTACT_487477] ........................................................................................................ 99
8.1 Statistical considerat ions................................................................................... 99
8.2 Definit ions of analysis sets ................................................................................ 99
8.2.1 Full analysis set ................................................................................................ 99
8.2.2 Safety analysis set ........................................................................................... 100
8.2.3 PRO analysis set ............................................................................................. 100
8.3 Calculation or derivat ion of efficacy variable(s) .............................................. 101
8.3.1 Primary endpo int (PFS) .................................................................................. 101
8.3.2 Secondary  endpoints ....................................................................................... 102
[IP_ADDRESS] Overall Survival .............................................................................................. 102
[IP_ADDRESS] Best overall RECIST response (BoR) ............................................................. 102
[IP_ADDRESS] Time fro m randomisat ion to second progression (PFS2) ................................. 103
[IP_ADDRESS] Time to first subsequent therapy  or death (TFST) ........................................... 103
[IP_ADDRESS] Time to second subsequent therapy  or death (TSST) ....................................... 103
[IP_ADDRESS] Time to study  treatm ent discont inuat ion or death (TDT) ................................. 104
[IP_ADDRESS] Disease Control  Rate (DCR) ........................................................................... [ADDRESS_642818] 2 0 1 9 
1 6( 1 3 3) 8. 4 Calc ulati o n or deri vat i o n of safet y varia ble(s) ................................................. 1 0 4 
8. 4. 1 Ot her si g nifica nt a d verse e ve nts ( O A E) .......................................................... [ADDRESS_642819] ical a nal yses ................................ ....................................... 1 0 9 
8. 8. 1 M ul ti plici t y  str at e g y  f or pri m ar y a n d ke y  sec o n dar y  e n d p oi nts ........................ 1 1 1 
8. 8. 2 A nal ysis of t he pri mar y  varia ble (s) ................................ ................................ 1 1 2 
8. 8. 3 Se nsit i vit y a nal ysis f or t he pri mar y  e n d p oi nt ................................................... 1 1 4 
8. 8. 3. 1 E val uat i o n- Ti me bias ................................ ...................................................... 1 1 4 
8. 8. 3. 2 At tri ti o n bias ................................ ................................ ................................... 1 1 5 
8. 8. 3. 3 Ascertai n me nt bias ................................ .......................................................... 1 1 5 
8. 8. 3. 4 De viat i o n bias (if mea ni n gf ul t o d o) ................................ ................................ 1 1 5 
8. 8. 4 A nal ysis of t he sec o n dar y v ari a ble(s) .............................................................. [ADDRESS_642820] o verall R E CI S T Res p o nse ( B o R) a n d O R R ......................... [ADDRESS_642821] 2 0 1 9 
1 7( 1 3 3) [ADDRESS_642822] u d y  Sc he d ule –Scree ni n g, O n St u d y  Tr e at m e nt, Di sc o nti n uati o n a n d 
F o ll o w- u p ................................ ................................ ................................ [ADDRESS_642823] 2 0 1 9 
1 8( 1 3 3) LI S T O F A P P E N DI C E S 
A p pe n di x A Si g nat ures 
A p pe n di x B A d dit i o nal Safet y I nf or mati o n  
A p pe n di x C I A T A 6. [ADDRESS_642824] i o ns Re q ui re d i n Cases of I ncreases i n Li ver Bi oc he mistr y  a n d  
E val uat i o n of H y’s La w 
A p pe n di x E Acce pta ble Birt h C o ntr ol Met h o ds 
A p pe n di x F G ui deli nes f or E val uati o n of O bject i ve T u m o ur Res p o nse Usi n g M o difie d  
R E CI S T 1. 1 ( Res p o nse E val uat i o n Cri t eri a i n S oli d T u m o urs) 
A p pe n di x H C Y P 3 A 4/ [ADDRESS_642825] 2019
19(133)LIST OF ABBREVIATION S AND DEFINITION OF TERMS
The fo llowing abbreviat ions and special terms are used in this study  Clinical Study  Protocol .
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642826] 2019
20(133)Abbreviation or 
special termExplanation
AE Adverse event (see definition in Section 6.1)
ALP Alkaline phophatase
ALT Alanine aminotransferase
AML Acute myeloid leukaemia
ANC Absolute neutrophil count
APTT Activated partial thromboblastin time
AST Aspartate aminotransferase
AUC Area under the plasma concentration -time curve
Baseline Refers to the most recent assessment of any variable prior to dosing with 
study treatment
BICR Blinded Independent Central Review
bid Bis in die (twice daily)
BoR Best Overall RECIST Respons e
BP Blood pressure
gBRCA germline Breast Cancer susceptibility gene
BRCA mutation or 
BRCAmBreast Cancer susceptibility gene mutation (see gBRCA mutation or 
gBRCAm )
BUN Blood urea nitrogen
CHO Chinese hamster ovary
CI Confidence Interval 
CR Complete Response
CRF Case Report Form (electronic/paper)
CRO Clinical Research Organisation
CSA Clinical Study Agreement
CSR Clinical Study Report
CT Computed Tomography
CTCAE Common Terminology Criteria for Adverse Event
DAE Discontinuation of Investigational Product due to Adverse Event
DCIS ductal carcinoma in situ
DCO Data Cut Off
DCO1 Data Cut Off for primary PFS analysis
DCO2 Data Cut Off for final formal OS analysis
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642827] 2 0 1 9 
2 1( 1 3 3) D C R Disease c o ntr ol r at e 
D N A De o x yri b o n ucleic aci d 
D S B D o u ble stra n d brea k 
E C G Electr ocar di o gra m 
E C Et hics C o m mittee, s y n o n y m o us t o I nstit uti o nal Re vie w B oar d (I R B) a n d 
I n de pe n de nt Et hics C o m mittee (I E C) 
E-c o de E nr ol me nt c o de (all ocate d b y I V R S/I W R S) 
 
e C R F Electr o nic Case Re p ort f or m 
E O R T C Q L Q -C [ADDRESS_642828] u g A d mi nistrati o n 
F F P E F or mali n Fi xe d Paraffi n E m be d de d 
F S H F ollicle sti m ulati n g h or m o ne 
g B R C A m utati o n or 
g B R C A m T he ter m " g B R C A m utati o n" is use d t o refer t o a ger mli ne B R C A 1 or 
B R C A 2 m utati o n classifie d as " deleteri o us" or "s us pecte d deleteri o us" i n 
acc or da nce wit h t he A merica n C olle ge of Me dical Ge netics a n d 
Ge n o mics rec o m me n dati o ns f or sta n dar ds f or i nter pretati o n a n d re p orti n g 
of se q ue nce varia nts 
g B R C A wt g B R C A wil dt y pe ( patie nts wit h o ut e vi de nce of B R C A 1 or B R C A 2 
deleteri o us or s us pecte d deleteri o us m utati o ns) 
G C P G o o d Cli nical Practice 
G- C S F Gra n ul oc yte c ol o n y -sti m ulati n g fact or 
G G T Ga m ma gl uta m yl tra nsferase 
G M P G o o d Ma n ufact uri n g Practice 
G Ra n d A Z Gl o bal Ra n d o misati o n s yste m 
H b Hae m o gl o bi n 
H D P E Hi g h- de nsit y p ol yet h yle ne C CI 
C CI C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642829] 2019
22(133)HIV Hum an Immunodeficiency Virus
HR Hazard Ratio
HRD Homologous recombination repair deficiencies
HRQoL Health-related Quality of Life
IATA International Air Transport Association 
IB Investigator’s brochure
ICH International Conference on Harmonisation
International 
Co-ordinating 
investigatorIf a study is conducted in several countries the Internationa l Co-
ordinating Investigator is the Investigator co -ordinating the investigators 
and/or activities internationally. 
IDMC   Independent Data Monitoring Committee
INR International Normalised Ratio
IPCW Inverse Probability of Censoring Weighting
IRB Institutional Review Board
IVRS Interactive Voice Response System
IWRS Interactive Web Response System
KM Kaplan Meier
LDH Lactic dehydrogenase
LH Luteinizing hormone
LIMS Laboratory Information Management System
m Metre
MCH Mean cell haemoglobin
MCHC Mean cell haemoglobin concentration
MCV Mean cell volume
MDS Myelodysplastic syndrome
mg Milli -gram
MRI Magnetic resonance imaging
nab nanoparticle albumen bound
NCI National Cancer Institute
NE Not evaluable
NTL Non-target lesions
OAE Other Significant Adverse Event (see definition in Section 8.4.1 )
ORR Objective response rates
OS Overall survival
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642830] 2 0 1 9 
2 3( 1 3 3) P D Pr o gressi ve disease 
P F S Pr o gressi o n Free S ur vi val 
p. o. Per os ( b y m o ut h, orall y) 
P R Partial res p o nse 
Q o L Q ualit y of Life 
R E CI S T Res p o nse E val uati o n Criteria I n S oli d T u m o urs.  T his st u d y will use 
m o difie d R E CI S T versi o n 1. [ADDRESS_642831] ural Fail ure Ti me 
S A E Seri o us a d verse e ve nt (see defi niti o n i n Secti o n 6. [ADDRESS_642832] u d y treat me nt Ola pari b or c o ntr ol ar m c he m ot hera p y 
 
 
 
 
T L Tar get lesi o ns 
U S Unite d States 
W B C W hite bl o o d cells 
W B D C We b Base d Data Ca pt ure 
wt Wil dt y pe ( patie nts wit h o ut e vi de nce of B R C A 1 or B R C A 2 deleter i o us or 
s us pecte d deleteri o us m utati o ns) C CI 
C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642833] 2019
24(133)1. INTRODUCTION
1.[ADDRESS_642834].  In 2013, it is estimated that there were 45,220 newly diagnosed pancreas cancer 
cases in the US, and approximately 38,460 people deat hs from pancreas cancer ( American 
Cancer Societ y 2013).  Worl dwide, i t was estimated that 266,000 people died of pancreas 
cancer in 2008 ( .
Fitzsimmons D et al 1999
Fitzsimm ons D, Johnson CD, George S, et al. Development of a disease specific qualit y of life 
(QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the 
QLQ -C30 in pat ients with pancreat ic cancer. Eur. J. Cancer 35: 939 -
941, 1999.
Fong et al 2009
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui -Roelvink M, et al. Inhibit ion of 
poly(ADP -ribose) polymerase in tumors from BRCA mutation carri ers. N Engl  J Med. 
2009;361(2):[ADDRESS_642835] cancer : ident ifying a subset of women 
at increased risk. Int J Radiat Onco l, Biol, Phys. 2001; 51 (3);679 -690.
Gaymes et al 2008
Gaymes TJ, Shall S, MacPherson LJ, Twine NA, Lea NC, Farzaneh F, and Muft i GJ. 
Inhibitors of poly ADP -ribose polymerase (PARP) induce apoptosis of myelo id leukemic 
cells: potential for therapy  of myel oid leukemia and myelodysplast ic syndro mes. 
Haematologica 2009; 94:638 -646. doi :10.3324/haematol.2008.[ZIP_CODE]
Ginsburg et al 2010
Ginsburg et al BRCA1 and BRCA2 families a nd the risk of skin cancer Springer 
Science+Business Media B.V. 2010
Goggins M. et al 1996
Germline M et al BRCA2 gene mutations in pat ients wi th apparently sporadic pancreat ic 
carcino mas. Cancer Res. 1996 Dec 1;56(23):5360 -4
Hay et al 2009
Hay T, Matthews JR, Pi[INVESTIGATOR_48816] L, Lau A, Cranston A, Ny gren AO, et al . Poly(ADP -ribose) 
polymerase -1 inhibitor treatm ent regresses autochthonous Brca2/p53 -mutant mammary 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642836] 2019
25(133)tumors in vivo and delays tumor relapse in combination with carboplat in. Cancer Res. 
2009;69(9):[ADDRESS_642837]. 
2003 Feb 5;95(3):214-21.
Helleday 2011
Helleday T. The underlying mechanism for the PARP and BRCA synthet ic lethalit y: Clearing 
up the misunderstandi ngs. Molecular Onco logy 2011; 5: 387 -393.
Jemal A et al 2011 ).
The poor prognosis of pancreas cancer (~90% of patients who are diagnosed will die of the 
disease) is a funct ion of late presentation of the disease when inoperable/ locally a dvanced or 
metastati c. Furtherm ore treatm ent of metastatic pancreas cancer even wit h the m ost “active” 
regimens such as FOLFIRINOX ( Conroy  et al  2011 ) or gemcitabine + nab paclitaxel ( Von 
Hoff et al  2013) is associated with median survivals of less than one y ear, and for single agent 
treatm ents at best only [ADDRESS_642838] active combinat ion 
chemotherapy regimens limits the duration of exposure to patients even if benefit ing from the 
treatm ent. The neurotoxi city of both FOLFIRINOX and gemcitabine + nab paclitaxel in the 
former case generally leads to discontinuation o f some or all  of the drugs at or before 6 
months of treatment and in the later case dose attenuat ion.  The FOLFIRINOX study  
recommended no more than a total of 6 months of chemotherapy for patients who had a 
response ( Conroy  et al  2011 ).Furtherm ore there are few if any established second line 
regimens available ( American Cancer Societ y 2013) and benefit if any, is at most a few 
months of survival ( Rahma et al  2013 ). Despi [INVESTIGATOR_499447] “act ive” regimens 
for first treatm ent of m etastati c pancreat ic cancer in the last decade, their limited absolute 
benefit and significant toxicit ystrongly  suggest that improving the results of init ial therapy of 
metastati c pancreas cancer const itutes an unmet medical need. Furthermore to date there has 
been no marker, clinical or molecular that would predict for increased likelihood of benefit 
from systemic th erapi[INVESTIGATOR_499448]. 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642839] 2019
26(133)Although carriers of deleterious germline mutations of the BRCA1 and particularly BRCA2 gene 
are known to have an increased risk of developi[INVESTIGATOR_499449] ( The Breast Cancer Linkage 
Consortium 1999 , Goggins M. et al 1996 ),the prevalence of  g BRCA m in the unselected cases of 
pancreas cancer is uncle ar but likely less than 5 % In a tissue based study, 7% of patients with 
resected pancreas cancer or human xenografts had “germline” mutations in their tumour 
(Goggins M. et al 1996) but this cohort may not represent the typi[INVESTIGATOR_499450].  There are specific populations, however, where the 
association is much stronger. In Ashkenazi Jewish patients with pancreas cancer, the prevalence 
of gBRCAm is 6-10%  in unselected patients ( Fayers et al 2001
Fayers et al. EORTC QLQ -C30 Scoring Manual (Third Edit ion). Bel gium : EORTC Qualit y of 
Life Group, 2001.
Ferrone CR et al 2009, Ozcelik et al 1997 ) and 15%  in patients with a family history of the 
disease ( Sadler ZK. 2012 ). In pancreas cancer patien ts with a family history of the disease, 
reported prevalence of carrying a germline BRCA2 mutation may be as high as 17-19% 
(Murphy KM et al 2002, Hahn et al 2003 ).Given the small size of the g BRCAm subpopulation in 
pancreas cancer, information comparing the natural history of this group with the overall 
pancreas cancer population i s minimal. One study of the natural history of Ashkenazi Jews with 
pancreas cancer treated with surgery (most of whom eventually died of the disease) could find no 
difference in survival between those who had germline BRCAm (n=8) vs. those who did not 
(n=137). The study however did not extend beyond 2004 and did not include patients treated 
with more modern chemotherapi[INVESTIGATOR_014] ( Fayers et al 2001
Fayers et al. EORTC QLQ -C30 Scoring Manual (Third Edit ion). Bel gium : EORTC Qualit y of 
Life Group, 2001.
Ferrone CR et al 2009 ). In a large study  of thenatural  history  of BRCAm associated pancreas 
cancer, the median all –stage overall survival (OS) for 58 patients was 14 months (95% CI 10 -
23 m onths). Medi an OS for pati ents wi th stage 1 -2 disease has not been reached at 60 months. 
Median OS for stage 3 -4 was 12 months (95% CI 6 -15). Superior OS was observed for 
patients wi th stage III and IV disease treated with plat inum versus those treated with non -
platinum chemotherapi[INVESTIGATOR_014] (22 vs 9 months; p=0.039 (Golan et al unpublished data). There are 
no approved treat ments for pati ents wi th germline BRCA1/[ADDRESS_642840] advanced pancreas ( Lowery  M et al  2011 )
.
Recent data suggest there may also be a number of pancreas cancer patients’ tumours with 
ATM defects or a gBRCA -like or HRD phenoty pe (Cowl ey et al  2013 ).The development of a 
test to ident ify such tum ours m ay broaden the patient population which could benefit from 
PARP inhibitors. Obtaining tumour tissue to look for the prevalence these other potential
markers of drug sensit ivity is another unmet need in advancing therapy of this serious illness.
1.1.[ADDRESS_642841] on PFS and OS. The 
“best” regimens for us e as init ial treatment of metastatic disease, FOLFIRINOX or 
Revised Clinical Study Pr otocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642842] 2019
27(133)gemcitabine + nab paclitaxel  have respectively PFS’s of 6.4 and 5.5 mos. and OS’s of 11.1 
and 8.5 m os. (Co nroy et al  2011 , Von Hoff et al 2013 ). Toxi city parti cularly  on the platinum
based regimen was substant ial (80% had hematol ogic toxici ty, 45% ≥grade 3; 70% had 
peripheral neurotoxi city, 9% ≥grade 3) and led to dose reductions and treatment 
discontinuat ions. It i s of note that m edian number of FOLFIRINOX cycles given was 10 (ie. 
~5 m onths of treatm ent) but the m edian PFS was 6.[ADDRESS_642843] igators should be familia r with the current Olaparib (AZD2281) Invest igator Brochure 
(IB).
Olaparib (AZD2281, KU- 0059436) i s a potent Pol yadenosine 5’diphosphoribose [poly  (ADP 
ribose)] polymerisat ion (PARP) inhibitor (PARP -1, -2 and -3) that is being developed as an 
oral therapy ,both as a monotherapy  (including maintenance) and for combinat ion with 
chemotherapy and other ant i-cancer agents.
PARP inhibit ion is a novel approach to targeting tumours with deficiencies in DNA repair 
mechanisms.  PARP enzymes are essent ial for repai ring DNA single strand breaks (SSBs).  
Inhibit ing PARPs leads to the persistence of SSBs, which are then converted to DNA double 
strand breaks (DSBs) during the process of DNA replicat ion.  During the process of cell 
divisio n, DSBs can be efficient ly repaired in normal cells by [CONTACT_499468] r.  Tum ours wi th homolo gous recombinat ion deficiencies (HRD), such as ovarian cancers 
in patients with g BRCA1/[ADDRESS_642844] ive tumours are intrinsically sensit ive to PARP inhibitors, both in 
tumour m odels in vivo Rottenberg et al 2008 , Hay  et al  2009 ) and in the c linic ( .
Fitzsimm ons D et al  1999 , Fong et al 2009, Fowble et al 2001). The m echanism o f action for 
Olaparib resul ts from the trappi[INVESTIGATOR_499451] -strand breaks prevent ing 
their repai r (Helleday 2011 , Murai  et al  2012 ).  Persistence of SSBs during DNA replication 
resul ts in thei r conversi on into the m ore seri ous DNA DSBs that would normally be repaired 
by [CONTACT_499469].  Olaparib has been shown to inhibit selected tumour cell lines in vitro 
and in xenograft and primary explant models as well as in genet ic BRCA knockout models, 
either as a stand- alone treatm ent or in co mbinat ion with established chemotherapi[INVESTIGATOR_014].
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642845] 2 0 1 9 
2 8( 1 3 3) 1. 1. [ADDRESS_642846] o ge nic i n t he C hi nese ha mster 
o var y  ( C H O) c hr o m os o m e a berrati o n test i n vitr o .  W he n d ose d orall y, Ola pari b als o i n d uce d 
micr o n uclei i n t he b o ne marr o w of rats.  T his pr ofile is c o nsiste nt wit h t he p ote ntial f or 
ge n ot o xi ci t y  i n ma n. 
Re pr o d ucti ve t o xic o l o g y  data i n dicate t hat Ola pari b ca n ha ve a d verse effects o n e m br y of o et al  
s ur vi val a n d de vel o p me nt at d ose le vels t hat d o n ot i n d uce si g nifica nt mater na l t o xi ci t y . 
F urt her i nf or mat i o n ca n be f o u n d i n t he c urre nt versi o n of t he Ola pari b I B. 
1. 1. [ADDRESS_642847] u dies i n p a ncre as c a ncer p atie nts 
 
 
All patie nts ha d see n a pri or ge mcita bi ne 
re gi me n a n d o ver half a pri or plat i n u m c o ntai ni n g re gi me n. T he O R R was 2 2 %, D C R 5 7 %, 
P F S 4. 6 m os. a n d O S 9. 8 m os ( Ka uf ma n B et al 2 0 1 3 ). T his l e vel of act i vit y c o m pares 
fa v o ura bl y  wi t h  t hat re p orte d f or ot her t hera pi[INVESTIGATOR_499452] p orte d i n a d va nce d pre vi o usl y  treate d 
pa ncreas ca ncer (Ra h ma et al 2 0 1 3 ). A retr os pecti ve a nal ysis o f t h e pati e nt data fr o m  
s u g geste d greatest be nefit fr o m Ola pari b i n t h ose ( 1 5) patie nts w h ose t u m o urs ha d n ot C CI 
C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642848] 2019
29(133)progressed on a prior platinum treatment (ORR 33%, DCR 66%, PFS 6.4 mos., OS 13.1 
mos.).
1.2 Research hypothesis
Single agent Olaparib tablet 300 mg bid has superior efficacy and acceptable tolerabilit y 
profile as co mpared with placebo in patients with deleterious or suspec ted del eterious 
germline mutation in BRCA1 and/or BRCA2 and metastatic pancreas cancer who have 
achieved disease control (absence of object ive progressio n) after receiving a minimum o f [ADDRESS_642849] line plat inum based chemotherapy .  The efficacy in this study  will be assessed 
by [CONTACT_499470] o f PFS defined as the time fro m randomisat ion unt il the date of 
objective radio logical disease progressi on according to m odified RECIST1.1 criteria, or death 
(by [CONTACT_347054]) regardless of whether the patient 
withdraws fro m rando mised therapy  or receives another anti -cancer therapy  prior to disease 
progression. To reduce bias, primary analysis of PFS will be based on blinded, independent 
central  review of RECIST scans. Secondary  endpoints include overall survival, DCR at 16 
weeks, ORR (in patients with baseline evaluable disease), PFS2, safet y assessments and 
patient-reported symptoms, funct ioning and healt h related quali ty of life.
1.3 Rationale for study design, doses and control group
Mutati ons in g BRCA1 and g BRCA2 are a very ra re but definable mo lecular subgroup of 
pancreas cancer which may be found in so me identifiable populat ions wit h a prevalence as 
high as 15%. Cells that lack g BRCA1/2 function, such as cancer cells fro m patients with 
germline mutations in these genes, are d eficient in their abilit y to repai r doubl e
-strand DNA 
breaks through ho molo gous recombination ( Roy et al 2012 ). This deficiency is presumed to 
underlie the observat ionthat gBRCA1/[ADDRESS_642850] and pancreas cancer, in addit ion to their 
established use in ovarian cancer. It is also presumed to underlie the observat ion that
gBRCA1/2 -deficient cells are sensit ive to treatment with inhibitors of poly -(ADP -ribose)-
polymerases (PARP inhibitors) ( Bryant et al 2005 ) which are presumed to force repair of 
single- strand breaks towards the ho molo gous repair pathway  rather than the p athways that 
usually address single -strand breaks.  Phase I and proof -of-concept phase II studies have 
shown that PARP inhibitors have significant activity  with limited toxi city when used as single 
agents in the treatment of g BRCA1/[ADDRESS_642851] and ovarian cancer ( Tutt A et 
al 2010 ; Audeh et al 2010) and pancreas c ancer ( Kaufman B et al 2013 ).The present trial is an 
important step in defining the role of Olaparib as a PARP inhibitor in patients with deleterious 
germline BRCA1/[ADDRESS_642852] 2 0 1 9 
3 0( 1 3 3) bee n s u g geste d f or gB R C A -m ut ate d o varia n ca ncer (Ki m et al 2 0 1 4 , Le der ma n n et al 2 0 1 3 ).  
T he st u d y  will  assess t he efficac y  of  Ol a pari b relati ve t o pl ace b o as m ai nte na nce t hera p y  af t er 
d oc u m e nt ati o n of  disease c o ntr ol (a bse nce of pr o gressi o n) o n a n i nit ial plat i n u m base d 
re gi me n f or metastatic g B R C A pa ncreas ca ncer. T he preli mi nar y a nal ysis o f  s u g gests 
select i n g patie nts wit h t u m o urs w hic h are n ot k n o w n t o be pl at i n u m resista nt w o ul d i ncrease 
t h e li keli h o o d of be nefit.  
 
 
  I n t he f ut ure it ma y be p ossi ble t o e xte n d 
t h e use of P A R Pi t o pati e nts wi t h  t u m o urs ha vi n g n o n -B R C A deficie ncies i n ds D N A 
re pai r. Ola pari b has s h o w n act i vit y i n A T M ne gat i ve gastric ca ncer ( Ba n g et al  2 0 1 3 ) a n d 
t h ere is s u g gest i o n of  a si milar s u b -p o p ul at i o n i n pa ncreas ca ncer ( Ki m et al 
2 0 1 4 ). F urt her m ore, i n de pe n de nt gr o u ps ha ve als o i de ntife d ge n o mic si g nat ures i n pa ncreas 
ca ncer pre dicte d t o be ass oci ate d wi t h  se nsi ti vit y t o P A R P i n hi bit ors ( Ale xa n dr o v et al 2 0 1 3 ; 
C o wle y  et al  2 0 1 3 ). I n or der t o f urt her u n dersta n d ca n di date met h o ds f or i de nt if yi n g t hese 
pati e nts i n f ut ure cli nical trials we are as ki n g all patie nts t o d o nate a t u m o ur sa m ple at 
scree ni n g. I n or der t o u n dersta n d t he pre vale nce a n d relat i o ns hi p of t hes e m ar kers t o B R C A 
stat us it i s i m p orta nt t hat we are a ble t o test sa m ples fr o m pat ie nt s wi t h  a n d wi t h o ut g B R C A 
m utati o ns. 
If t he tri al  i s s uccessf ul  i t will gi ve pati e nts a rel at i vel y n o n -t o xi c oral  t hera pe ut ic w hic h will 
d el a y pr o gressi o n after st o p pi n g f ir st li ne plat i n u m base d c he m ot hera p y. 
1. 3. [ADDRESS_642853] ure, w hic h s u p p orts hi g h v o l u me testi n g wit h t ur nar o u n d ti mes t hat ca n meet t he 
nee ds of a cli nical trial. 
1. 4 Be nefit/ris k a n d et hic al assess me nt 
As of [ADDRESS_642854] u dies. Ol a pari b has bee n gi ve n as eit her m o n ot hera p y  ( [ADDRESS_642855] 2 0 1 9 
3 1( 1 3 3) esti mate d 1 2 1 4 patie nts) or i n c o m bi nat i o n wi t h  ot her c he m ot hera p y /a ntica ncer a ge nts 
( [ADDRESS_642856] i mate d 8 8 9 patie nts). Ma n y o f t hese c o m bi nat i o ns st u dies are o n g oi n g. T he 
maj orit y of  p ati e nts t o da te ha ve recei ve d t he ca ps ule f or m ulat i o n of Ola pari b (a n esti mate d 
1 6 3 5 pati e nts). A p pr o xi matel y [ADDRESS_642857] u di es i n 
9 7 5 pati e nts w h o ha ve bee n gi ve n Ola pari b ca ps ule esti mate d t hat 1 6. 1 % ( 1 5 7/ 9 7 5) of patie nts 
ha d bee n e x p ose d t o Ola pari b ca ps ule f or ≥ [ADDRESS_642858] u di es.  F urt her m ore, 4 1/ 9 7 5 pati e nts recei ve d treat me nt f or > 2 4 m o nt hs (l o n gest d urati o n 
was 4 4 m o nt hs).  Fr o m  t he a vaila ble data t o date, t here is n o e vi de nce o f a n y u ne x pecte d 
t o xi ci t y  f oll o wi n g l o n g- t er m  Ola pari b (ca ps ule) m o n ot hera p y  e x p os ure. 
A d dit i o nall y  st ati st ical a nal ysis o f t h e p o ol e d Q T/ Q Tc data fr o m 2 st u dies i n a t otal of 
1 0 9 pati e nts f or t he pri mar y m ult i ple d ose a nal ysis a n d 1 1 9 pati e nts f or t he s u p p orti ve si n gle 
d ose a nal ysis s h o we d t hat f o ll o wi n g m ul ti ple d osi n g of ol a pari b ( 3 0 0 m g b d), t he u p per 
c o nfi de nce li mit of t he 2 -si de d 9 0 % c o nfi de nce i nter val ( CI) ar o u n d t he mea n treat me nt effect 
f o r Q T Fri dericia C orrecti o n F or m ula ( Q Tc F) was < 1 0 ms at all ti me p o i nt s. F urt her m ore, t he 
s u p p orti ve a nal ysis s h o we d t h at f oll o wi n g a si n gle d ose of ola pari b, of eit her 1 0 0 m g or 3 0 0 m g 
t h e u p per c o nfi de nce li mit of t he 2 -si de d 9 0 % CI ar o u n d t he mea n treat me nt effect f or Q Tc F 
was als o < [ADDRESS_642859] of ola pari b o n car diac 
re p ol arisat i o n (as deter mi ne d b y  pr ol o n gati o n of  Q Tc F) f o ll o wi n g m ul ti ple d osi n g 
( 3 0 0 m g b d) or f oll o wi n g si n gle d osi n g. 
As a f urt her s u p p orti n g a nal ysis, c o nce ntrati o n- effect m o delli n g o f t h e p o ol e d Q T/ Q Tc data 
fr o m t h e sa me patie nts was c o n d ucte d. Pre dict i o ns, fr o m t h e c o nce ntrati o n -effect relati o ns hi p 
o btai ne d of t he li kel y ma g nit u de of effect of ola pari b o n Δ Q Tc F, s h o we d t hat at t he ra n ge of 
pl as ma c o nce ntrati o ns ac hie ve d f oll o wi n g t he [ADDRESS_642860] c o m m o n  A Es i ncl u di n g na usea, fat i g ue, v o mit i n g, a nae mia mai nl y  mil d -t o -m o derate 
( C T C A E Gra de ≤ 2) i n se verit y.   I n a d di ti o n, i n a s mall n u m ber of pat ie nt s M D S/ A M L or 
p ne u m o nit is ha ve bee n o bser ve d a n d i de nt ifie d as i m p orta nt ri s ks. C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642861] 2 0 1 9 
3 2( 1 3 3) 1. 4. [ADDRESS_642862] o me/ ac ute m yel oi d le u k ae mi a 
T here ha ve bee n [ADDRESS_642863] o me ( M D S) a n d/ or ac ute m yel o i d 
le u kae mia ( A M L) i n patie nts treate d wit h Ola pari b as of [ADDRESS_642864] 2 0 1 3; [ADDRESS_642865] u dies wit h car b o plat i n a n d 
paclita xel ( n = 4) or ce dira ni b ( n = 1).  A t otal of 2 1 0 3 patie nts are esti mate d t o ha ve recei ve d 
Ol a pari b, gi vi n g a c u m ulat i ve i nci de nce of 0. 7 6 % f or M D S/ A M L, si milar t o t he c u m ulat i ve 
i nci de nce re p orte d fr o m c o ntr ol ar ms of Ola pari b ra n d o mise d st u dies 0. 7 % .  
All 1 6 pat ie nt s ha d pri mar y  o varia n or peri t o neal  ca ncer a n d 1 2 of t he m were g B R C A 1/ 2 
p osi ti ve ( 3 cases g B R C A stat us u n k n o w n; 1 case ne gati ve).  It has be e n h y p ot hesise d t hat a 
deficie nc y i n t he e x pressi o n o f B R C A ge nes ma y lea ve patie nts m ore v ul nera ble t o t he a d verse 
effects of c he m ot hera p y, a n d t heref ore, at a n i ncrease d ris k of M D S/ A M L as a res ult of ca ncer 
treat m e nt ( C o le a n d Strair 2 0 1 0 ).  M ost pati e nts ha d bee n treate d wit h e xte nsi ve pre vi o us 
c he m ot hera p y ra n gi n g fr o m [ADDRESS_642866] at i n u m a ge nts, t o p ois o merase I I i n hi bit ors, al k ylati n g a ge nts a n d ta xa nes.  T he me dia n ti me 
fr o m dia g n osis of ca ncer t o o nset of M D S was 5. 3 yrs (ra n ge 2. 9 -1 2. 7).  T he me dia n t i me 
fr o m start of Ola pari b treat me nt t o o nset of M D S was 0. 9 y ears ( 0. 1 t o 4. 8 y ears).  T he 
re p orte d e ve nts o f M D S/ A M L occ urre d p ost disc o nt i n uat i o n of Ola pari b treat me nt i n [ADDRESS_642867] treat me nt disc o nt i n uat i o n (ra n ge: 0. 1 t o 1 
years).  Half o f t h e pati e nts ( n = 8) ha d recei ve d Ola pari b f or ≤ 1 2 m o nt hs ( 5 patie nts ha d ≤ 6 
m o nt hs e x p os ure) a n d t he ot her 8 cases occ urre d f oll o wi n g l o n ger t ha n 1 2 m o nt h Ola pari b 
e x p os ure ( 3 patie nts f o ll o wi n g 1 2 -1 8 m o nt hs e x p os ure a n d 5 patie nts f oll o wi n g > 2 years 
e x p os ure t o Ola pari b). 
Si nce b o ne marr o w is k n o w n t o be a tar get or ga n f or O la p ari b t o xicit y, a ris k of M D S/ A M L 
wi t h  l o n g- t er m  e x p os ure t o Ola pari b ca n n ot be e xcl u de d, b ut t here is i ns ufficie nt data at 
prese nt t o e val uate t he stre n gt h, if a n y, of t his relati o ns hi p. M ore o ver, w hile n o n -cli nical data 
s u g gest b o ne marr o w pr o ge nit or c ell p o p ulati o ns are re d uce d te m p oraril y f o ll o wi n g Ola pari b 
treat m e nt, t here is n o e vi de nce t o date li n ki n g Ola pari b treat me nt t o t he ge nerati o n o f 
a b n or m al  b o ne marr o w prec urs ors.  F urt her m ore, all pat ie nt s w h o de vel o pe d M D S/ A M L ha d 
e xte nsi ve pri or c he m ot h era p y  a n d w hile it i s n ot p ossi ble t o e xcl u de t he c o ntri b ut i o n of 
Ol a pari b, i t i s als o c o nsi dere d t hat t here were ot her p ote ntial c o ntri b uti n g fact ors i n all cases.  
Precli nical data als o s u g gest p ote n ti al  b e nefi t wi t h  P A R P i n hi bit ors i n M D S/ A M L a n d cli nic al  
tri als are n o w u n der wa y  t o assess t hi s effect ( Ga y mes et al 2 0 0 8 ). 
T o e ns ure r o b ust safet y m o nit ori n g, pati e nts i n t his cli nical trial will ha ve wee kl y  s af et y  
asses s me nts d uri n g t he first c y cle a n d t he n safet y assess me nts e ver y  [ADDRESS_642868] 2 0 1 9 
3 3( 1 3 3) 1. 4. 1. [ADDRESS_642869] 2 0 1 3, 1 0 patie nts o ut of a t otal o f 2 1 0 3 pati e nts esti mate d t o ha ve recei ve d 
Ol a pari b ha ve re p orte d p ne u m o nit is, gi vi n g a c u m ulat i ve i nci de nce of 0. 5 % f or p ne u m o nit is.  
P ne u m o nit is was als o re p orte d f or  ( 0. 7 %) of   t hat recei ve d plac e b o or 
c o m parat or i n t he Ol a pari b tri al  pr o gra m me ( [ADDRESS_642870] ace b o i n  a n d 1 pati e nt o n 
paclita xel i n ).  T he pati e nts were treate d wit h Ola pari b f or breast ca ncer ( n = 2), 
o vari a n ca ncer ( n = 2), n o n -s mall  cell l u n g ca ncer ( n = 2), s mall ce ll l u n g ca ncer ( n = 1), pa ncreas 
ca ncer ( n = 1), gastric ca ncer ( n = 1) a n d t h y mic ca ncer ( n = 1).  Fi ve of t he [ADDRESS_642871] or y  of  t o bacc o s m o ki n g.  T he m aj ori t y  of  patie nts ha d recei ve d pri or ra di ot hera p y  a n d/ or 
c he m ot hera p y.  T he maj orit y of  pat ie nt s h a d rel e v a nt m e dical  hist ori es i ncl u di n g p ne u m o nit is, 
i nt erst itial l u n g fi br osis, d y s p n oea, hae m o pt ysis, c hest i nfect i o n, aller gic ast h ma, ple ural 
eff usi o n, a n d ple ural metastases.  
I n vest i gat i o n of a n y  ne w or w orse ni n g p ul m o nar y  s y m pt o ms has bee n i m ple me n te d as a 
safet y ma na ge me nt pla n (sect i o n 6. 7. 2 ). 
1. 4. 1. 3 Ne w Pri m ar y M ali g n a ncies 
O verall, t he n u m ber of re p orts of ne w pri mar y  m ali g na ncies is l o w, wi t h  2 1 e ve nts (i n 1 9 
pati e nts) bei n g re p orte d i n [ADDRESS_642872] 2 1 0 3 Ola pari b treate d patie nts ( 0. 9 %) a n d o ne e ve nt 
( bla d der ca ncer) re p orte d i n t he place b o ar m of t he d o u ble -bli n d .  I n ra n d o mise d 
c o ntr olle d st u dies, [ADDRESS_642873] b o treate d patie nt: 
I n t he d o u bl e bli n d mai nte na nce  t w o e ve nts of ne w pri mar y mali g na ncies ha ve bee n 
re p orte d i n Ola pari b treate d patie nts a n d o ne e ve nt i n a place b o treate d patie nt.  I n t he o pe n 
la bel g B R C A o vari a n m o n ot hera p y  d ose -fi n di n g , t hree e ve nts were re p orte d i n t w o 
Ol a pari b treate d patie nts. 
Of  t he [ADDRESS_642874] ca ncer ( n = 2), breast ca ncer i n sit u , gastri c ca ncer, l u n g 
ne o pl as m  ( pl us e ve nt of rec urre nce of t he l u n g carci n o ma), plas ma cell m yel o ma, c ol o n 
ca ncer, mali g na nt m uscle ne o plas m (lesi o n prese nt pre -Ola pari b treat me nt) a n d o ne fatal 
e ve nt of T -l y m p h o blast ic l y m p h o ma/le u kae mia. 
Of  t he [ADDRESS_642875] recei vi n g Ola pari b treat me nt ( 1 6 patie nts).  I n 3 patie nts t he 
e ve nt was re p orte d after Ola pari b disc o nt i n uat i o n 
T he d urati o n of Ola pari b treat me nt  f or t he 1 9 pati e nts was: C CI C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642876] 2 0 1 9 
3 4( 1 3 3)  < 6 m o nt hs f or 3 pati e nts 
 6 t o 1 2 m o nt hs f or 6 patie nts 
 1 2 t o 1 8 m o nt hs f or 2 patie nts 
 1 8 t o 2 4 m o nt hs f or 2 patie nts 
 > [ADDRESS_642877] ca ncer p o p ulat i o ns re p orte d i n t he literat ure ( Ber gfel dt et al 
1 9 9 5 ,.
Fi t zsi m m o n s D et al  1 9 9 9 , F o n g et al 2 0 0 9 , F o w ble et al 2 0 0 1 , Wes o l o ws ki  et al  2 0 0 7 ), or 
were ca ncers s uc h as s ki n ca ncer, k n o w n t o be t he m ost c o m m o n ca ncer i n t he ge neral 
p o p ul at i o n a n d ass ociate d wit h hi g h c ure rates .
O varia n ca ncer patie nts ha ve bee n re p orte d t o ha ve a n i ncrease d ris k o f de vel o pi n g sec o n d 
pri mar y  m ali g na ncies.  Patie nts wit h g B R C A m ut ati o ns are at ri s k of de vel o pi n g ot her pri mar y  
ca ncers n ota bl y breast ca ncer ( Gi ns b ur g et al 2 0 1 0 ) re p orte d hi g her rates of s ki n ca ncers i n 
pati e nts wi t h  g B R C A 1 ( 1. 6 %) a n d g B R C A 2 ( 3. 0 %) m utati o ns. 
T here were ot her c o ntri b uti n g fact ors/ p ote ntial alter nat i ve e x pla nat i o ns f o r t he de vel o p me nt of 
t h e ne w pri mar y  m ali g na nc y i n all [ADDRESS_642878] ories o f ca ncer ( o varia n, cer vi x, breast, perit o neal) a n d [ADDRESS_642879] u d y  treat m e nt) pri or t o t he ca ncer u n der i n vest i gat i o n i n t he Ola pari b 
st u di es. 
T here i s i ns ufficie nt e vi de nce f or a n ass ociat i o n bet wee n Ola pari b treat me nt a n d t he 
de vel o p me nt of ne w pri mar y  m ali g na ncies i n t he cli nical trial pr o gra m me t o date. 
1. 4. [ADDRESS_642880] i ve res p o nse rate ( O R R) of u p t o 4 1 %.  I n o varia n ca ncer patie nts, t he 
pi v otal   C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642881] 2 0 1 9 
3 5( 1 3 3)  T he pr o gressi o n -fr ee s ur vi val ( P F S) f oll o wi n g Ola pari b mai nte na nce t hera p y was 
si g nifica nt l y l o n ger c o m pare d wit h t he place b o gr o u p ( H R 0. 3 5; 9 5 % CI: 0. 2 5, 0. 4 9; 
p < 0. 0 0 0 0 1) i n t he o verall p o p ulat i o n.  I n t he s u b gr o u p of pat ie nt s wi t h  B R C A m ut a nt o vari a n 
ca ncer, t he effect was e ve n greater wit h a P F S H R of 0. 1 8 ( 9 5 % CI: 0. 1 1, 0. 3 1; p < 0. 0 0 0 0 1; 
me dia n 1 1. 2 vers us 4. 3 m o nt hs).  A n i nteri m a nal ysis of O S was perf or me d at 5 8 % mat urit y.   
I n t he o verall p o p ulat i o n, t he a nal ysis de m o nstrate d a n o n -statisticall y  si g nifica nt n u meri c al  
a d va nta ge f or Ola pa ri b-treate d pati e nts ( O S H R 0. 8 8; 9 5 % CI 0. 6 4 -1. 2 1; p = 0. 4 3 8 0 8) a n d 
t h ere was a gai n a greater effect i n t he g B R C A -m ut ate d s u b gr o u p:  t he O S H R was 0. 7 4 ( 9 5 % 
CI 0. 4 6 t o 1. 1 9; p = 0. 2 0 8 1 3) wit h a n u merical a d va nta ge i n me dia n o verall s ur vi val o bser ve d 
wi t h  Ola p ari b ( m e dia n [ADDRESS_642882] b o).  A m o n g t he [ADDRESS_642883] 
pr o gressi o n.  
 
 T here were 1 C R a n d 4 P R’s ( O R R 2 2 %) wit h a 
di sease c o ntr ol  rate of 5 7 %, a P F S of 4. [ADDRESS_642884] i gat i o nal ar m  recei ve m o n ot hera p y  
Ol a pari b 3 0 0 m g ta blet bi d ( or c o ntr ol place b o) u nt il disease pr o gressi o n or de vel o p me nt of 
u nacce pta ble t o xicit y. T here i s n o i nte nt t o ca p d urati o n o n Ola pari b f or t hese patie nts.  
Base d o n t he a vaila ble data o n efficac y a n d safet y,  we a ntici pate t hat i n t he metastatic disease 
setti n g, Ola pari b will ha ve a p osit i ve be nefit ris k pr ofile f or t he treat me nt of t he ver y s mall 
well -defi ne d p o p ul at i o n of a d va nce d pa ncreas ca ncer patie nts wit h g B R C A m ut ati o ns. 
1. [ADDRESS_642885] 2019
36(133)Figure [ADDRESS_642886] 2 0 1 9 
3 7( 1 3 3) T his is a p hase III, ra n d o mise d, d o u ble -bli n d, pl ace b o -c o ntr olle d, m ult i-ce ntre st u d y  t o assess 
t h e efficac y  of  Ol a pari b mai nte na nce m o n ot hera p y i n metastatic pa ncreat ic ca ncer patie nts 
wi t h  gB R C A m ut ati o ns [ d oc u m e nt e d m ut ati o n i n g B R C A 1 or g B R C A 2 t h at i s pre dicte d t o be 
d el et eri o us or s us pecte d deleteri o us ( k n o w n or pre dicte d t o be detri me ntal/lea d t o l oss of 
f u nct i o n) a n d w h ose t u m o urs ha ve n ot pr o gresse d o n at least [ADDRESS_642887] li ne plat i n u m 
base d c he m ot hera p y .
A p pr o xi matel y  1 4 5 p ati e nts will be ra n d o mise d usi n g a n I nteracti ve V oice Res p o nse S yste m / 
I nteracti ve We b Res p o nse S y st e m  (I V R/I W R s yste m) i n a 3: 2 rati o ( Ola pari b: place b o) t o t he 
treat m e nts as s p ecifie d bel o w: 
 Ol a pari b ta blets p. o. 3 0 0 m g t wice dail y 
 Matc hi n g place b o ta blets p. o. t wi ce dail y 
Eli gi ble pat ie nt s will be t h ose patie nts wit h pa ncreas ca ncer pre vi o usl y treate d f or metastatic 
di sease g B R C A m ut ate d, w h o ha ve n ot pr o gresse d f o ll o wi n g c o m p let i o n of at least 1 6 wee ks 
(ca n be m ore) of first li ne plat i n u m -base d c he m ot hera p y .  
All patie nts m ust ha ve a k n o w n deleteri o us or s us pecte d deleteri o us ger mli ne B R C A m utati o n 
t o be ra n d o mise d; t his ma y ha v e bee n deter mi ne d pri or t o e nr ol me nt i nt o t he st u d y  or m a y be 
assesse d as part of t he e nr o l me nt pr oce d ure f or t he st u d y ( via ce ntrall y pr o vi de d M yria d 
I nte grate d B R A C A n alysis test) 
P ati e nts m ust ha ve c o m plete d a mi ni m u m of [ADDRESS_642888] li ne plat i n u m -base d t hera p y  
(e g, o xali plat i n, car b o plat i n or cis plat i n) gi ve n c o nti n u o usl y bef ore ra n d o misat i o n t o t he st u d y  
a n d s h o ul d i n t he o pi [INVESTIGATOR_9384] o n of t he i n vest i gat or ha ve ha d at least disease c o ntr ol. T here m ust be 
a bse nce of pr o gressi o n b y  i ma gi n g d o ne wi t hi n [ADDRESS_642889] u g(s) i n t hei r re gi me n (f or 
e xa m ple F O L FI RI f or F O L FI RI N O X etc.) a n d f ulfil all ot her eli gi bilit y re q uire me nts 
(i ncl u di n g n o n -pr o gressi o n at t he ti me of e nr ol me nt).  
P ati e nts k n o w n t o ha ve ger mli ne B R C A m ut ati o n/s pri or t o ra n d o misat i o n ca n e nter t he st u d y  
base d o n t hi s res ul t pr o vi de d t he y  m eet all  ot her eli gi bilit y cri t eri a.  T he t y pe of B R C A 1/ [ADDRESS_642890] 2 0 1 9 
3 8( 1 3 3) P ati e nts wi t h  u n k n o w n B R C A stat us m ust c o nse nt t o gi ve 2 bl o o d sa m ples f or ger mli ne B R C A 
testi n g b y  M y ri a d (a n d all l o c al  et hical  pr oce d ures f or s uc h ge net ic testi n g).  O ne sa m ple will 
be use d t o test f o r B R C A m ut ati o ns usi n g t he c urre nt c o m mercial M yria d B R C A a nal ysis test 
pri or t o st u d y  e ntr y  ( M y ri a d I nte grate d B R A C A n alysis ).  T he sec o n d bl o o d sa m ple fr o m all 
teste d patie nts (i ncl u di n g t h ose w h o d o n ot ha ve a B R C A m ut ati o n) is re q ui r e d f or assess me nt 
of  c urre nt a n d f ut ure B R C A m ut ati o n assa ys.  W he n t he res ult fr o m t he M y ri a d test i n dicates 
t h e pati e nt d oes ha ve a deleteri o us or s us pecte d deleteri o us ger mli ne B R C A m ut ati o n a n d t he 
pati e nt meets all ot her eli gi bilit y cri teria, t he pati e nt ca n be ra n d o mi se d i nt o t he st u d y .T he 
pati e nts will  als o s u b mi t t he dia g n osti c pat h ol o g y  s peci me ns ( bl oc k or sli des) if a vaila ble . 
 
 
 
T he [ADDRESS_642891] as a c o m pa ni o n dia g n ostic f or Ola pari b i n 
t h e U S A.  I n a d dit i o n resi d ual material ma y  b e use d f or t he assess me nt of ot her c urre nt a n d 
f ut ure B R C A m ut ati o n dia g n osti c assa ys a n d/ or assa ys t hat pre dict se nsit i vit y t o Ol a pari b. 
P ati e nts will  b e ra n d o mise d wit hi n [ADDRESS_642892] d ose of c he m ot hera p y (l ast d ose i s 
t h e da y  of  t h e l ast i nf usi o n) a n d treat me nt starte d as s o o n as p ossi ble b ut n o less t ha n [ADDRESS_642893] 4 wee ks of 
treat m e nt ( Da ys 8, 1 5, 2 2 a n d 2 9). Patie nts will t he n atte n d cli nic visits e ver y  [ADDRESS_642894] i gat or’s 
o pi [INVESTIGATOR_9384] o n t he y  a re be nefit i n g fr o m treat m e nt a n d t he y  d o n ot m e et a n y  ot her di sc o nt i n uat i o n 
cri teria as o utli ne d i n Sect i o n 3. [ADDRESS_642895] u d y  tr e at m e nt, f urt her treat me nt will be at t he discret i o n of t he 
i n vesti gat or h o we ver it is a nt ic i pate d ( b ut n ot re q uire d) t hat patie nts will be retreate d wit h 
t h ei r pl at i n u m base d re gi me n.  Details o f a n y f urt her s y ste mic a nt i- ca ncer treat me nt will be 
c ollecte d u nt il deat h, l oss t o f o ll o w- u p or wi t h dr a w al  of  c o nse nt.  I n a d di ti o n t o t hei r r e g ul ar [ADDRESS_642896] 2019
39(133)weekly contact, patients will be contact[CONTACT_367406] 7 days fo llowing a specified date (data cut off 
date) to capture survival status at that point for each survival analysis.  Assessments will be 
perform ed as described in Table 1.
Patients will  have tumour assessments according to RECIST at baseline and every  8 weeks 
(±1week) up to 40 weeks and then every 12 weeks (±1 week) relative to date of rando misation 
until object ive radio logical  disease progressi on according to modified RECIST criteria. All 
CT/MRI scans will be sent to an [COMPANY_008] appointed Clinical Research Organisat ion 
(CRO) for blinded independent central review. All treatment decisio ns will be based on site 
assessment of scans. After the final primary progressio n free survival (PFS) analy sis, central  
review of scans will no longer be required and investigators will be advised when to stop 
sending copi[INVESTIGATOR_499453].  Ongoing co llection of 
site review tum our assessment i s requi red and m ust be record ed in the electronic case report 
form (eCRF).
RECIST will be modified to assess pat ients with clinical CR at entry  who will  be assessed as 
having no evidence of disease (NED) until they have progressed based on the appearance of 
new lesio ns.
Any pat ient who discont inues study treatment for reasons other than object ive radio logical 
progression should cont inue, to undergo scheduled object ive tumour assessments according to 
the study  plan (see Table 1) in order to assess objective radio logical progressi on of  disease. 
Failure to do so may result in bias to the study  resul ts.
Once a pat ient has progressed the patient will be followed for second progression (PFS2) 
every [ADDRESS_642897] 
occurred, although an interim analysis for futility will be done when 50% of the planned PFS 
events have occurred (see statist ical Sect ion 8).  
The primary  analysis will be based on a blinded independent central review (BICR) of disease 
progression by  [CONTACT_100694]; however, a sensit ivity analysis will be performed using the 
investigator -recorded assessment.  All efficacy variables including overall survival will be 
analysed at the time o f the primary  analysis (providing sufficient events are available to make 
the analyses meaningful).
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081 FC00001
Edition Number [ADDRESS_642898] 2019
40(133)2. STUDY OBJECTIVES
2.1 Primary objective
Primary Objective: Outcome Measure:
To determine the efficacy  of Olaparib 
maintenance monotherapy  com pared to 
placebo by  [CONTACT_499471] 
(PFS)Progression Free Survival (PFS) by [CONTACT_499472] 1.1
2.2 Secondary objectives
Secondary Objective: Outcome Measure :
To determine the efficacy o fOlaparib 
maintenance monotherapy  com pared to 
placeboOverall Survival (observed and predicted 
using observed PFS and OS data)
Time fro m rando misat ion to second 
progression (PFS2)
Time fro m randomisat ion to first subsequent 
therapy  or death (TFST)
Time fr om randomisat ion to second 
subsequent therapy  or death (TSST).
Time fro m randomisat ion to study  treatm ent 
discontinuat ion or death (TDT)
Object ive Response Rate by [CONTACT_499473] 1.1 cri teria for evaluable 
patients
Disease Control  Rate at [ADDRESS_642899] 1.1 criteria
To assess the effect of Olaparib on the 
Health-related Qualit y of Life 
(HRQoL) as measured by [CONTACT_54656] -C30 gl obal QoL scale.Adjusted m ean change fro m baseline in 
global QoL score from  the EORTC -QLQ -C30 
questionnai re
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642900] 2 0 1 9 
4 1( 1 3 3) 2. 3 S afet y o bjecti ves 
S afet y O bjecti ve: O utc o me Me as ure: 
T o assess t he safet y a n d t ol era bilit y of 
Ol a pari b mai nte na nce m o n ot hera p y A d verse e ve nt ( A E), p h y sical e xa mi nat i o n, 
vit al  si g ns i ncl u di n g bl o o d press ure ( B P), 
p ul s e, el ectr ocar di o gra m  ( E C G) a n d 
la b orat or y  f i n di n gs i ncl u di n g cli nical 
c he mistr y  a n d hae mat ol o g y 
2. [ADDRESS_642901] or at or y O bjecti ve: O utc o me Me as ure: 
  
 
 
 
 
 
 
   
 
 
 
 
  
 
  
 
 
 
 
 
  
 C CI C CI 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642902] 2 0 1 9 
4 2( 1 3 3)  
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T he e x pl orat or y  a nal yses m a y n ot be re p orte d i n t he cli nical st u d y  re p ort ( C S R).  If n ot, t he y  
will be re p orte d se paratel y .
3. P A TI E N T S E L E C TI O N, E N R O L M E N T, R A N D O MI S A T I O N, 
R E S T RI C TI O N S, DI S C O N TI N U A TI O N A N D WI T H D R A W A L 
Eac h patie nt s h o ul d meet all o f t h e i ncl usi o n cri teria a n d n o ne of t he e xcl usi o n cri t eri a f or t his 
st u d y pri or t o ra n d o misat i o n.  U n der n o circ u msta nces ca n t here be e xce pt i o ns t o t his r ule. C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642903] 2019
43(133)3.1 Inclusion criteria
For inclusio n in the study  patients shoul d fulfil the fo llowing criteria:
1. *Provisio n of informed consent prior to any study  specific procedures 
2. *Patients m ust be m ale or female ≥18 years of age
3. *Histologically or cy tologically  confirmed pancreas adenocarcinoma receiving 
initial chemotherapy  for metastati c disease and without evidence of disease 
progression on treatment
4. Patients wi th measurable disease and/or non -measurable or no evidence of disease 
assessed at baseline by  [CONTACT_4654] (or MRI where CT is contraindicated) will be entered in 
this study . RECIST 1.1 has been modified to allow the assessment of progression 
due to new lesio ns in pat ients with no evidence of di sease at baseline.
5. Docum ented m utation in gBRCA1 or gBRCA2 that is predicted to be deleterious or 
suspected deleterious (known or predicted to be detrimental/lead to loss of funct ion) 
(See Section 1.5)
6. Patients are on treatm ent wi th a first line platinum -based (cisplatin, carboplat in or 
oxaliplat in) regimen for metastatic pancreas cancer, have received a minimum o f [ADDRESS_642904] igator’s opi[INVESTIGATOR_3078] n.  Patients who have received at least [ADDRESS_642905] received plat inum as potentially curative treatment for a prior 
cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for p ancreas cancer 
are eligible provided at least [ADDRESS_642906] ion measured wit hin 4 
weeks prior to administration of study  treatm ent as defined below:
Haem oglobin ≥  9.0 g/dL wi th no bl ood transfusio ns (packed red blood cells 
and platel et transfusions) in the past 28 day s
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
White blood cells (WBC) >3 x 109/L
No features suggestive of MDS/AML on peripheral blood smear
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642907] 2 0 1 9 
4 4( 1 3 3) Pl at el et c o u n t ≥ 1 0 0 x 1 0 9/ L 
T ot al  bili r u bi n ≤ 1. [ADDRESS_642908] it uti o nal  u p per li mi t of  n or m al  
A S T ( S G O T)/ A L T ( S G P T) ≤ 2. [ADDRESS_642909] be ≤ 5 x U L N 
S er u m  creati ni ne ≤ 1. [ADDRESS_642910] it uti o nal  u p per li mi t of  n or m al  ( U L N) 
9. 
1 0. * P ost m e n o pa usal  or e vi de nce of n o n -c hil d beari n g stat us f or w o me n of c hil d beari n g 
p ote nti al: ne gati ve uri ne or ser u m pre g na nc y test. P ost me n o pa usal is defi ne d as: 
A me n orr heic f or 1 y ear or m or e f ol l o wi n g cessat i o n of e x o ge n o us h or m o nal 
treat m e nts 
L ut ei nizi n g h or m o ne ( L H) a n d F o llicle st i m ulati n g h or m o ne ( F S H) l e vels i n 
t h e p ost me n o pa usal ra n ge f or w o me n u n der 5 0 
Ra diati o n -i n d uce d o o p h orect o m y  wi t h  l ast m e nses > 1 y ear a g o 
C he m ot h era p y -i n d uce d me n o pa use wit h > [ADDRESS_642911] me nses 
S ur gical sterilisati o n ( bilateral o o p h orect o m y  or h ysterect o m y) 
1 1. * Pati e nt is willi n g a n d a ble t o c o m pl y wit h t he pr ot oc ol f or t he d urati o n of t he st u d y  
i ncl u di n g u n der g oi n g treat me nt a n d sc he d ule d visits a n d e xa mi nat i o ns 
1 2. F or mali n fi xe d, paraffi n e m be d de d ( F F P E) t u m o ur sa m ple fr o m t h e pri mar y t u m o ur 
or a m etastati c si t e if a vaila ble or [ADDRESS_642912] u d y  i f a n y of t he f o ll o wi n g e xcl usi o n cri t eri a are f ulfille d: 
1. *I n v o l ve me nt i n t he pla n ni n g a n d/ or c o n d uct of t he st u d y (a p plies t o Astra Ze neca 
sta ff a n d/ or staff at t he st u d y  si t e). 
2. g B R C A 1 a n d/ or g B R C A 2 m ut ati o ns t hat are c o nsi dere d t o be n o n detri me ntal (e g, 
“ Varia nts of u ncertai n cli nical si g nifica nce” or “ Varia nt of u n k n o w n si g nifica nce” 
or “ Varia nt, fa v o ur p ol y m or p his m” or “ be ni g n p ol y m or p his m” etc.). 
3. Pr o gressi o n of t u m o ur bet wee n start of first li ne plati n u m base d c he m ot hera p y f or 
metastati c pa ncreas ca ncer a n d ra n d o misat i o n. C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642913] 2019
45(133)4. Cytotoxi c chem otherapy  or non -horm onal targeted therapy  within [ADDRESS_642914] 2 weeks prior to study treatm ent.
5. *Previous rando misation in the present study.
6. Exposure to an invest igational product within 30 days or 5 half lives (whichever is 
longer) prior to randomisat ion
7. *Any previous treatment with a PARP inhibitor, including Olaparib.
8. *Pati ents wi th second primary  cancer, EXCEPTIONS: adequately  treated non -
melano ma skin cancer, curatively treated in -situ cancer of the cervix, Ductal 
Carcino ma in Situ (DCIS), stage 1 grade 1 endometrial carcino ma, or other solid 
tumours including lympho mas (without bone marrow invo lvement) curatively 
treated with no evidence of disease for ≥ 5 y ears prior to study  entry .
9. Resting ECG with QTC ≥
450 msec detected on 2 or more time po ints within a 24 
hour peri od or family  history  of long QT syndrome. If ECG demonstrates QTC ≥
450 msec, patient will only be eligible if repeat ECG demonstrates QTC ≤450 
msec.
10. Concomitant use of known potent CYP3A4/5 inhibitors such as ketoconazole, 
itraconazo le, ritonavir, indinavir, saquinavir, telit hromycin, clarithro mycin and 
nelfinavir.  F or further detail refer to Appendix H.
11. Persi stent toxi cities (≥CTCAE grade 2) caused by  [CONTACT_499474] , 
excluding alopecia and CTCAE grade 3 peripheral neuropathy.
12. *Pati ents wi th myelodysplast ic syndro me/acute myelo id leukaemia.
13. Major surgery  within 2 weeks of starting study  treatm ent: pati ents m ust have 
recovered fro m any effects of any  major surgery .
14. *Imm unocom promised pati ents, eg, pati ents who are known to be serologically 
positive for human immunodeficiency  virus (HIV).
15. *Clinically significant uncontrolled medical condit ions are not permitted (eg active 
infect ion requiring IV ant ibiotics, symptomat ic congestive heart failure, unstable 
angina pectoris, recent (3 months) myocardial infarction, extensive bilateral 
interstitial lung disease, psychi atric illness that woul d limi t abili ty to com ply with 
study  procedures, and any  other m edical condit ion that, in the opi[INVESTIGATOR_3078] n of the 
investigator, places the patient at unacceptable risk of toxicit y. NB: Di abetes which 
is controlled by [CONTACT_499475] e xclude participat ion in the study
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642915] 2019
46(133)16. *Pati ents wi th a history  of treated CNS m etastases are eligible, provided they  meet 
all of the following cri teria: Di sease outsi de the CNS is present. No evidence of 
interim progression between the complet ion of CNS -direct ed therapy  and the 
screening radiographic study . No hi story  of intracranial haemorrhage or spi[INVESTIGATOR_499454]. Minimum o f 2 weeks between co mpletion of radiotherapy  and cycle 
1 Day  1 and recovery  from significant (Grade ≥3) acute toxicit y with no ongo ing 
requi rement for ≥ 10mg of prednisone per day or an equivalent dose of other 
corticosteroi d.
17. *Pati ents unable to swallow orally  administered medi cation and patients with 
gastrointestinal disorders likely  to interfere wi th absorpti on of  the study  medicat ion.
18. *Pregnant or breast feeding wo men.
19. *Previous allogeneic bone marrow transplant.
20. *Pati ents wi th a known hypersensit ivity to Ol aparib or any  of the excipi[INVESTIGATOR_355614].
21. *Who le blood transfusio ns in the last 120 day s prior to enrolment to th e study  
which may  interfere wi th gBRCA testing (packed red blood cells and platelet 
transfusio ns are acceptable, for timing refer to inclusion criteria no.8)
Procedures for withdrawal of incorrectly  enrolled pati ents see Secti on 3.4.
3.[ADDRESS_642916] igator(s) should keep a record, the patient screening log, of patients who entered pre -
study  screening.
The Principal Invest igator will:
1. Obtain signed informed consent fro m the potenti al patient before any  study  specific 
procedures are performed.
2. Assign potential pat ients a unique enro lment number, beginning with ‘E#’.  (This 
number will be obtained through Interactive Voice/Web Response System 
[IVRS/IWRS]).
3. Determine patient eligibilit y. See Secti ons 3.1and 3.2
4. Obtain the rando misat ion code (patient number) through IVRS/IWRS.
As pati ents are screened for the study , they  must be all ocated an enrolment code (E -code). The 
E-code is a 7 -digit number made up of the centre number and the patient number within that 
particular centre (eg, the first patient screened at centre number [ADDRESS_642917] 2019
47(133)code E0001001, the second patient screened would be E0001002 and so on). This number is 
the pati ent uni que ident ifier and is used to identify the patient on the eCR Fs. If a patient 
withdraws fro m participat ion in the study , then his/her enrolment/randomisat ion code cannot 
be reused.
3.4 Procedures for handling incorrectly enrolled or randomised 
patients
Patients who fail to meet the inclusion/exclusion criteria shoul d not, under any  
circumstances, be randomised or receive study  medication.  There can be no except ions to this 
rule.
Where pat ients that do not meet the select ion criteria are randomised in error or incorrectly  
started on treatment, or where patients subsequen tly fail to m eet the study  criteria post 
initiation, a discussio n should occur between the [COMPANY_008] Study  Team  Physician and the 
investigator regarding whether to continue or discont inue the patient fro m treatm ent. Once a 
decisio n is made, Invest igators need to ensure they comply wit h all applicable requirements 
for human patient protection and ethical review.
The [COMPANY_008] Study  Team  Physician is to ensure all such decisio ns are appropriately 
docum ented. In si tuations where an agreement cannot be reac hed, the patient should have their 
study  treatm ent stopped and be withdrawn fro m the study
3.[ADDRESS_642918] igator (or nominated assistant) should contact [CONTACT_152472]/IWRS Centralised Rando misat ion Centre for allocat ion of rando mised study  treatm ent.
The actual  treatm ent given to individual patients will be determined by a rando misation
scheme that has been loaded into the (IVRS/IWRS) database. The rando misation scheme will 
be produced by  a com puter software program  called GRand (AZ Global Rando misat ion
system ) that incorporates a standard procedure for generat ing rando m numbers.
A blocked rando misation will be generated and all centres will use the same list in order to 
minimise any  imbalance in the number of patients assigned to each treatment group. 
Patients will  be ident ified to the Centralised Randomisat ion Centre using patient Eco de and 
month/ year of  birth.
Randomisat ion codes will be assigned strict ly sequent ially as pati ents beco me eligible for 
rando misat ion.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642919] 2019
48(133)Eligible pat ients will be randomised in a 3:2 ratio (Ol aparib:placebo) as specified below:
 Olaparib tablets p.o. 300 mg t wice daily
 Placebo tabl etsp.o.twice daily  
It is recommended that patients commence study  treatm ent as soon as possible after 
rando misat ion, and ideally  within 3 days.
The IVRS/IWRS Centralised Rando misation Centre will inform the Invest igator of the Kit ID 
number to be allocated to the patient at the rando misation visit. The Invest igator will call/log 
in to the IVRS/IWRS for each subsequent dispensing visit for assignment of a new Kit ID 
number (s) .
The Kit ID number dispensed at each visit will correspo nd to the treatment to which the 
patient was ori ginally rando mised .
3.[ADDRESS_642920] acebo treatm ent will be blinded .
The study  medicat ion will be labelled using a unique Kit ID number, which is linked to the 
rando misat ion scheme. The active and placebo tablets will be ident ical and presented in the 
same packaging to ensure blinding of the study  medication.
If a patient is cont inuing to deri ve benefit from o laparib at the end of the study  (at DCO3), 
then they  may cont inue to receive treatment as open labelled drug via manual supply outside 
of the study  setting once the IVRS/IWRS has been closed. 
3.7.[ADDRESS_642921] igator(s) from the IVRS/IWRS. Routines for this will be 
described in the IVRS/IWRS user manual that will be provided to each centre.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642922] 2019
49(133)The treat ment code shoul d not be broken except in medical emergencies when the appropriate 
management of the patient requires knowledge of the treatment randomisat ion. The 
investigator documents and reports the action to [COMPANY_008], without revealing the treatment
given to patient to the [COMPANY_008] staff.
[COMPANY_008] retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to an invest igational product and that potentially  require 
expedited reporting to regulatory  authori ties. Treatment codes will not be broken for the 
planned analyses of data until all decisio ns on the evaluabilit y of the data from  each individual 
patient have been m ade and docum ented.
Except for medical reasons, patients, invest igators and study m onitors in the field will  have no 
access to the individual treatment code until final analysis.
3.[ADDRESS_642923] dose of study  drug.  For details please refer to 
Appendix 
E Acceptable Birth Control Method.
3.8.2 Olaparib and CYP3A4/5
Patients shoul d avoi d concomitant use of drugs, herbal supplements and/or ingest ion of foods 
known to modulate CYP3A4/5 enzyme activit y (see Secti on 7.7.2 ) starting [ADDRESS_642924]
Patients m ay discontinue study  treatm ent in the fo llowing si tuations:
 Patient deci sion.  The pati ent is at any  time free to discontinue treatment, without 
prejudice to further t reatment
 Object ive radio logical  disease progressi on
 Adverse Event
 Severe non -compliance to study  protocol  
 Death
Revised Clinical Study Pr otocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642925] 2019
50(133)3.9.[ADDRESS_642926] 
A pat ient that decides to discont inue study  treatm ent will always be asked about the reason(s) 
and the presence of any adverse events.  If possible, they  will be seen and assessed by  [CONTACT_98225](s).  Adverse events will be fo llowed up (See Secti ons 6.3and 6.4); questionnaires
and all study  drugs shoul d be returned by [CONTACT_102].
If a patient is wit hdrawn from study , see Secti on 3.10.
Any pat ient discontinuing study  treatment shoul d be seen at [ADDRESS_642927] discontinuation for 
the evaluat ions outlined in the study  schedule.  The pati ent’s tum our sta tus should be assessed 
clinically and, if appropriate, disease progression should be confirmed by [CONTACT_499476].  After discont inuat ion of study  treatm ent, the principal invest igator/sub-
investigator will perform the best possible observation(s), test(s) and evaluat ion(s) as well as 
give appropriate medicat ion and all possible measures for the safet y of the pati ent.  In 
addition, they  will record on the eCRF the date of discontinuat ion, the reasons, manifestation 
and treatment at the time of disco ntinuat ion.  Patients will be required to attend the treatment 
discontinuat ion visit.  The patient should return all study medicat ion.
After di scontinuat ion of the study  treatm ent at any  point in the study , all ongoing AEs or 
SAEs m ust be fo llowed unt il resolution unless, in the invest igator’s opi[INVESTIGATOR_3078] n the condit ion is 
unlikely  to resolve due to the patients underlying disease, or the patient is lost to follow up 
(see Sections 6.3and 6.4).  All new AEs and SAEs occurring during the [ADDRESS_642928] be reported (if SAEs, they  must be reported to 
[COMPANY_008] within [ADDRESS_642929] ion 6.4) and fo llowed to resol ution as above.  
Patients shoul d be seen at l east [ADDRESS_642930] and / or 
complete AE informat ion.  Any untoward event occurring subsequent to the 30- day follow-up 
AE reporti ng period that the investigator assesses as possibly  related to the study  treatm ent 
shoul d also be reported as an AE.
Patients who discont inue treatment prior to dis ease progressi on shoul d continue to have 
RECIST assessments as per the study  schedule. All  patients m ust be fo llowed for obj ective 
progression (as per RECIST 1.1) and survival, up to the final analysis.
3.10 Criteria for withdrawal 
Patients are at any  time fre e to wi thdraw from  study  (study  treatm ent and assessments), 
without prej udice to further treatment (withdrawal of consent).  Such patients will always be 
asked about the reason(s) and the presence of any adverse events.  If possible, they  will be 
seen and assessed by  [CONTACT_2413].  Adverse events will be fo llowed up (See Secti ons 6.3
and 6.4); quest ionnaires (eg, for patient reported outcomes )and all study  drugs shoul d be 
returned by [CONTACT_102].
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642931] 2019
51(133)Withdrawn patients will not be replaced. 
Reasons for withdrawal from the study :
 Voluntary  withdrawal by  [CONTACT_499477] i s at any time free to discont inue their 
participat ion in the study, without prejudice to further treatment*
 Incorrectly enrolled patients ie, the patient does not meet the required 
inclusio n/excl usion criteria for the study
 Patient lost to foll ow-
up
 Death
*If a patient decides at any point in the trial that they  do not wi sh to continue with the full 
study  schedule of assessments but are still willing to provide important study  information (eg 
disease recurrence informat ion and/or survival status informat ion) the n the patient should 
continue in the study  and inform ation shoul d continue to be collected on the clinical database.  
However if a patient does not wish to have any further data collected, only then should they  be 
considered as withdrawing consent fro m thestudy .  To minimise the number of cases of early  
withdrawal  the invest igator should discuss the options with the patient in case they would st ill 
be willing to undergo reduced assessments and/or reduced data collect ion, in which case they  
woul d rem ain in the study .
*If a patient withdraws consent, they  will be specifically asked if they  are wi thdrawing 
consent to:
to further participat ion in the study including any further follow up (eg, 
survival calls)
withdrawal  of consent to the use of their study  gener ated data
withdrawal  to the use of any  samples (see Sect ion 5.6.5 )
Data obtained prior to withdrawal o f consent will be maintained in the clinical database and 
used in the study  reporting.
The status of ongoing, withdrawn (fro m the study ) and ‘lo st to fo llow up’ pat ients at the time 
of an overall survival analysis should be obtained by [CONTACT_367401], hospi [INVESTIGATOR_1097], con tactin g the patients general practit ioner and checking 
publicly  available death registries.  In the event that the patient has act ively wit hdrawn 
consent to collect ion of further data the vital status of the patient can be obtained by [CONTACT_499478] m publicl y available resources where it is possible to do so under applicable 
local laws.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642932] 2019
52(133)3.10.[ADDRESS_642933] th e reason for study  
withdrawal  recorded as ‘Incorrect Enrolment’ (ie, patient does not meet the required 
inclusio n/excl usion criteria).  This reason for study withdrawal is only  valid for screen failures 
(not randomised patients).
3.10.2 Withdrawal of the informed consent
Patients are free to withdraw from the study  at any time (invest igational product and 
assessments), without prejudice to further treatment.
A pat ient who wi thdraws consent will always be asked about the reason(s) and the presence of 
any adverse ev ents (AE).  The Invest igator will fo llow up AEs outside of the clinical study . 
The patient will return electronic PRO (ePRO) devices.  
If a patient withdraws fro m participat ion in the study , then his/her enrolment/randomisat ion 
code cannot be reused. With drawn pati ents will  not be repl aced. 
3.11 Discontinuation of the study
The study  may be stopped if, in the judgment of [COMPANY_008], trial patients are placed at 
undue risk because o f clinically significant findings that:
 meet individual stoppi[INVESTIGATOR_499455] e otherwise considered significant 
 are assessed as causally related to study  drug, 
 are not considered to be consistent with cont inuat ion of the study
Regardless of the reason for terminat ion, all data available for the patient at the time of 
discontinuat ion of fo llow
-up m ust be recorded in the CRF. All reasons for discont inuat ion of 
treatm ent m ust be docum ented.
In terminat ing the study, the Sponsor will ensure that adequate considerat ion is given to the 
protecti on of  the pati ents’ interests
4. S TUDY PLAN AND TIMING OF PROCEDURES 
A study  initiation visit must be conducted at the centre prior to the commencement of any 
study  activities requiring informe d consent. A schedule for the tests and evaluat ions to be 
conducted in this study  is contained in this sect ion and in Table 1.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642934] 2019
53(133)Table 1 Study Sch edule –Screening, On Study Treatment, Discontinuation and Follow -up
Screen 
PART 1 
(Patients 
with 
unknown 
BRCA
status only)Screen 
PART 2 
(All 
patients)Treat ment Duration Study 
treatment 
discontinued30-Day 
follow-
upSurvival Follow -
up v
Cycle/ Visit 1 (28 days) 2 3+ (every 
28 days)Until 
DCO2Between 
DCO2 & 
DCO3
Day -28 to 0 1 8 15 22 29 57+ Every 
8 
weeksEvery 12 
Weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d ±7d
Infor med consent X X
Randomisation fX f
Demographics X X
Medical and 
surgical history, 
including blood 
transfusions aX
Prior cancer 
therapi[INVESTIGATOR_499456]/exclusion 
criteriaX (all *  
criteria) bX
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642935] 2 0 1 9 
5 4( 1 3 3) Scree n 
P A R T 1 
( P atie nts 
wit h 
u n k n o w n 
B R C A 
st at us o nl y) Scree n 
P A R T 2 
( All 
p atie nts) Tre at me nt D ur ati o n St u d y 
tre at me nt 
disc o nti n ue d 3 0- D a y 
f o ll o w -
u p S ur vi v al F oll o w -
u p v
C ycle/ Visit 1 ( 2 8 d a ys) 2 3 + (e ver y 
2 8 d a ys) U n til 
D C O 2 Bet wee n 
D C O 2 & 
D C O 3 
D a y -2 8 t o 0 1 8 1 5 2 2 2 9 5 7 + E ver y 
8 
wee ks E ver y 1 2 
Wee ks 
Visit wi n d o w ± 3 d ± 3 d ± 3 d ± 3 d ± 3 d ± 7 d ± 7 d ± 7 d ± [ADDRESS_642936] 2019
55(133)Screen 
PART 1 
(Patients 
with 
unknown 
BRCA
status only)Screen 
PART 2 
(All 
patients)Treat ment Duration Study 
treatment 
discontinued30-Day 
follow-
upSurvival Follow -
up v
Cycle/ Visit 1 (28 days) 2 3+ (every 
28 days)Until 
DCO2Between 
DCO2 & 
DCO3
Day -28 to 0 1 8 15 22 29 57+ Every 
8 
weeksEvery 12 
Weeks
Visit window ±3d ±3d ±3d ±3d ±3d ±7d ±7d ±7d ±7d
Tumour assessment 
(modified RECIST 
1.1) jX (no 
more 
than 28 
days 
before 
start of 
treatment
) jEvery 8 weeks (± 1 week) until week 40 then 
every 12 weeks (±1 week), relative to the 
date of randomisation jIf patient does 
not have 
disease 
progression at 
the time of 
treatment 
discontinuatio
n tumour 
assessments 
should be 
continued per 
the CSP 
schedule k
Haematology/clinic
al chemistry X X lX X X X X X X
Coagulation mX As clinically indicated
Urinalysis nX As clinically indicated
Pregnancy test  oX X X
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642937] 2 0 1 9 
5 6( 1 3 3) Scree n 
P A R T 1 
( P atie nts 
wit h 
u n k n o w n 
B R C A 
st at us o nl y) Scree n 
P A R T 2 
( All 
p atie nts) Tre at me nt D ur ati o n St u d y 
tre at me nt 
disc o nti n ue d 3 0- D a y 
f o ll o w -
u p S ur vi v al F oll o w -
u p v
C ycle/ Visit 1 ( 2 8 d a ys) 2 3 + (e ver y 
2 8 d a ys) U n til 
D C O 2 Bet wee n 
D C O 2 & 
D C O 3 
D a y -2 8 t o 0 1 8 1 5 2 2 2 9 5 7 + E ver y 
8 
wee ks E ver y 1 2 
Wee ks 
Visit wi n d o w ± 3 d ± 3 d ± 3 d ± 3 d ± 3 d ± 7 d ± 7 d ± 7 d ± 7 d 
Bi o mar ker bl o o d 
s a m ple pX X ( o nl y at 
pr o gressi o n) 
E O R T C Q L Q -C [ADDRESS_642938] 2 0 1 9 
5 7( 1 3 3) Scree n 
P A R T 1 
( P atie nts 
wit h 
u n k n o w n 
B R C A 
st at us o nl y) Scree n 
P A R T 2 
( All 
p atie nts) Tre at me nt D ur ati o n St u d y 
tre at me nt 
disc o nti n ue d 3 0- D a y 
f o ll o w -
u p S ur vi v al F oll o w -
u p v
C ycle/ Visit 1 ( 2 8 d a ys) 2 3 + (e ver y 
2 8 d a ys) U n til 
D C O 2 Bet wee n 
D C O 2 & 
D C O 3 
D a y -2 8 t o 0 1 8 1 5 2 2 2 9 5 7 + E ver y 
8 
wee ks E ver y 1 2 
Wee ks 
Visit wi n d o w ± 3 d ± 3 d ± 3 d ± 3 d ± 3 d ± 7 d ± 7 d ± 7 d ± [ADDRESS_642939] be rec or de d i n t he patie nt’s n otes. 
cPatie nts m ust ha ve a k n o w n deleteri o us or s us pecte d deleteri o us B R C A m uta ti o n t o be ra n d o mise d t o t he st u d y; t his ca n be eit her a l ocal la b res ult or a 
M y ria d test res ult. Patie nts f or w h o m t heir g B R C A stat us is alrea d y k n o w n, s h o ul d be c o nse nte d t o t he st u d y wit hi n [ADDRESS_642940] 2 0 1 9 
5 8( 1 3 3) fPatie nts will be ra n d o mise d wit hi n [ADDRESS_642941] d ose of c he m ot hera p y (last d ose is t he da y of t he last i nf usi o n) a n d treat me nt starte d as s o o n 
as p ossi ble b ut n o less t ha n [ADDRESS_642942], a b d o me n a n d pel vis ( or M RI w here C T is c o ntrai n dica te d) a n d s h o ul d be 
perf or me d n o m ore t ha n [ADDRESS_642943] d ose of 
c he m ot hera p y. R E CI S T f oll o w -u p assess me nts will be perf or me d e ver y 8 wee ks ( ± 1 wee k) f or t he first 4 0 wee ks, t he n e ver y 1 2 wee ks ( ± 1 wee k) 
irres pecti ve of treat me nt decisi o ns. F oll o w -u p assess me nt will i ncl u de C T assess me nts of c hest, a b d o me n a n d pel vis ( or M RI w here C T is 
c o ntrai n dicate d) f or all patie nts. A n y ot her sites at w hic h n e w disease is s us pecte d s h o ul d als o be a p pr o priatel y i ma ge d. Patie nts m ust be f oll o we d u ntil 
disease pr o gressi o n assesse d usi n g m o difie d R E CI S T 1. [ADDRESS_642944] u d y treat me nt pri or t o disease pr o gressi o n, R E CI S T assess me nts will c o nti n ue u ntil o bjecti ve d isease pr o gressi o n (e ver y 
8 wee ks ( ± 1 wee k) f or t he first 4 0 wee ks, t he n e ver y 1 2 wee ks ( ± 1 wee k) relati ve t o date of ra n d o misati o n, u ntil o bjecti ve disease pr o gressi o n as defi ne d 
b y m o difie d R E CI S T 1. 1.). 
lHae mat ol o g y a n d cli nical c he mistr y s h o ul d be perf or me d at scree ni n g , c y cle [ADDRESS_642945] be ca pt ure d fr o m ti me of c o nse nt. O n l y  S A E’s relate d t o bl o o d sa m pli n g f or t he M yria d g B R C A test will be c ollecte d at t his visit. 
sC o nti n u o us Ola pari b 3 0 0 m g/ place b o t wice dail y d osi n g. S ufficie nt st u d y tre at me nt s h o ul d be dis pe nse d f or at least eac h treat me nt peri o d pl us o vera ge, 
h o we ver a d diti o nal treat me nt ca n be dis pe nse d t o patie nts t o last l o n ger i n acc or da nce wit h l ocal practice. 
tAll a nti -ca ncer treat me nts (i ncl u di n g, b ut n ot li mite d t o, c he m ot hera p y a n d tar gete d a ge nts), a n d t he I n vesti gat or’s o pi [INVESTIGATOR_9384] o n of res p o nse t o t he m nee d t o 
be rec or de d u ntil e n d of st u d y peri o d ( D C O 3), pl us t he date of pr o gressi o n p ost disc o nti n uati o n of st u d y treat me nt, nee d t o be rec or de d. C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642946] 2 0 1 9 
5 9( 1 3 3) uSec o n d disease pr o gressi o n ( P F S 2 ) assess me nt will be perf or me d b y t he I n vesti gat or a n d defi ne d acc or di n g t o l ocal sta n dar d cli nical practice a n d ma y 
i n v ol ve a n y of; o bjecti ve ra di ol o gical or s y m pt o matic pr o gressi o n or deat h.  S u bse q ue nt t hera p y will be c ollecte d f or t hese p atie nts fr o m t he ti me of 
treat me nt disc o nti n uati o n u ntil e n d of st u d y peri o d ( D C O 3). 
vT he stat us of o n g oi n g, wit h dra w n (fr o m t he st u d y) a n d ‘l ost t o f oll o w -u p’ patie nts at t he ti me of a n O S a nal ysis s h o ul d be o btai ne d b y t he site pers o n nel 
b y c hec ki n g t he patie nts n ote s, h os pi[INVESTIGATOR_21036], c o ntacti n g t he patie nt’s ge neral practiti o ner a n d c hec ki n g p u blicl y a vaila ble deat h re gistries.  I n t he 
e ve nt t hat t he patie nt has acti vel y wit h dra w n c o nse nt t o t he pr ocessi n g of t heir pers o nal data t he vital stat us of t he patie n t ca n be o btai ne d b y site 
pers o n nel fr o m p u blicl y a vaila ble res o urces w here it is p ossi ble t o d o s o u n der a p plica ble l ocal la ws (see Secti o n 3. 1 0 ). I n a d diti o n t o t heir re g ular [ADDRESS_642947], patie nts will be c o ntacte d i n t he 7 da ys f oll o wi n g a s pecifie d date ( data c ut off date) f or eac h s ur vi val a na l ysis u ntil fi nal f or mal a nal ysis 
of O S ( D C O 1 & D C O 2) .P ost D C O [ADDRESS_642948] 2 0 1 9 
6 0( 1 3 3) 4. 1 E nr ol me nt/scree ni n g peri o d 
Pr oce d ures will be perf or me d acc or di n g t o t he St u d y  Pl a n. 
At  scree ni n g, c o nse nt i n g patie nts are assesse d t o e ns ure t hat t he y  m eet eli gi bili t y  cri t eri a. 
P ati e nts w h o d o n ot meet t hese criteria m ust n ot be e nr olle d i n t he st u d y .
T he f o ll o wi n g assess me nts a n d pr oce d ures s h o ul d be perf or me d d uri n g scree ni n g Part 1 a n d 
Part 2 as per Ta ble 1.
F or details o f t h e sc he d ule a n d nat ure of assess me nts see bel o w: 
 M o nt h/ y ear of birt h, se x, race a n d et h nicit y 
 Me dical a n d s ur gical hist or y  i ncl u di n g pre vi o us ca ncer a n d ra di ot hera p y  a n d hist or y  
of  bl o o d tra nsf usi o n s i n pre vi o us 1 2 0 da ys 
 Pre vi o us c he m ot hera p y 
If pat ie nt  recei ve d a pri or plati n u m dr u g, i n w hat setti n g (a dj u va nt or a d va nce d) 
a n d reas o n f or disc o nt i n uat i o n ( pr o gressi o n o n t hera p y , disc o nti n uati o n of  
t h era p y  f or reas o n ot her t ha n pr o gressi o n, c o m plet i o n of pla n ne d pr o gra m 
wi t h o ut pr o gressi o n,) 
 C urre nt a n d c o nc o mita nt me dicat i o ns i ncl u di n g pre vi o us ca ncer t hera pi[INVESTIGATOR_014] 

 Vi t al  si g ns ( bl o o d press ure a n d p ulse; b o d y  t e m perat ure), b o d y  w ei g ht, hei g ht 
 Hae m at ol o g y  / Cli nical  c h e mistr y / Uri nal ysis 
 C oa g ulati o n test 
acti vate d partial t hr o m b o blast i n ti me { A P T T } will be perf or me d at baseli ne a n d 
if cli nicall y i n dicate d 
i nt er nat i o nal n or m alise d rati o {I N R } will be perf or me d at baseli ne a n d if 
cli nicall y i n dicate d u n le ss t he patie nt is recei vi n g warfari n. Patie nts ta ki n g 
warfari n ma y  p arti ci pate i n t hi s st u d y; h o we ver, i t is rec o m me n de d t hat 
pr ot hr o m bi n t i me (I N Ra n d A P T T) be m o nit ore d caref ull y at least o nce per 
wee k f or t he first m o nt h, t he n m o nt hl y if t he I N R is sta ble 
 P h ysical e xa mi nat i o nC CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642949] 2 0 1 9 
6 1( 1 3 3)  C T ( or M RI if C T is c o ntrai n dicate d) of c hest, a b d o me n a n d pel vis 
 E C G ( wi t hi n [ADDRESS_642950] u d y  tr e at m e nt) 
 Me n o pa usal stat us; ser u m or uri ne pre g na nc y test f or w o me n of c hil d beari n g 
p ote nti al .  T he pre g na nc y  t est s h o ul d be pri or t o perf or mi n g t he g B R C A bl o o d test 
d uri n g scree ni n g part 1, wit hi n [ADDRESS_642951] u d y  treat m e nt a n d 
c o nfir me d o n da y  1 pri or t o d osi n g 
 F or pati e nts wi t h  u n k n o w n g B R C A stat us: g B R C A 1/ 2 m ut ati o n stat us. 2 bl o o d 
sa m ples: O ne bl o o d sa m ple t o test f or g B R C A m ut ati o ns usi n g t he c urre nt 
c o m mercial M yria d B R A C A n alysis test, a n d t he sec o n d bl o o d sa m ple f or a bri d gi n g 
st u d y  t o vali date t he c o m pa ni o n  di a g n ostic test f or Ola pari b a n d/ or assess me nt of 
c urre nt or f ut ure B R C A m ut at i o n assa ys 
 P ati e nt Re p orte d Q ualit y of life q uest i o n naire: E O R T C Q L Q -C 3 0 a n d  
s h o ul d b e c o m plete d pri or t o ra n d o misati o n o nce eli gi bilit y is c o nfir me d 
 A d verse e ve nts m ust be ca pt ure d fr o m t i me of c o nse nt.  O nl y S A E’s rel ate d t o 
bl o o d s a m pli n g f or t he M yri a d g B R C A test will be c ollecte d at t his visit. I n 
Scree ni n g P art 2 all A Es/ S A Es will be c ollecte d 
 Arc hi val paraffi n e m be d de d t u m o ur tiss ue sa m ple or c yt ol o g y  sa m ple re q ueste d, if 
a vaila ble 
T he Pri nci pal I n vest i gat or/ S u b -I n vesti gat or s h o ul d a d here t o t h e st u d y pla n, pr oce d ures a n d 
perf or m  tests/ o bser vat i o ns i n acc or da nce wit h t he pr ot oc ol. 
4. 2 Tre at me nt peri o d 
T he visit sc he d ule is base d o n 2 8 -d a y  c ycles. 
P ati e nts will  atte n d t he cli nic wee kl y o n da ys 1 ( 1st da y  of  treat m e nt), 8, [ADDRESS_642952] u d y  treat m e nt a n d t he n e ver y  4 wee ks ( da y  1 of  e ver y  c ycle) u nt il 
di sc o nti n uat i o n of treat m e nt. T he f oll o wi n g assess me nts will be perf or me d at ti me p oi nts 
s pecifie d i n t he st u d y  sc he d ule (see Ta ble 1): 
 Vi t al  si g ns: Da y  [ADDRESS_642953] u d y  tr e at m e nt, if it has n ot bee n assesse d wit hi n 7 da ys of ra n d o misati o n.  A n y 
ot her ti me as cli nicall y  i n dicate d 
  
 C CI C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642954] 2 0 1 9 
6 2( 1 3 3)  Hae mat ol o g y  a n d cli nical  c he mistr y : c ycle [ADDRESS_642955] i gat or belie ves t hat it is li kel y t o ha ve c ha n ge d 
si g nifica nt l y. 
 P h ysical e xa mi nat i o n: Da y  [ADDRESS_642956] be re p orte d as a n A E. 
 C T of c hest, a b d o me n a n d pel vis ( or M RI if C T is c o ntrai n dicate d) perf or me d u nt il 
o bj ect i ve disease pr o gressi o n. R E CI S T assess me nts t o be sc he d ule d e ver y 8 wee ks 
( ± 1 wee k) fr o m ra n d o misat i o n f o r t he first 4 0 wee ks a n d t he n e ver y  1 2 wee ks ( ± 1 
wee k). If pr o gressi o n is n ot c o nfir me d b y  BI C R a n a d di ti o n al  sca n will be re q ueste d 
at t he ne xt sc he d ule d visit. C T/ M RI of c hest, a b d o me n a n d pel vis t o be perf or me d 
u nt il o bject i ve disease pr o gressi o n. 
 E C G at baseli ne a n d a n y ti me if cli nicall y i n dicate d 
 Ur i nal ysis at baseli ne a n d a n y t i me if cli nicall y i n dicate d 
 S er u m  or uri ne pre g na nc y  t est f or w o m e n of c hil d beari n g p ote ntial ( pri or t o 
treat m e nt o n da y  [ADDRESS_642957] u d y  treat m e nt).  If t he test is p osit i ve t he n a 
c o nfir mat or y  test s h o ul d be perf or m e d 
 F or pati e nts wi t h  k n o w n gB R C A st at us: g B R C A 1/ 2 m ut ati o n stat us. 2 bl o o d 
sa m ples: O ne bl o o d sa m ple t o test f or g B R C A m ut ati o ns usi n g t he c urre nt 
c o m mercial M yria d B R A C An alysis test, a n d t he sec o n d bl o o d sa m ple f or a bri d gi n g 
st u d y  t o vali date t he c o m pa ni o n  di a g n ostic test f or Ola pari b a n d/ or assess me nt of 
c urre nt or f ut ure B R C A m ut at i o n assa ys 
 A E a n d c o nc o mit a nt m e dicat i o ns (i ncl u di n g a n y bl o o d tra nsf usi o ns) at e ver y  visi t
 P ati e nt Re p orte d Q ualit y of life q uest i o n naire: E O R T C Q L Q -C 3 0 at baseli ne ( pri or 
t o ra n d o misati o n o nce eli gi bilit y is c o nfir me d), e ver y  [ADDRESS_642958] d ose.  

 
 C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642959] 2 0 1 9 
6 3( 1 3 3)   
 
 
 
 
 
 
O nce pat ie nt s ha ve disc o nt i n ue d st u d y  treat me nt, ot her treat me nt o pti o ns will be at t he 
di screti o n of  t he i n vest i gat or. 
4. [ADDRESS_642960] i ve ra di o l o gi c al  
di sease pr o gressi o n acc or di n g t o m o difie d R E CI S T 1. 1 criteria (see A p pe n di x F ). 
F o ll o wi n g ra di ol o gi cal  disease pr o gressi o n pat ie nt s will be f o ll o w e d f or P F S 2 a n d O S. 
4. 3. 2 Tre at m e nt disc o nti n u ati o n visit d ue t o a n y ot her disc o nti n u ati o n criteri a 
 P ati e nts s h o ul d be disc o nt i n ue d fr o m st u d y treat me nt if a n y disc o nt i n uat i o n cri teria 
are f ulfille d (see Secti o n 3. 9 ).  T he assess me nts t o be carrie d o ut at t he visit are 
detaile d i n t he st u d y  sc he d ule ( Ta ble 1). 
P ati e nts w h o ha ve disc o nt i n ue d fr o m treat me nt b ut d o n ot ha ve ra di o l o gi cal  disease 
pr o gressi o n will c o nt i n ue t o be f o ll o we d f or P F S b y  m o difie d R E CI S T 1. 1 assess me nts e ver y  
8 wee ks ( +/ -1 wee k) fr o m date of ra n d o misat i o n d uri n g t he first 4 0 wee ks a n d t he n e ver y 1 2 
wee ks ( +/ -1 wee k) t hereafter. 
4. 3. [ADDRESS_642961] i ve ra di o l o gi c al  
di sease pr o gressi o n acc or di n g t o R E CI S T (see A p pe n di x F), h o we ver, patie nts ma y be 
all o we d t o c o nti n ue st u d y  treat m e nt if t he i n vest i g at or belie ves, a n d A Z St u d y  P h ysicia n 
c o nc urs, t hat t he patie nt c o ul d c o nt i n ue t o recei ve be nefit, t he patie nt is n ot e x perie nci n g 
seri o us t o xicit y,  a n d t here i s n o a vaila ble better alter nat i ve treat me nt t hat c o ul d be nefit t he 
patie nt. T hese patie nts will c o nt i n ue st u d y  pr oce d ures as per Ta ble 1a n d will be f o ll o we d f or C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642962] 2 0 1 9 
6 4( 1 3 3) O S. Safet yassess me nt ca n occ ur wit h t he sa me fre q ue nc y as t he visits u nless m ore fre q ue nt 
testi n g is cli nicall y  i n dicate d. 
4. 3. [ADDRESS_642963] u d y tre at m e n t (f oll o w -u p visit) 
A f o ll o w- u p visit s h o ul d be c o n d ucte d [ADDRESS_642964] u d y  tr e at m e nt.  A n y 
seri o us a n d/ or n o n -seri o us A Es o n g oi n g at t he ti me of t he Disc o nt i n uat i o n Visit or w hic h ha ve 
occ urre d d uri n g t he defi ne d [ADDRESS_642965] b e f oll o we d -u p (i n acc or da nce wit h 
Secti o n 6. 3 ).  A p pr o priate safet y  e val uat i o ns s h o ul d be re peate d a n d/ or a d dit i o nal tests 
perf or m e d at a n y  ti me w he n cli nicall y i n dicate d, or at t he discreti o n o f t h e i n vesti gat or, u ntil 
res ol ut i o n, u nless, i n t he i n vest i gat or’s o pi [INVESTIGATOR_9384] o n, t he c o n diti o n is u nli kel y  t o res ol ve d ue t o t he 
pati e nt’s u n derl yi n g disease.  If t he patie nt is l ost t o f o ll o w- u p, t he n t hi s s h o ul d be n ote d i n t he 
e C R F.  T he assess me nts t o be carrie d o ut at t he [ADDRESS_642966] u d y  
sc he d ule ( Ta ble 1). 
4. 3. 5 S ur vi v al 
S ur vi val data s h o ul d be c ollecte d, e ver y  8 wee ks u nt il fi nal f or mal s ur vi val a nal ysis ( D C O 2) 
a n d e v er y  1 2 wee ks u nt il t he ( D C O 3) , f ol l o wi n g 
o bj ect i ve ra di o l o gi c al  disease pr o gressi o n.  S ur vi val  i nf or mat i o n ma y be o btai ne d via 
t el e p h o ne c o ntact wi t h  t he pati e nt, pati e nt’s fa mil y or b y  c o ntact wi t h  t he pati e nt’s c u rre nt 
p h ysicia n. I n a d dit i o n, pati e nts s h o ul d be c o ntacte d i n t he wee k f oll o wi n g t he data c ut -off f or 
t h e pri mar y  P F S ( D C O 1), fi nal  f or m al  s ur vi val  a n al yses ( D C O 2, at 1 0 6 O S e ve nts) a n d at t he 
 
t o pr o vi d e c o m plete s ur vi val data. 
P ati e nts will  b e f ol l o we d u p as per Ta ble 1t o t he p oi nt of  
  At t hi s p oi nt i n vesti gat ors will 
be n otifie d t hat n o f urt her data c ollect i o n f o r t he st u d y  i s re q ui re d.  M o ni t ori n g a n d rec or di n g 
of  S A Es will c o nt i n ue as per Secti o n 6. 4 .
T he stat us of patie nts at t he ti me of a n o verall s ur vi val a nal ysis s h o ul d be o btai ne d b y t he site 
pers o n nel b y  c h ec ki n g t he patie nt’s n otes, h os pi[INVESTIGATOR_21036], c o ntacti n g t he patie nts ge neral 
pra cti ti o ner a n d c hec ki n g p u blicl y a vaila ble deat h re gistries. I n t he e ve nt t hat t he patie nt has 
acti vel y wit h dra w n c o nse nt t o t he pr ocessi n g of t heir pers o nal data t he vital stat us of t he 
pati e nt ca n be o btai ne d b y  si te pers o n nel  f r o m  p u blicl y  a v aila ble res o urces w here it is p ossi ble 
t o d o s o u n der a p plica ble l ocal la ws (see Sect i o n 3. 1 0 ). 
4. 3. [ADDRESS_642967] i ve pr o gressi o n, c o pi[INVESTIGATOR_1309] t he patie nt’s r a di ol o gi c al  sca ns are n o l o n ger 
re q ui re d t o be se nt f or bli n de d i n de pe n de nt ce ntral re vie w. Patie nts will be assesse d e ver y  8 
wee ks f or a sec o n d pr o gressi o n ( usi n g t he patie nts’ stat us at first pr o gressi o n as t he refere nce C CI 
C CI 
C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642968] 2019
65(133)for assessment of second progres sion). A patient’s progression status is defined according to 
local standard clinical pract ice and may invo lve any  of; objective radi ological or symptom atic 
progression or death. RECIST measurements will not be collected for assessment of PFS2. 
The date of PFS2 assessment and invest igator opi[INVESTIGATOR_3078] n of progression status (progressed or 
non
-progressed) at each assessment will be recorded in the eCRF.
4.3.[ADDRESS_642969] 1.1, copi[INVESTIGATOR_113502]’ s 
radiological  scans are no l onger requi red to be sent for blinded independent central review, 
provi ded that the central read confirms progression. If progression is not confirmed, one 
additional scan will  be requi red at the next scheduled visit. Following object ive progression 
patients will be assessed every 8 weeks for survival (see Section 4.3.5 ) but also for nature of 
subsequent treatment, response to subsequent treatment and investigator assessment of time to 
progression on the subsequent treatment. While other than the PFS2, response and t ime to 
progression on later therapi[INVESTIGATOR_499457] a specific endpoint of the trial, the informat ion garnered 
will help determine i f there is an optimal sequencing of treatments for gBRCA -associated 
pancreas cancer and for planning of future clinical studies.
The data cut -off date for the final statist ical analysis for the primary  object ive of the study  will 
be established when approx imately 87confi rmed progressi on events are expected to have 
occurred.
Patients on study  treatm ent at the time o f the data cut -off will cont inue to receive study 
treatm ent until they meet any  discontinuat ion criteria as per Secti on 3.9. 
Patients on study  treatm ent will be fo llowed for core safet y assessments (haematology , 
clinical chemistry , AEs/SAEs, concomitant medications and study  treatm ent dosing details)
Once the primary  PFS analysis has been performed the collect ion of RECIST data for 
independent central review will cease. Patients who have not had an object ive disease 
progression at the time of the data cut off for the primary analysis should continue to hav e 
RECIST assessments unt il first obj ective disease progression is determined by [CONTACT_1275]. RECIST assessments should be performed every  12 weeks (± 1week) from the 
last assessment prior to the data cut off date.  Patients will also be fo llowed f or inform ation on 
vital status to obtain the data needed for the OS analysis and informat ion on subsequent 
treatm ent.  
4.[ADDRESS_642970] final analysis
The data cut -off date (DCO3) for the final statist ical analysis o f the study  will be established 
12 m onths after the time when ~ 106confirmed OS events (~75 % maturity  for OS analysis) 
are expected to have occurred.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642971] 2019
66(133)At this time point, the clinical study  database will close to new data.  Patients who are 
receiving treatment can eit her choose to discont inue fro m the study  or where the investigator 
believes patients are gaining clinical benefit ; patients may continue to receive study  treatm ent.  
All patients will receive fo llow up care in accordance wit h standard local clinical pract ice.
[COMPANY_008] will con tinue to supply  Olaparib after com pletion of  this study  until ei ther 
Olaparib is licensed in that coun try, or it is determined that the benefit to risk profile does not 
support conti nued development of Olaparib, or the national healt h authorit y has deemed the 
drug not approvable.  In all these scenarios, [COMPANY_008] will work with investigators on the 
proper transit ion of patients to alternat ive therapi[INVESTIGATOR_499458].
SAEs will cont inue to be reported to [COMPANY_008] Patient Safet y Department, for any  patients 
who continue on Olaparib unt il [ADDRESS_642972] igator learns of any SAEs, including deat h, at any  time after a patient has completed 
the study , and he/she considers there is a reasonable possibilit y that the event is causally 
related to the invest igational product, the invest igator should notify [COMPANY_008], Patient 
Safety.
Drug accountabilit y shoul d cont inue to be performed until the patient stops study treatment 
completely
5. STUDY ASSESSMENTS  
The Rave Web Based Data Capture (WBDC) system will be used for data collect ion and
query  handling. The invest igator will ensure that data are recorded on the electronic Case
Report F orms as specified in the study  protocol  and in accordance with the instructions
provi ded.
The invest igator ensures the accuracy, completeness and timeliness of the data recorded and
of the provisio n of answers to data queries according to the Clinical Study  Agreement. The
investigator will sign the completed electronic Case Report Forms. A copy  of the com pleted
electroni c Case Report Forms will be archived at the study  site.
5.[ADDRESS_642973] and MRI scans Tumour assessments (Modified RECIST 1.1)
Following the baseline assessment, subsequent tumour assessments according to modified 
RECIST 1.1 should be performed every 8 weeks (±1 week) for the first 40 weeks and then 
every 12 weeks (± 1 week) thereafter, relative t o the date of rando misat ion, up to object ive 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642974] 2019
67(133)disease progressi on by  [CONTACT_393]. Pati ents who are determined to have progressed according to 
modified RECIST 1.[ADDRESS_642975] visit ([ADDRESS_642976] scan).  
For those patients with no evidence o f disease at baseline, following a clinical complete 
response to chemotherapy , progressi on is defined by  [CONTACT_499479] (m odified RECIST 1.1).
The imaging modalit ies used for RECIST assessment will be CT (MRI where CT is 
contraindicated) scans of the chest, abdo men and pelvis wit h other regions as clinically 
indicated for the assessment of disease .  Any  other si tes at which new disease is suspected 
shoul
d also be appropri ately imaged.  The methods of assessment of tumour burde n used at 
baseline must be used at each subsequent fo llow-up assessment.
Radiological examinat ions performed in the conduct of this study  shoul d be retained at site as 
source data.
Any missed copi[INVESTIGATOR_499459].
All treatment decisio ns will be based on site assessment of scans.  After the primary PFS 
analysis, central review of scans will no longer be required and invest igators will be advised 
when to stop sending copi[INVESTIGATOR_499453].  
It is important to follow the assessment schedule as closely  as possible. If scans are performed 
outsi de of  scheduled visit ± [ADDRESS_642977] 1.1 as per the study  schedule (see Table 1), and then fo llowed f or second progression 
and survival, regardless o f whether study  treatm ent is discont inued or delayed and/or protocol 
violations, unless they wit hdraw consent.
5.1.[ADDRESS_642978] 1.1 criteria will be used to assess patient response to treatment by  
[CONTACT_499480] (PFS) times.  (The modified RECIST 1.[ADDRESS_642979] ive tumour resp onse 
criteria (com plete response, partial response, stable disease, no evidence of disease or 
progression of disease) are presented in 
Appendix F.) 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642980] 2019
68(133)The m ethods of assessment of tumour burden used at baseline 
-CT or MRI scans of chest, 
abdo men and pelvis, with other regi ons as clinically  indicated for the assessment of disease 
must be used at each subsequent fo llow-up assessment, see Section 4.3. 
Following the baseline assessment, efficacy for all patients will be assessed by  [CONTACT_499481] 8 weeks (±1 week) up to 40 weeks then every  12 weeks (±1 week) 
relative to date of randomisat ion, according to the planned study  schedule Table 1until 
objective radio logical disease progressi on as defined by  [CONTACT_100694]. If a pati ent 
discontinues treatment (and/or receives a subsequent cancer therapy ) prior to progressi on then 
the pati ent shoul d still continue to be fo llowed unt il objective radio logical disease progressi on 
as defined by  [CONTACT_100694] 1.1.
Categorization of object ive tum our response assessment will be based on the modified 
RECIST cri teria of response: complete response (CR), partial response (PR), stable disease 
(SD), progression o f disease (PD), no evi dence of di sease (NED) and not evaluable (NE).  
Target l esion (TL) pro gression will be calculated in co mpar ison to when the tumour burden 
was at a minimum (ie, smallest sum of diameters previously recorded on study ).  In the 
absence of a best response of progression, tumour response (CR, PR, SD) will be calculated in 
comparison to the baseline tumour measurements obtained before rando misat ion.
For pati ents wi th non-measurable disease only at baseline, categorizat ion of object ive tumour 
response assessment will be based on the RECIST criteria of response: CR (complete 
response ), PD (progressi on of  disease) and Non CR/Non PD. Patients with no disease at 
baseline will be assessed according to modified RECIST 1.1 criteria for new lesio ns wi th 
responses o f No Evi dence of Disease (NED) or progression of disease.
If the invest igator is in doubt as to whether disease progression has occurred on study  therapy , 
particularly wit h response to NTL (non -target lesio n) or the appearance of a new lesio n, it is 
advisable to continue treatment until the next scheduled assessment or sooner if cli nically 
indicated and reassess the patient’s status.  If repeat scans confirm disease progression, then 
the date of the init ial scan shoul d be decl ared as the date of disease progression. 
To achieve ‘unequivocal progression’ on the basis of non- target di sease, there m ust be an 
overall level o f substant ial worsening in non -target disease such that, even in presence of SD 
or PR in target disease, the overall tumour burden has increased sufficient ly to merit 
discontinuat ion of therapy .  A m odest increase in the size o f one or m ore non -target l esions is 
usually not sufficient to qualify  for unequivocal progression status.
Following progression, patients should continue to be followed up for survival every  [ADDRESS_642981]/MRI scans in sect ion 5.1.[ADDRESS_642982] 2019
69(133)5.1.[ADDRESS_642983] Research Organisat ion (CRO) 
for central  analysis. Result s of thi s independent review will not be communicated to 
investigators (with the except ion of confirmat ion of progression assessments), and the 
management of patients will be based so lely upon the resul ts of the RECIST assessment 
conducted by  [CONTACT_17062].
The primary  analysis for this study  will be based on the blinded independent central review 
(BICR) of the radio logical scans.
5.2 Safety assessments
5.2.1 Laboratory safety assessments
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, coagulati on, 
and urinalysis will be taken at the times indicated in the Study  Schedule (see Table 1).
These tests will be performed by [CONTACT_5035][INVESTIGATOR_307]’s local laboratory .  Addi tional analyses may  be 
perform ed if clinically  indicated. 
Any clinically  significant abnormal laboratory  values shoul d be repeated as clinically  
indicated and recorded on the eCRF.
Thefollowing l
aboratory  variables will be measured:
Table 2 Laboratory Safety Variables
Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
B-Haemoglobin S-Sodium
B-Red blood cells [RBC] S-Potassium
B-Platelets S-Magnesium (baseline only and if clinically 
indicated)
B-Mean cell volume [MCV] S-Calcium 
B-Mean cell haemoglobin concentration [MCHC] S-Creatinine
B-Mean cell haemoglobin [MCH] S-Total bilirubin
B-White blood cells [WBC] S-Gamma glutam yltransferase [GGT] 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_642984] 2019
70(133)Haematology/Haemostasis (whole blood) Clinical Chemistry (serum or plasma)
B-Absolute differential white cell count
(neutrophils, lymphocytes, monocytes, 
eosinophils and basophils) and absolute 
neutrophil count or segmented neutrophil 
count and Band forms should be 
performed at each visit and when clinically
indicated. If absolute differentials not 
available please provide % differentials.S-Aalkaline phosphatase [ALP]
S-Aspartate transaminase [AST]
S-alanine transaminase [ALT]
S-Urea or blood urea nitrogen [BUN]
S-Total protein
S-Albumin
S-Lactate dehydrogenase (LDH)
Urine Tests
Urinalysis (Dipstick, baseline only and if clinically 
indicated)
U-Hb/Erythrocytes/Blood
U-Protein/Albumin
U-Glucose
Urinalysis (Microscopic analysis, baseline only 
and if clinically indicated)
The Investigator should make an assessment of the available results with regard to clinically 
relevant abnorm alities.  The l aboratory  resul ts shoul d be si gned and dated and retained at 
centre as source data for laboratory  variables.  For informat ion on how AEs based on 
laboratory  tests shoul d be recorded and reported, see Section 5.2.
NB. In case a patient shows an AST orALT ≥3xULN ortotal bilirubin ≥ 2xULN pl ease refer 
to Appendix D ‘Actions required in cases of co mbined increase o f Aminotransferase and Total 
Bilirubin –Hy’s Law’, for further instructions.
For bl ood vol ume see Secti on 5.6.1 .
5.2.2 Physical examination
For timing o f individual measurement refer to study schedule ( Table 1).
A physical examinat ion will be performed and include an assessment of the fo llowing: general  
appearance, respi[INVESTIGATOR_696] , cardi ovascular, abdom en, skin, head and neck (including ears, eyes, 
nose and throat), lymph nodes, thy roid, abdomen, muscul o
-skeletal  (including spi[INVESTIGATOR_499460]) and neuro logical systems.
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642985] 2 0 1 9 
7 1( 1 3 3)  
 
 
 
 
 
5. 2. [ADDRESS_642986] u d y da ys w he n t he y  are c ollecte d. 
E C Gs will be rec or de d at 2 5 m m/sec.  All E C Gs s h o ul d be assesse d b y t he i n vesti gat or as t o 
w het her t he y  are cli nicall y  si g nifica nt l y a b n or mal / n ot cli nicall y si g nifica ntl y a b n or mal.  If 
t h ere is a cli nicall y si g nifica nt a b n or mal fi n di n g, t he i n vest i gat or will rec or d it as a n A E o n t he 
e C R F.  T he ori gi nal E C G traces m ust be st ore d i n t he pat ie nt  m e dical  rec or d as s o urce data. 
5. 2. [ADDRESS_642987] 2019
72(133)[IP_ADDRESS] Pulse and blood pressure
Blood pressure and pulse rate will be measured preferably  using a semi  autom atic BP 
recording device wit h an appropriate cuff size.
[IP_ADDRESS] Body temperature
Body  temperature will be measured in degrees Celsi us using an autom ated therm ometer.
5.2.6 Other safety assessments
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, coagulati on, 
and urinalysis will be taken at the times indicated in the Study  Schedule (see Table 1).
These tests will be performed by [CONTACT_5035][INVESTIGATOR_307]’s local laboratory .  Addi tional analyses may  be 
perform ed if clinically  indicated. 
Any clinically  significant abnormal laborato ry values shoul d be repeated as clinically  
indicated and recorded on the eCRF.
[IP_ADDRESS] Serum or urine pregnancy test
Pregnancy tests on blood or urine samples will be performed for women of childbearing 
potenti al within 28 days pri or to the start of study  treatm ent, on Day  1 of the study  prior to 
commencing treatment, at the time po ints shown in Table 1during study  treatm ent. Tests will 
be perform ed by [CONTACT_5035][INVESTIGATOR_307]’s local labo ratory . If resul ts are posi tive the patient is 
ineligible/must be discontinued from study  treatm ent immediately.  Details o f the pregnancy  
tests must be recorded in the patient’s medical records.
Any changes in vital signs should be recorded as an AE, if a
pplicable.
5.2.[ADDRESS_642988] 2 0 1 9 
7 3( 1 3 3) 5. [ADDRESS_642989] 2 0 1 9 
7 4( 1 3 3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C CI C CI 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642990] 2 0 1 9 
7 5( 1 3 3)  
 
 
  
  
  
 
  
 
 
 
 
 
 
 
 C CI 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642991] 2 0 1 9 
7 6( 1 3 3)  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642992] 2 0 1 9 
7 7( 1 3 3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642993] 2 0 1 9 
7 8( 1 3 3) P ati e nts will  b e re q ui re d t o pr o vi de: 
  
 
 
 
 
 
 
5. [ADDRESS_642994] ete scree ni n g, 6 c y cles of treat m e nt, a 
treat m e nt disc o nt i n uat i o n visit a n d t he 3 0 -d a y  f ol l o w -u p visit, is 2 5 5 m L. 
S af et y la b orat or y  assess me nts will be perf or me d l o call y at eac h ce ntre’s la b orat or y  b y  m ea ns 
of  t h ei r esta blis he d met h o ds.  T he n u m ber of sa m ples/ bl o o d v ol u mes is t heref ore patie nt t o 
si t e -s pecific c ha n ge.  E x tr a bl o o d sa m ples ma y  al s o be c ollecte d if, f o r e xa m ple, a d dit i o nal 
sa m ples are re q uire d f or re peat safet y assess me nts. 
T he t otal v ol u me o f bl o o d t hat will be dra w n fr o m eac h patie nt i n t his st u d y  i s as f o ll o ws: C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_642995] 2 0 1 9 
7 9( 1 3 3) T a ble [ADDRESS_642996] a w n fr o m e ac h p atie nt 
Assess m e nt S a m ple v ol u me 
( m L) N o. of 
s a m ples T ot al v ol u me 
( m L) 
Safet y Cli nical c he mistr y [ADDRESS_642997] (retr os pecti ve/ pr os pecti ve) 
W h ole bl o o d sa m ple f or assess me nt of 
c urre nt a n d f ut ure B R C A m utati o n 
assa y(s) [ADDRESS_642998] (site ma y use uri ne 
i nstea d) Site de pe n de nt Site ma y use 
uri ne i nstea d 
 
 
 
 
 
T otal [ADDRESS_642999] Pati e nt’s Last Vi si t i n t he st u d y .  
T he res ults fr o m f ut ure a nal ysis will n ot be re p orte d i n t he Cli nical St u d y  Re p ort b ut 
se paratel y  i n a Sci e nt ific Re p ort. 
5. 6. [ADDRESS_643000] i gat or e ns ures t hat sa m ples are la belle d a n d s hi p pe d i n acc or da nce wit h 
t h e La b orat or y  Ma n ual a n d t he Bi o l o gi cal  S u bsta nce, Cate g or y  B Re g ulati o ns ( m at eri als 
c o ntai ni n g or s us pecte d t o c o ntai n i nfect i o us s u bsta nces t hat d o n ot m eet Cate g or y  A cri t eri a), C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643001] 2019
80(133)Any samples ident ified as Infect ious Category  A materi als are not shipped and no further 
samples will be taken from the patient unless agreed with [COMPANY_008] and appropriate 
labelling, shipment and containment provisio ns are app roved.
5.6.[ADDRESS_643002] orage at the centre until shipment or disposal (where appropriate) 
and keeps documentation of receipt of arrival.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps documentation of receipt of arrival.
[COMPANY_008] keeps oversight of the ent ire life cycle through internal procedures, monitoring o f 
study  sites and audi ting of  external  laboratory  providers.
Samples retained for further use are registered in th e [COMPANY_008] bio bank system during the 
entire life cycle.
If required, [COMPANY_008] will ensure that remaining bio logical samples are returned to the site, 
according to local regulations or at the end of the retention period, whichever is the sooner.
5.6.5 Withdrawal of informed consent for donated biological samples
If a patient withdraws consent to the use of donated bio logical samples, the sam ples will  be 
disposed of/destroy ed, and the acti on documented.  If samples are already  analysed ,
[COMPANY_008] is not obliged to destroy  the resul ts of this research.
gBRCA sample: As collect ion of the bio logical  samples is an integral  part of the study , then 
the pati ent is withdrawn from  further study  parti cipati on.
Archival tumour sample: If consent to use the sample is withdrawn this will not impact 
eligibilit y to study . The pati ent m ay cont inue in the study  if the pati ent is already  randomised.
Blood sam ples f or biomarker analysis: Although mandatory , the patient m ay continue in the 
study  if the pat ient is already rando mised.
The Principal Invest igator:
 Ensures pat ients’ withdrawal of informed consent to the use of donated samples is 
notified immediately to [COMPANY_008]
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643003] 2019
81(133) Ensures that bio logical samples from that patient, if stored at the study  site, are 
immediately  identified, disposed of /destroy ed, and the action documented
 Ensures the laboratory  (ies) hol ding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed/destroyed, the action 
docum ented and the sign ed docum ent returned to the study  site
 Ensures that the patient and [COMPANY_008] are informed about the sample disposal.
[COMPANY_008] ensures the central laboratory  (ies) holding the samples is/are informed about the 
withdrawn consent immediately and that sa mples are disposed of/destroy ed and the act ion 
docum ented and returned to the study  site.
6. SAFETY REPORTING AND MEDICAL MANAGEMENT
The Principal Invest igator is responsible for ensuring that all staff invo lved in the study  are 
familiar wit h the content of t his sect ion.
6.[ADDRESS_643004] a 
causal relat ionship with this tre atment.  An AE can therefore be any unfavourable and 
unintended sign (e.g.  an abnormal laboratory  finding), symptom (for example nausea, chest 
pain), or disease temporally associated with the use of a medicinal product, whether or not 
considered related t o the medicinal product.  
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence.  An AE may occur at any  time, including 
run-in or washout periods, even if no study  treatm ent has been administered.
6.2 Definitions of serious adverse event
A serious adverse event is an AE occurring during any study  phase (ie, run -in, treatment, 
washout, follow -up), that fulfils one or more of the fo llowing cri teria:
Results in death
Is immediately l ife-threatening
Requi res in -patient hospi [INVESTIGATOR_499461]_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643005] 2019
82(133)Results in persistent or significant disabilit y/incapacit y or substantial disrupt ion 
of the abilit y to conduct norm al life f unctions
Is a congenital abnormalit y or birth defect
Is an important medical event that may jeopardise the patient or may require 
medical intervention to prevent one of the outcomes listed above.
Adverse Events (AEs) for malignant tumours reported during a study  shoul d generally  be 
assessed as Seri ous AEs. If no other seriousness criteria apply, the ‘Important Medical Event’ 
criterion shoul d be used. In certain situat ions, however, medical judgement on an individual 
event basis should be applied to clarify that the malignant tumour event sho uld be assessed 
and reported as a Non -Serious AE. For example, if the tumour is included as medical history  
and progression occurs during the study , but the progressi on does not change treatment and/or 
prognosi s of the m alignant tum our, the AE m ay not fulf ill the attributes for being assessed as 
Serious, al though reporting of the progression of the malignant tumor as an AE is valid and 
shoul d occur. Al so, som e types of  malignant tum ours, whi ch do not spread remotely after a 
routi ne treatm ent that does not r equire hospi[INVESTIGATOR_3094], may be assessed as Non -Serious; 
examples include Stage [ADDRESS_643006] ion is a new 
malignant t umour (i.e., it is not the tumour for which entry into the study  is a cri terion and that 
is being treated by  [CONTACT_499482] ). Malignant tum ours that –as part of normal, if 
rare, progression –undergo transformat ion (e.g., Richter's transformat ion of B cell chronic 
lymphocy tic leukemia into diffuse large B cell lympho ma) should not be considered a new 
malignant tumour.
For further guidance on the definit ionof a SAE, see 
Appendix B to the Clinical Study  
Protocol .
6.3 Recording of adverse events
6.3.1 Time period for collection of adverse events
Adverse Events will be co llected fro m time of signature [CONTACT_499505] 30 -day follow-up peri od.  All ongoing and any  new 
AEs/SAEs ident ified during the [ADDRESS_643007] be fo llowed to resol ution. After any interim analysis, any  ongoing AEs/SAEs 
need to be unlocked and fo llowed for resol ution.
SAEs will be recorded from the time of informed consent.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643008] 2019
83(133)[IP_ADDRESS] Adverse events after the [ADDRESS_643009] igator learns of any SAE 
including sudden dea th of unknown cause, and he/she considers there is a reasonable 
possibilit y that the event is causally related to the investigational product, the invest igator 
shoul d notify [COMPANY_008], Patient Safet y.
If pat ients who are gaining clinical benefit are allo wed to continue study  treatment post data 
cut off and/or post study  com pletion (after DCO3) then all SAEs must continue to be collected 
and reported to Patient Safet y within the usual timeframe. After study  com pletion (after 
DCO3) SAE reporting to be fo llowed using paper reporting process.
Otherwi se, after study  treatm ent com pletion (i.e. after any  scheduled post treatm ent follow-up 
period has ended) there is no obligation to actively report information on new AEs or SAEs 
occurring in former study  patients.This includes new AEs/SAEs in pat ients still being 
followed up for survival but who have co mpleted the post treatment fo llow up peri od (30 
days).
6.3.[ADDRESS_643010] additional informat ion for any  patient 
with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.
6.3.[ADDRESS_643011] for each AE;
AE (verbat im)
The date when the AE started and stopped
Whether the AE is serious or not
Invest igator causalit y rating against the Investigat ional Product (yes or 
no)Act ion taken with regard to invest igational product
Outcom e.
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for seri ous AE
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643012] 2019
84(133)Date Invest igator became aware of serious AE
AE is seri ous due to
Date of hospi[INVESTIGATOR_72913]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to Study  procedure(s)
Causalit y assessment in relat ion to Other medication
Descript ion of AE.
It is important to d istinguish between serious and severe AEs.  Severit y is a measure of 
intensity whereas seri ousness is defined by [CONTACT_362028] 6.2.  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Section 6.2. On the other hand, a stroke that results in only  a limi ted degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Section 6.2.
Severity of AE
For each epi[INVESTIGATOR_367384], all changes to the CTCAE grade attained as well as the 
highest attained CTC grade should be reported.
It is important to dist inguish between serious and severe AEs.  Severit y is a measure of 
intensity whereas seri ousness is defined by [CONTACT_362028] 6.2.  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE. On the other hand, a stroke 
that resul ts in only  a limi ted degree of di sabili ty may  be considered a mild stroke but would be 
a SAE .
The grading scales found in the National Cancer Institute (NCI) CTCAE versio n 4.[ADDRESS_643013] 2019
85(133)A copy  of the CTCAE versio n can be downloaded fro m the NCI website.
6.3.[ADDRESS_643014] and each 
Adverse Event, and answer ‘yes’ or ‘no’ to the question ‘Do y ou consi der that there is a 
reasonable possibilit y that the event m ay have been caused by  [CONTACT_286661]?’
For SAEs causal relationship will also be assessed for other medicat ion and study  procedures.  
Note that for SAEs that could be associated with any  study  procedure the causal relationship is 
implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in 
Appendix B to the Clinical 
Study  Protocol .
6.3.5 Adverse events base d on signs and symptoms
All AEs spontaneously reported by  [CONTACT_427394]: ‘Have you had any health problems since the previous visit/you 
were last asked?’ , or reveal ed by  [CONTACT_499483].  
When co llecting AEs, the recording of diagnoses is preferred (when possible) to recording a 
list of signs and symptoms.  However, if a diagnosis is known and there are other signs or 
symptoms that are not generally pa rt of the di agnosis, the diagnosis and each sign or symptom 
will be recorded separately.
6.3.6 Adverse events based on examinations and tests
The reporti ng of laboratory /vital signs/ECG abnormalit y as AE shoul d be avo ided unless one 
of the fo llowing is met:
Any criterion for an SAE i s fulfilled
Causes study  treatm ent discont inuation
Causes study  treatm ent interruption
Causes study  treatm ent dose reduction
The invest igator believes that the abnormalit y shoul d be reported as an AE
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion.  Wherever possible the reporting invest igator 
uses t he clinical, rather than the laboratory  term  (eg, anaemia versus low haemoglo bin value). 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081 FC00001
Edition Number [ADDRESS_643015] 2019
86(133)In the absence of clinical signs or symptoms, clinically relevant deteriorations in non -
mandated parameters should be reported as AE(s).
Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE.
NB. Cases where a patient shows an AST orALT ≥3xULN ortotal bilirubin ≥ 2xULN may  
need to be reported as SAEs, please refer to 
Appendix D ‘Act ions required in cases of 
combined increase o f Aminotransferase and Total Bilirubin – Hy’s Law’, for further 
instructi ons.
6.3.7 Hy’s Law
Cases where a patient shows an AST orALT ≥3xULN ortotal bilirubin ≥ 2xULN may  need 
to be reported as SAEs. Please refer to Appendix D for further instruction in cases of 
combined increase o f aminotransferase and total bilirubin.
6.3.8 Disease progression
Disease progressi on can be considered as a worsening of a patient’s condit ion attributable to 
the disease for which the invest igational product is being studied.  The development of local 
regional recurrence or di stant metastasi s to the prim ary cancer under study  shoul d be 
considered as disease progression and not an AE.  Events, which are unequivocally due to 
disease progressi on, shoul d not be reported as an AE during the study .
New cancers
The development of a new primary cancer (including skin cancer) should be regarded as an 
AE and will generally meet at least one of the serious criteria (see Sect ion 6.2).  New primary  
cancers are those that are not the primary reason for the administration of the study  treatm ent 
and have developed after the inclusion o f the pati ent into the study .  They  do not include 
metastases of the original cancer.  Symptoms of metastasis or the metastasis itself should not 
be reported as an AE/SAE, as they  are consi dered to be disease progression.
Lack of efficacy
When there is deterioration in the cancer, for which the study treatment(s) is being used, there 
may be uncertaint y as to whether this is lack o f efficacy or an AE.  I n such cases, unless the 
Sponsor or the reporting physician considers that the study  treatm ent contributed to the 
deteri oration of  the condi tion, or l ocal regul ations state to the contrary , the deteri oration 
shoul d be considered to be a lack of efficacy an d not an AE.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643016] 2019
87(133)Deaths
All deaths that occur during the study , or wi thin the protocol -defined [ADDRESS_643017] be reported 
as fo llows:
 Death cl early  the resul t of disease pro gression should be reported to the study 
monitor at the next monitoring visit and should be documented in the DEATH 
eCRF but should not be reported as an SAE
 Where death is not due (or not clearly  due) to progressio n of the disease under 
study , the AE caus ing the death must be reported to the study  monitor as a SAE 
within 24 hours (see Section 6.4for further details).  The report should contain a 
comment regarding the co -involvement of progression of disease, if appropriate, 
and should assign main and contributory  causes of death.  This informat ion can be 
captured i n the ‘death eCRF’.
Deaths with an unknown cause should always be reported as a SAE.  A post mortem maybe 
helpful in the assessment of the cause of death, and if performed a copy  of the post -mortem 
resul ts shoul d be f orwarded to [COMPANY_008] wit hin the usual timeframes.
Olaparib adverse e vents of special interest
Adverse events of special interest [AESI] are events of scient ific and medical interest specific 
to the further understanding of olaparib’s safet y profile and require close monitoring and rapid 
communicat ion by [CONTACT_251615] t o [COMPANY_008]. Adverse Events of Special Interest for 
olaparib are the Important Potential Risks of MDS/AML, new primary malignancy  (other than 
MDS/AML) and pneumo nitis.  
A quest ionnaire will be sent to any  invest igator reporting an AESI, as an aid to provide further 
detailed informat ion on the event.  During the study there may be other events identified as 
AESIs that require the use of a quest ionnaire to help characterise the event and gain a better 
understanding regarding the relat ionship between the event and study  treatm ent.
6.[ADDRESS_643018], or to the study  procedure(s). All SAEs will be recorded in the CRF.
If any SAE occurs i n the course of the study , then investi gators or other si te personnel inform 
appropriate [COMPANY_008] representatives immediately, or no later than [ADDRESS_643019] 2019
88(133)The designated [COMPANY_008] representative works with the inve stigator to ensure that all the 
necessary  informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site within one
calendar day of initial receipt for fatal and life threatening events and within five calendar
days of initial receipt for all ot her SAEs.
For fatal  or life -threatening adverse events where important or relevant informat ion is missing, 
active fo llow-up is undertaken immediately .  Investi gators or other site personnel inform 
[COMPANY_008] representatives of any  follow-up informat ion on a previously  reported SAE 
immediately , or no later than [ADDRESS_643020] igators or other site personnel indicate an AE is serious in the WBDC system, 
an autom ated email alert is sent to the designated AstraZe neca representative.
If the WBDC system is not available, then the Investigator or other study  site personnel  
reports a SAE to the appropriate [COMPANY_008] representative by [CONTACT_756].
The [COMPANY_008] representative will advise the Investigator/study  site personnel how to 
proceed
6.4.[ADDRESS_643021] itutional Review Boards (IRB)/Independent Ethics Committees 
(IEC), and invest igators.
For all studies except those utilizing medi cal devices investigator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regul atory  requi rements and sponsor policy and forwarded to invest igators as necessary.
An invest igator who receives an i nvest igator safety report describing a SAE or other specific 
safet y informat ion (e.g., summary  or list ing of SAEs) from the sponsor will review and then 
file it along wit h the Invest igator’s Brochure or and will notify the IRB/IEC, if appropriate 
according to local requi rements.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643022] 2019
89(133)6.[ADDRESS_643023] only  be used in accordance wit h the dosing recommendat ions in this protoco l. 
Any dose or frequency  of dosing that exceeds the dosing regimen specified in this protocol 
shoul d be reported as an overdose. The Maximum Tolerated Dose is 300 mg twice daily  
(tablet).
Adverse reactions associated with overdose should be treated symptom atically and should be 
managed appropriately. 
An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the relevant 
AE m odules in the CRF and on the Overdose CRF module.
An overdose without associated symptoms is only  reported on the Ov erdose CRF m odule.
If an overdose on an [COMPANY_008] study  drug occurs in the course of the study , then 
Invest igators or other site personnel inform appropriate [COMPANY_008] representatives 
immediately , or no l ater than [ADDRESS_643024] reporting timelines apply (se e Sect ion 6.4).  For 
other overdoses, reporting should be done within [ADDRESS_643025] iveness of a 
contraceptive medicat ion.  Congenital abnormalit ies/bi rth defects and spontaneous 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643026] 2019
90(133)miscarri ages shoul d be reported and handled as SAEs.  Elect
ive abortions without 
complicat ions should not be handled as AEs.   The outcome of all pregnancies (spontaneous 
miscarri age, el ective terminat ion, ectopic pregnancy, normal birth or congenital abnormalit y) 
occurring from the date of the first dose of study  medi cation until [ADDRESS_643027] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site wi thin 1 or 5 
calendar day s for SAEs (see Secti on6.4) and wi thin [ADDRESS_643028] dose.  Pregnancy  of the pati ent’s partners i s not considered to be 
an adverse event.  However, the outcome of all pregnancies (spontaneous miscarriage, elect ive 
termination, ectopic pregnancy, normal birth or congenital abnormalit y) shoul d if possible be 
followed up and documented.
The outcome o f any concept ion occurring fro m the date of the first dose until [ADDRESS_643029] dose should be fo llowed up and do cumented.
To capture informat ion about a pregnancy fro m the partner of a male patient, the male 
patient’s partner consent must be obtained to collect informat ion related to the pregnancy  and 
outcom e; the m ale pat ient shoul d not be asked to provide this inf ormation. A consent form 
specific to this situation must be used.
6.7 Management of toxicity of Olaparib
Any toxicit y observed during the course of the study  coul d be managed by  [CONTACT_499484] ( Table 8) Repeat dose interruptions are allowed as 
requi red, for a m aximum  of [ADDRESS_643030] 2019
91(133)6.7.1 Management of haematological toxicity Olaparib
[IP_ADDRESS] Management of anaemia
Patients can enter the study  with a haem oglobin value of > 9g/dl, this should be taken into 
account when considering the management of anaemi a. Anaemia should be managed as 
described in Table 6.
Table 6 Management of anaemia
Haemoglobin Action to be taken
Hb ≥8 g/dl (CTCAE 
Grade 1 or 2)aFirst occurrence:
Give appropriate supportive treatment and investigate causality. 
Investigator judgement to continue study treatment with supportive 
treatment (eg transfusion) orinterrupt dose for a maximum of 4 weeks. 
Study treatment can be restarted if Hb has recovered to > 9g/dl.
Subsequent occurrences:
If  Hb< 10 but≥ 9 g/dl investigator judgement to continue study treatment   
Consideration could be given to supportive treatment (eg transfusion) or
dose interrupt (for max of 4 weeks) and upon recovery dose reduction (to 
[ADDRESS_643031] step and to 200 m g twice daily as a second 
step). 
If  Hb< 9 but≥ 8 g/dl , dose interrupt (for max of 4 weeks) until Hb ≥ 9 
g/dl and upon recovery dose reduction maybe considered (to [ADDRESS_643032] step and to 200 m g twice daily as a second step). 
Hb < 8 g/dl
(CTCAE Grade 3)aGive appropriate supportive treatment (e.g. transfusion) and investigate 
causality. 
Interrupt study treatment for a m axim um of 4 weeks until improved to Hb 
≥9 g/dl.
Upon recovery dose reduce to [ADDRESS_643033] step and to 
200 m g twice daily as a second step in the case of repeat Hb decrease.
aCTCAE Version 4.
Commo n treatable causes of anaemia (e.g., iron, vitamin B12 or folate deficiencies and 
hypothy roidism ) shoul d be invest igated and appropriately managed. In some cases 
management of anaemia may require blood transfusions. If a patient has been treated for 
anaemia wit h multiple blood transfusio ns w ithout study  treatm ent interruptions and beco mes 
blood transfusio n dependant as judged by [CONTACT_1697], study treatment should be interrupted 
for up to a m aximum of [ADDRESS_643034] 2019
92(133)For cases where pat ients develop prolonged haematological toxicit y (≥2 week 
interrupti on/delay in study  treatm ent due to CTC grade 3 or worse anaemia and/or 
development of blood transfusio n dependence), refer to guidance la ter in this sect ion for the 
management of this. 
[IP_ADDRESS] Management of neutropenia, leukopenia and thrombocytopenia
Adverse event of neutropenia, leukopenia and thrombocytopenia should be managed as 
described in Table 7.  
Table 7
Management of neutropenia, leukopenia and thrombocytopenia
Toxicity Study treatment dose adjustment
CTCAE Grade 1 -2 Investigator judgement to continue treatment or if dose interruption, this 
should be for a maximum of 4 weeks; appropriate supportive treatment 
and causality investigation
CTCAE Grade 3 -4 Dose interruption until recovered to CTCAE gr 1 or better for a maximum 
of 4 weeks. If repeat CTCAE grade 3 -4 occurrence, d ose reduce <<select 
olaparib or study treatment>> to [ADDRESS_643035] igator with close fo llow up an d interruption of study  drug if CTC grade 3 or worse 
neutropeni a occurs.
Primary prophylaxis wit h Granulocyt e col ony-stimulat ing factor (G -CSF) is not 
recommended, however, if a pat ient develops febrile neutropenia, study  treatm ent shoul d be 
stopped and appropri ate m anagement including G -CSF shoul d be given according to local 
hospi [INVESTIGATOR_48799]. Pl ease note that G -CSF should not be used within at least 24 h (7 days for 
pegylated G -CSF) of the last dose of study  treatm ent unl ess absol utely necessary .
Platelet transfusio ns, if indicated, should be done according to local hospi[INVESTIGATOR_48799].
For cases where pat ients develop prolonged haematological toxicit y (≥2 week 
interrupti on/delay in study  treatm ent due to CTC grade 3 or worse), refer to guidance la ter in 
this secti on for the m anagement of thi s. 
Management of prolonged haematological toxicities while on study treatment
If a patient develops prolonged haematological toxicit y such as:
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643036] 2019
93(133) ≥2 week interruption/delay in study  treatm ent due to CTC grade 3 or worse anaemia 
and/or development of blood transfusio n dependence
 ≥2 week interruption/delay in study  treatm ent due to CTC grade 3 or worse 
neutropeni a (ANC < 1 x 109/L)
 ≥2 week interruption/delay in study  treatm ent due to CTC grade 3 or worse 
thrombocy topenia and/or development of platelet transfusio n dependence (Platelets 
< 50 x 109/L)
Check weekly  different ial blood counts including reticulocytes and peripheral blood smear. If 
any blood parameters remain clinically abnormal after [ADDRESS_643037] igations. Bone marrow analysis 
and/or blood cy togeneti c analysis should be considered at this stage according to standard 
haematological pract ice. Study treatment should be discont inued if bl ood counts do not 
recover to CTC gr [ADDRESS_643038] igator to [COMPANY_008] 
Patient Safet y. Olaparib treatm ent shoul d be discont inued if patient’s diagnosis of MDS 
and/or AML is confirmed.
6.7.2 Management of non -haematological toxicity Olaparib
[IP_ADDRESS] Management of new or worsening pulmonary symptoms 
If new or worsening pu lmonary symptom s (eg, dyspnoea) or radio logical abnorm ality occurs, 
an interrupti on in study  treatm ent dosing is recommended and a diagnostic workup (including 
a high resolut ion CT scan) should be performed, to exclude pneumonit is.  Fo llowing 
investigat ion, if no evidence of abnorm ality is observed on CT imaging and symptoms 
resolve, then study  treatm ent can be restarted, if deemed appropriate by  [CONTACT_3170].  If 
significant pulmo nary abnormalit ies are i dentified,  these need to be discussed wit h the 
[COMPANY_008] Study  Physician. 
[IP_ADDRESS] Management of nausea and vomiting
Events of nausea and vo miting are known to be associated with Olaparib treatment. In Study 
D0810C00019 nausea was reported in 71% of the Olaparib treated patients and 36% in the 
placebo treated patients and vo miting was reported in 34% of the Olaparib treated patients and 
14% in the placebo treated patients. They  are generally  mild to m oderate (CTCAE Grade 1 or 
2) severit y, intermittent and manageable on continued treatment. The first onset gener ally 
occurs in the first month of treatment for nausea and within the first [ADDRESS_643039] 2019
94(133)vomiting. For nausea, the incidence generally plateaus at around [ADDRESS_643040] onset of nausea 
or vomit ing and as required thereafter, in accordance with local treatment practice guidelines. 
As per int ernat ional guidance on ant iemetic use in cancer patients (ESMO, NCCN), generally 
a single agent antiemetic should be considered eg dopamine receptor antagonist, 
antihistamines, dexamethasone.
[IP_ADDRESS] Interruptions for intercurrent non -toxicity related events
Study treatm ent dose interrupti on for condi tions other than toxi city resol ution shoul d be kept 
as short as possible.  If a patient cannot restart study  treatm ent wi thin 4 weeks for resolut ion 
of intercurrent condit ions not rel ated to di sease progressio n or toxi city, the case shoul d be 
discussed wi th AZ study  physician.
All dose reductions and interruptions (including any missed doses), and the reasons for the 
reducti ons/interrupti ons are to be recorded in the eCRF.
Study  treatm ent shoul d be stopped at l east [ADDRESS_643041] 
interruption: Dose reduction 1Dose reduction 2
300 mg twice daily 250 mg twice daily 200 mg twice daily
6.7.3 Management of toxicity on placebo
Adverse events on placebo will be handled in the same manner as those arising on Olaparib 
(see sect ions 6.7)
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643042] 2019
95(133)6.7.4 Renal impairment
If subsequent to study  entry  and while still on study  therapy , a pati ent’s est imated CrCl falls 
below the thresho ld for study  inclusio n (≥51 ml/min), retesting should be performed prompt ly. 
A dose reduction is reco mmended for patients who develop moderate renal impairment 
(calculated creatinine clearance by [CONTACT_3158] -Gault equation or based on a [ADDRESS_643043] 
of between 31 and 50 ml/min) for any  reason during the course of the study : the dose of 
olaparib shoul d be reduced to [ADDRESS_643044] ion, in instances where the 
CrCl  falls to between 31 and 50 mL/min, the investigator should use his or her discretion in 
determining whether a dose change or discont inuatio n of therapy  is warranted .
Olaparib has not been studied in pat ients with severe renal impairment (creatinine clearance ≤ 
30 ml/min) or end -stage renal disease; if patients develop severe impairment or end stage 
disease is i t recommended that ol aparib be di scontinued.
6.8 Study govern ance and oversight
6.8.1 Data Monitoring Committee
This study  will use an external independent data monitoring committee (IDMC) to perform 
interim reviews of accumulat ing study  safet y data and the interim analyses for fut ility based 
on PFS.  
This committee will be co mposed of therapeutic area experts and statist icians, who are not 
employed by  [CONTACT_324575], and do not have any major conflict of interest.  Following the review the 
IDMC will reco mmend whether the study should continue unchanged, be terminated, or be 
modified in any way.  Once the IDMC has reached a recommendat ion, a report will be 
provi ded to [COMPANY_008].  The report will only  include the recommendat ion and any  potenti al 
protocol  amendments and will not contain any unblinding informat ion.
A separate IDMC char ter will  be devel oped which will  contain details of the IDMC members 
and clearly  define the responsibilit ies of the IDMC.
7. INVESTIGATIONAL PROD UCT AND OTHER TREATM ENTS
7.[ADDRESS_643045](s)
[COMPANY_008]’s Pharmaceut ical Development, R&D Supp ly Chain will supply Olaparib and 
matching placebo to the Investigator as film -coated tablets as shown below.
Revised Clinical Study Pr otocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643046] 2019
96(133)Investigational product Dosage form and strength
OlaparibaTablet –100mg and 150 mg 
Placebo to match Olaparib Tablet to match each strength of Olaparib
aDescriptive information for Olaparib can be found in the Investigator’s Brochure
7.2 Dose and treatment regimens
Study  treatm ent is available as a green film -coated tablet containing 150 m g or 100 m g of 
Olaparib or matching placebo.
For all centres , Olaparib and m atching placebo will be packed in high- densi ty polyethylene 
(HDPE) bottles with child -resistant cl osures.  The randomised study  treatm ent will  be 
dispensed to pati ents.  Each dosing container will contain sufficient medicat ion for at least 
each treatment period plus overage.  The planned dose of 300 mg bid will be made up of two 
(2) x 150 m g tabl ets bid wi th 100 m g tablets used to manage dose reductions.  Tablets should 
be taken at the same t imes each morning and evening of each day, approxi mately  12 hours 
apart with approximately  240 mL of water.  The Olaparib tablets should be swallowed who le 
and not chewed, crushed, disso lved or divided.  Olaparib tablets can be taken wit h a light 
meal/snack (eg, two pi[INVESTIGATOR_367387] a couple of biscuits ). Mul tiple bottl es of Olaparib or 
matching placebo maybe required for dispensing in order to make up the desired dose. 
No cross over to Olaparib will be provided in this study . 
If vomiting occurs shortly after the Olaparib tablets are swallowed, the dos e should only be 
replaced if all o f the intact tabl ets can be seen and counted.  Should any pat ient enrolled on the 
study  miss a scheduled dose for whatever reason (eg, as a result of forgetting to take the 
tablets or vomit ing), the patient will be allowed to take the scheduled dose up to a maximum 
of [ADDRESS_643047] igator. If a patient is continuing to derive benefit from o laparib at 
the end of the study  (at DCO3), then they  may continue to receiv e treatment as open labelled 
drug vi a manual  supply  outsi de of  the study  setting once the IVRS/IWRS has been closed. 
7.3 Labelling
Labels for Olaparib will be prepared in accordance with Good Manufacturing Practice (GMP) 
and local regulatory  guidelines.  The labels will fulfil GMP Annex [ADDRESS_643048] 2019
97(133)Specific dosing instructions will not be included on the label; the site must complete the 
“Patient Dispensing Card” with the details of the do sing instructi ons at the time of dispensing.  
The patient emergency contact [CONTACT_76446], unless it is a country -specific 
regul atory  requi rement, but can be found in the informed consent and the ‘Patient Dispensing 
Card’.  For emergency purposes the patient must be in possessio n of the emergency contact 
[CONTACT_499485] t imes.
7.[ADDRESS_643049] 
label on the Olaparib bottle and the IB specifies the appropriate storage condit ions. 
7.5 Compliance
The administration of all study  drugs (including Olaparib and placebo) should be recorded in 
the appropriate sections o f the eCRF.
Patients shoul d be given clear instructions on how and when to take their Olaparib.  Patients 
will self -administer Ol aparib.  Study  site staff will make tablet counts at regular intervals 
during treatment.  Compliance will be assessed by [CONTACT_499486].  After the tablet count has been performed, 
the rem aining tablets will not be returned to the patient, but will be retained by  [CONTACT_499487].  All  patients must 
return their bottle(s) of Olaparib at the appropriate scheduled visit, when a new bottle will be 
dispensed.  Pati ents will be instructed to notify  study  site personnel  of missed doses.  Dates of 
missed or hel d doses will be recorded by  [CONTACT_499488].
Patients m ust return all containers and any  remaining tablets at the end of the study .
7.[ADDRESS_643050] 2019
98(133)7.7 Concomitant and other treatments 
Any medicat ions (with the detailed exceptions) which are considered necessary for the 
patient's welfare, and which i t is believed will not interfere with the study  medicat ion, may be 
given at the discret ion of the investigator, providing the medicat ions, the doses, dates and 
reasons for administration are recorded.
In addit ion, any unplanned diagnost ic, therapeut ic or surgical procedure performed during the 
study  period m ust be recorded.  This includes any blood transfusio ns.
The reasons for the use, doses and dates of treatment should be recorded in the patient’s 
medical records and appropriate sections of the eC RF.
All medications (prescript ions or over the counter medicat ions) continued at the start of study  
or started during the study  or until [ADDRESS_643051] be documented.
7.7.1 Medicat ions that m ay NOT be administered
No other anti -cancer therapy  (chem otherapy , immunotherapy , horm onal therapy  (Horm one 
replacement therapy  (HRT) i s acceptable), radiotherapy , biological  therapy  or other novel  
agent) is to be permitted while the patient is receiving study  medicati on.
Live virus and bacterial vaccines should not be administered whilst the patient is receiving 
study  medicat ion and during the [ADDRESS_643052] ion by 
[CONTACT_499489] o f live virus and bacte rial vaccines has been observed with convent ional 
chemotherapy drugs and the effects with Olaparib are unknown.
7.7.2 CYP3A4/5 restrictions 
The use of any  natural /herbal  products or other “folk remedies” should be discouraged but use 
of these products, as well as use of all  vitamins, nutri tional supplements and all other 
concomitant medicat ions must be recorded.
Olaparib is an invest igational drug for which no data on in vivo interact ions are current ly 
available.  Based on in vitro data and clinical exposure dat a, Olaparib is considered unlikely to 
cause clinically  significant drug interactions through inhibit ion or i nducti on of  cytochrom e 
P450 enzyme activit y.  In vitro data have, however, also shown that the principal enzyme 
responsible for the format ion of the 3 main metaboli tes of  Olaparib is CYP3A4/5 and 
consequent ly, to ensure patient safet y, the fo llowing potent inhibitors of CYP3A4/[ADDRESS_643053] 2019
99(133)While this is not an exhaust ive list, i t covers the k nown potent inhibitors, which have most 
often previously been reported to be associated with clinically  significant drug interactions:
 ketoconazo le, itraconazole, ritonavir, idnavir, saquinavir, telithro mycin, 
clarithromycin and nelfinavir 
For pati ents ta king any o f the above, the required wash -out peri ods pri or to starti ng Olaparib 
is one week.
In addit ion, to avoid potential reduct ions in exposure due to drug interactions, the fo llowing 
CYP inducers should be avo ided:
 Phenyto in, rifampi[INVESTIGATOR_2513], rifapentin, r ifabutin, carbamazepi[INVESTIGATOR_050], phenobarbitone, 
nevirapi[INVESTIGATOR_050], modafinil and St John’s Wort (Hy pericum  perforatum ) 
For pati ents taking any  of the above, the required wash -out peri ods pri or to starti ng Olaparib 
are phenobarbitone 5 weeks, and for any  of the others, 3 weeks.
After rando misat ion if the use of any potent CYP inducers or inhibitors of CYP3A4/5 are 
considered necessary  for the pati ent’s safet y and welfare, the invest igator must contact [CONTACT_499490].  A decisio n to allow the patient to c ontinue in the study  will be 
made on a case -
by-case basis.
7.7.3 Other concomitant treatment
Other medication other than that described above, which is considered necessary  for the 
patient’s safet y and well being, may  be given at the di scret ion of the Invest igator and recorded 
in the appropriate sections of the Case Report Form.
7.7.4 Anti-emetics/ Anti -diarrhoeals
Shoul d a pati ent devel op nausea, vomit ing and/or diarrhoea, then these symptoms should be 
reported as AEs (see section 6.3) and appropri ate treatm ent of the event given.
7.7.5 Anticoagulant Therapy
Patients who are taking warfarin may participate in this trial; however, it is recommended that 
prothrombin t ime (INR and APTT) be monitored carefully at least once per week for the first 
month, then monthly if the INR is stable.  Subcutaneous heparin is permitted.
7.7.[ADDRESS_643054] 2019
100(133)Treatment with bisphosphonates or RANKL inhibitor for the prevent ion of skeletal related 
events in pat ients with bone metastasi s is permitted and must be started at least [ADDRESS_643055] and subsequent therapi[INVESTIGATOR_499462], will be 
collected.   Response to subsequent therapi[INVESTIGATOR_499463].
The cho ice of subsequent system ic anticancer treatment will be entirely at the discret ion of the 
investigator although it is expected that many/most patients upon progression on study  will be 
treated with a platinum based regimen
8. STATISTICAL ANALYSIS AND SAMPLE SIZE 
DETERMINATION BY [CONTACT_499491]
8.1 Statistical considerations
 All personnel invo lved wit h the analysis o f the study  will remain blinded unt il 
database lock and protocol vio lators ident ified. Please refer to Section 3.7.
 Analyses will be performed by [CONTACT_244979]. 
 A co mprehensive statist ical analysis plan (SAP) will be prepared and finalised 
before first patient in (FPI).
8.2 Definitions of analysis sets
Table 9gives a summary  of outcom e variables and analysis populat ions
8.2.1 Full analysis set
Intention to treat (ITT) : The primary  statistical  analysis o f the efficacy of Olaparib will 
include all ra ndomised pat ients and will co mpare the treatment groups on the basis o f 
rando mised treatment, regardless of the treatment actually received.  Patients who were 
rando mised but did not subsequent ly go on to receive study treatment are included in the Full 
Analysis Set (FAS). Therefore, all efficacy and health -related QoL data will be summarised 
and analysed using the FAS on an intent ion-to-treat (ITT) basis. 
In addit ion, key  sensi tivity analyses of efficacy  endpoints will be performed in the subgroup 
of patients in the FAS that have a g BRCA mutation confirmed by [CONTACT_499492].
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643056] 2 0 1 9 
1 0 1( 1 3 3) 8. 2. [ADDRESS_643057] i o ns, 
err o ne o usl y treate d Ola pari b patie nts (t h ose ra n d o mise d t o Ola pari b b ut act uall y gi ve n 
pl ace b o at a n y  ti me) will be acc o u nte d f or i n t he Ola pari b treat me nt gr o u p.  Err o ne o usl y 
treate d place b o patie nts (t h ose ra n d o mise d t o place b o b ut act uall y recei ve d at least o ne d ose 
of  Ol a pari b) will be acc o u nte d f or i n t he Ola pari b treat me nt gr o u p. 
 
T a ble 9 S u m m ar y of O utc o me V ari a bles a n d A n al ysis P o p ul ati o ns 
O utc o me V ari a ble P o p ul ati o ns 
Effic ac y D at a 
-Pri mar y: P F S F A S  (I T T), M yria d c o nfir me d B R C A m s u b gr o u p 
-Sec o n dar y e n d p oi nts t o be a nal yse d: 
O S, P F S 2, ti me t o first s u bse q ue nt t hera p y 
( T F S T), ti me t o sec o n d s u bse q ue nt t hera p y 
( T S S T), ti me t o treat me nt disc o nti n uati o n ( T D T) F A S  (I T T), M yria d c o nfir me d B R C A m s u b gr o u p 
  
 
-Sec o n dar y e n d p oi nts t o be s u m marise d: 
-O bjecti ve res p o nse rate F A S  (I T T) ( patie nts wit h meas ura ble disease at 
baseli ne o nl y) , M yria d c o nfir me d B R C A m 
s u b gr o u p 
-Disease c o ntr ol rate F A S  (I T T), M yria d c o nfir me d B R C A m s u b gr o u p 
De m o gra p h y F A S (I T T) 
Safet y Data 
-E x p os ure Safet y 
-A d verse E ve nts Safet y 
-La b meas ure me nts Safet y 
-Vital Si g ns Safet y C CI 
C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643058] 2019
102(133)8.3 Calculation or derivation of efficacy variable(s)
At each visit patients will be assigned a RECIST visit response of CR, PR, SD, PD, NE, NED 
depending on the status of their disease compared to baseline and previous assessments, based 
on the BICR review. This will be repeated using the Invest igator assessed RECIST data.
8.3.1 Prim ary endpoint (PFS)
PFS i s defined as the time from randomisat ion unt il the date of object ive radio logical disease 
progression according to modified RECIST 1.1 or death (by  [CONTACT_499493]) regardl ess of whether the patient wit hdraws fro m rando mised therapy or 
receives another ant icancer therapy prior to disease progression.  Patients who have not 
progressed or died at the time of analysis will be censored at the time of the latest date of 
assessment fro m their last evaluable RE CIST assessment.  However, if the pat ient progresses 
or dies after two or m ore missed visits, the patient will be censored at the time of the latest 
evaluable RECIST assessment. If the patient has no evaluable visits or does not have a 
baseline assessment they will be censored at day  1 unless they  die wi thin two tum our 
assessment visits of rando misat ion (17 weeks allo wing for visit window).
The PFS time will always be derived based on scan/assessment dates not visit dates.
RECIST assessments/scans contributing towards a particular visit may  be perform ed on 
different dates. The fo llowing rul es will  be applied :
a)Date of progression will be determined based on the earliest of the RECIST 
assessment/scan dates of the component that triggered the progressi on
b)When censoring a patient for PFS the patient will be censored at the latest of the 
RECIST assessment/scan dates contribut ing to a particular overall visit assessment
Overall visit assessments will be determined for each assessment (scheduled or unschedu led) 
and will contribute to the derivat ion of PFS.
Object ive progression is defined as at least a 20% increase in the sum o f the diameters of the 
target lesio ns (compared to previous minimum sum) and an abso lute increase of > 5 mm, or an 
overall non -target lesion assessment of progression or a new lesio n. 
The primary  analysis will be based on the blinded independent central review (BICR) of the 
radiological  scans. A charter for the BICR will be developed in advance of the start of the 
study . A sensi tivity analysis based on the programmat ically derived PFS based on 
Invest igator -recorded assessments will be carried out.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643059] 2019
103(133)8.3.2 Secondary endpoints 
[IP_ADDRESS] Overall Survival
Overall survival is defined as the time from the date of rando misat ion unt il death due to any 
cause.  A ny pat ient not known to have died at the time of analysis will be censored based on 
the last recorded date on which the patient was known to be alive.
Note: Survival calls will be made in the week fo llowing the date of Data Cut Off (DCO) date 
for the analysis, and if pat ients are confirmed to be alive or if the death date is post the DCO 
date these patients will be censored at the date of DCO.
[IP_ADDRESS] Best overall RECIST response (BoR)
Best overall RECIST response (BoR) is calculated based on the overall visit responses from 
each RECIST assessment, described in 
Appendix F. It is the best response a patient has had 
after randomisat ion but pri or to starting any  subsequent cancer and prior to RECIST 
progression or the last evaluable assessment in the absence of RE CIST progressi on. 
Categorisat ion of best overall response will be based on the RECIST criteria (Appendix F) 
using the fo llowing response categories: co mplete response (CR), partial response (PR), stable 
disease (SD), No Evidence of Disease (NED; applies o nly to those patients entering the study 
with no di sease at baseline), progressive disease (PD) and not evaluable (NE).
Best overall response will be determined programmat ically based on the RECIST criteria 
using BICR data.   In addit ion, thi s will also be reported using investigator -recorded 
assessment.
For pati ents whose progression event is death, BoR will be calculated based on data up until 
the last evaluable RECIST assessment prior to death.
For pati ents who die wi th no evaluable RECIST assessments, if the death occurred ≤ 17 weeks 
(ie 16 weeks ±1 week) after randomisat ion then BoR will be assigned to the progression (PD) 
category . For pati ents who di e with no eval uable RECIST assessments, if the death occurred 
17 weeks (ie 16 weeks ±1week) after random isation then BoR will be assigned to the 
nonevaluable (NE) category .
Progression events that have been censored due to them being more than two missed visits 
after the l ast evaluable assessment will not contribute to the BoR derivation.
A pat ient will be c lassified as a responder if the RECIST criteria for a CR or PR are satisfied 
at any  time up to and including the defined analysis cut -off point. For each treatment group, 
the object ive response rate (ORR) is the number of CR and PR divided by [CONTACT_499494]_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643060] 2019
104(133)patients in the group in the FAS with measurable disease at baseline. Only pat ients with PR 
and measurable disease at enrolment can achieve an object ive response of CR or PR, other 
permissible categories of BoR are NE, PD.
The disease control rate (DCR) i s defined as the percentage of patients who have at least one 
confirmed visit response o f CR or PR or have demonstrated SD or NED for at least 15 weeks 
(ie 16 weeks ±1 week) prior to any  evidence of progressio n. In the case of SD and NED, 
follow up assessm ents m ust have m et the SD or NED cri teria for a minimum interval of 15 
weeks fo llowing rando misation.
[IP_ADDRESS] Time from randomisation to second progression (PFS2)
Time fro m randomisat ion to second progression (PFS2) is defined as the time from the date of 
rando misation to the earliest of the progression event subsequent to that used for the primary 
variable PFS or death. 
The date of second progression will be recorded by  [CONTACT_499495]; object ive radio logical or symptom atic 
progression or death. RECIST measurements will not be collected for assessment of PFS2. 
The date of the PFS2 assessment and invest igator opi[INVESTIGATOR_3078] n of progression status (progressed or 
non-progressed) at each assess ment will be recorded in the eCRF. Second progression status 
will be reviewed every  8 weeks foll owing the progressio n event used for the primary variable 
PFS (the first progression) and status recorded. Patients alive and for whom a second disease 
progres sion has not been observed should be censored at the last time known to be alive and 
without a second disease progression, ie censored at the last progression assessment date if the 
patient has not had a second progression or death).
[IP_ADDRESS] Time to first subseque nt therapy or death (TFST)
Time to start of first subsequent therapy  or death (TFST) will be assessed. TFST is defined as 
the time fro m rando misat ion to the earlier of first subsequent therapy start date following 
study  treatm ent di scontinuati on, or death. Any patient not known to have died at the time o f 
the analysis and not known to have had a further intervent ion of this ty pe will be censored at 
the last known time to have not received subsequent therapy , ie the last follow -up visit where 
this was confir med.
[IP_ADDRESS] Time to second subsequent therapy or death (TSST)
Time to start of second subsequent therapy  or death (TSST) will be assessed. TSST is defined 
as the time from randomisat ion to the earlier of the second subsequent therapy start date 
following study  treatm ent di scontinuat ion, or death. Any pat ient not known to have died at the 
time of the analysis and not known to have had a further intervention o f this type will be 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643061] 2019
105(133)censored at the last known time to have not received secon d subsequent therapy , ie the last 
follow-up visit where this was confirmed.
[IP_ADDRESS] Time to study treatment discontinuation or death (TDT)
Time to study  treatm ent discont inuat ion or death (TDT) will be assessed. TDT is defined as 
the time fro m rando misat ion to the earlier of the date of study  treatm ent di scont inuat ion or 
death. Any pat ient not known to have died at the time of analysis and not known to have 
discontinued study  treatm ent will be censored based on the last recorded date on which the 
patient was known to be alive. 
Note: Survival calls will be made in the week fo llowing the date of DCO for the analysis, and 
if pat ients are confirmed to be alive or if the death date is post the DCO date these patients 
will be censored at the date of DCO.
[IP_ADDRESS] Disease Control Rate (DCR)
The disease control rate (DCR) is defined as the percentage of patients who have at least one 
confirmed visit response o f CR or PR or have demonstrated SD for at least 16 weeks (ie 17 
weeks ±1 week) pri or to any  evidence of progression. In the c ase of SD, fo llow up 
assessments must have met the SD criteria for a minimum interval o f 16weeks fo llowing 
rando misat ion.
8.4 Calculation or derivation of safety variable(s)
Safety and tol erabilit y will  be assessed in term s of AEs, deaths, l aboratory  data, vital signs 
and ECG.  These will be co llected for all pat ients.  Appropriate summaries of these data will 
be presented.
8.4.1 Other significant adverse events (OAE)
During the evaluat ion of the AE data, an [COMPANY_008] medically qualified expert will review 
the list of AEs that were not reported as SAEs and DAEs.  Based on the expert’s judgement, 
significant adverse events of particular clinical importance may , after consul tation wi th the 
Global Patient Safet y Physician, be considered OAEs and reported as such in the Clinical 
Study  Report.  A similar review of laboratory /vital si gns/ECG data will be performed for 
ident ificat ion of OAEs.
Examples of these are marked haematological and other laboratory  abnorm alities, and certain 
events that lead to intervention (othe r than those already  classified as serious), dose reduction 
or significant addit ional treatment.
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643062] 2 0 1 9 
1 0 6 (1 3 3 ) 
 
 
 
 
 
 
 
 
 C CI 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643063] 2 0 1 9 
1 0 7( 1 3 3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C CI 
C CI C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643064] 2 0 1 9 
1 0 8( 1 3 3)  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 C CI C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola par i b   
St u d y C o de D [ADDRESS_643065] 2 0 1 9 
1 0 9 (1 3 3 ) 
 
 
 
 
 
 
 
 
 
 
 
 C CI 
C CI 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643066] 2 0 1 9 
1 1 0( 1 3 3)  
 
8. [ADDRESS_643067] atistic al a n al yses 
A si n gle i nteri m P F S a nal ysis f or f ut ilit y will be perf or m e d w he n 5 0 % of t he n u m ber of 
pr o gressi o n e ve nts re q uire d f or t he pri m ar y P F S a n al ysis has bee n reac he d (a p pr o xi matel y  
4 4 P F S e ve nts).  T he i nteri m a nal ysis will be perf or me d b y a n I n de pe n de nt Data M o nit ori n g 
C o m mittee (I D M C) a n d f ull details will be pr o vi de d i n t he I D M C c harter. A fi nal P F S 
a nal ysis will be perf or me d w he n a p pr o xi matel y 8 7 pr o gressi o n e ve nts ha ve occ urre d ( 6 0 % 
mat urit y) .  N o f urt her a nal yses of P F S are pla n ne d be y o n d t his p oi nt u nless re q ueste d b y  
healt h a ut h orit ie s
Ti mi n g of t he statist ical a n al yses are gi ve n i n Ta ble [ADDRESS_643068] atistic al a n al yses 
Ti mi n g of a n al yses O utc o me V ari a ble 
Efficac y Data 
I nteri m P F S a nal yses ( ~ 44P F S e ve nts) -P F S 
Fi nal P F S ( ~ 8 7P F S e ve nts, D C O 1) -P F S, P F S 2, T D T, T F S T, T S S T, O S, a dj uste d mea n 
c ha n ge fr o m baseli ne i n gl o bal Q o L sc ore 
Fi nal f or mal O S a nal yses ( ~ 1 0 6 O S e ve nts, 
D C O 2) -O S, P F S 2, T F S T, T S S T, a dj uste d mea n c ha n ge fr o m 
baseli ne i n gl o bal Q o L sc ore 
 
T he treat me nt c o m paris o n is Ola pari b [ADDRESS_643069] ical a nal ysis will be pre se nte d usi n g a 9 5 % c o nfi de nce i nter val a n d [ADDRESS_643070] 2019
111(133)Table 13 Formal Statistical Analyses to be Conducted and Pre -Planned 
Sensitivity Analyses
Endpoints Analysed Notes
PFS (Time from randomisation to first 
progr ession or death)Primary analysis: log- rank test using BICR data
Key sensitivity analysisa: log rank test using 
BICR data in randomised patients confirmed as 
gBRCA mutation positive by [CONTACT_499496] 
(if subset of FAS) 
Additional sensitivity analyses:
1) Evaluation time bias analysis; log -rank test
using BICR data
2) Attrition bias analysis (using alternative 
censoring rules); log -rank test using BICR data
3) Ascertainment bias analysis; log -rank test 
using investigator data
4) Deviation bias analysis (if meaningful to do); 
log-rank test using BICR data
Overall Survival (Time from randomisation to 
death due to any cause)Primary analysis: log- rank test 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by [CONTACT_499496] (if subset 
of FAS)
Supportive analysis: KM plot of time to censoring 
for OS
Second Progression Free Survival (PFS2) Primary analysis: log- rank test 
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by [CONTACT_499496] (if subset 
of FAS)
Time to treatment discontinuation (TDT) Primary analysis: log rank test of time from 
randomisation to treatment discontinuation 
Key sensitivity analysis: log rank t est using in 
randomised patients confirmed as gBRCA
mutation positive by [CONTACT_499496] (if subset 
of FAS)
Time to first subsequent therapy (TFST) Primary analysis: log rank test of time from 
randomisation to first subsequent therapy or death 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643071] 2019
112(133)Endpoints Analysed Notes
Key sensitivity analysis: log rank test using in 
randomised patients confirmed as gBRCA
mutation positive by [CONTACT_499496] (if subset 
of FAS)
Time to second subsequent therapy (TSST) Primary analysis: log rank test of time from 
randomisation to sec ond subsequent therapy or 
death 
Primary analysis: log rank test of time from 
randomisation to treatment discontinuation 
Adjusted mean change from baseline in global 
QoL score from the EORTC QLQ -C30 
questionnairePrimary analysis: mixed model for repeated 
measures (MMRM) analysis of all of the post -
baseline scores for each visit
Supportive analysis: logistic regression on global 
QoL score improvement rate.
aSee Section 8.8.3 for further details
8.8.1 Multiplicity strategy for primary and key secondary endpoints
In order to describe the nature of the benefits o f Olaparib maintenance treatment, PFS, PFS2 
and OS will be t ested at a 1- sided significance l evel of 2.5%.
However, in order to strongly control the ty pe I error at 2.5% 1 -sided, a m ultiple testing 
procedure will also be emplo yed across the primary endpo int and secondary endpo ints 
intended for key  label claims (i e OS). 
A hierarchical testing strategy  will be empl oyed where PFS is tested first using the full test 
mass (full test mass = alpha 5% 2 sided) and the key secondary endpo int of OS will then be 
tested using a mult iple testing procedure with a recycling strat egy (ie, the MTP will recycle 
the test mass to the endpo int not y et rej ected in the hierarchy outlined in Figure 2).
Figure 2 Multiple Testin g Procedures
OS will only  be tested if the null hypothesis (of no difference) is rejected for PFS. One interim 
analysis for OS will be performed at the time o f the final PFS analysis (approximately 87 PFS 
events) (DCO1).  A final formal analysis o f OS wi ll be performed when approximately [ADDRESS_643072] 2 0 1 9 
1 1 3( 1 3 3) deat h e ve nts ha ve occ urre d ( D C O 2). H o we ver, t he m ult i ple testi n g strate g y  will  n ot a p pl y  t o 
t h e  a n d o nl y descri pt i ve a nal ysis will be d o ne f or t his 
a nal ysis ( D C O 3). T he La n a n d De Met s a p pr oac h t hat a p pr o xi mates t he O’ Brie n & Fle mi n g 
s pe n di n g f u nct i o n will be e m pl o ye d t o preser ve t he o verall 1 -si de d t y pe I err or rate of 2. 5 % 
(La n a n d De Mets 1 9 8 3 ).  If t he i nteri m a nal ysis f o r O S ( D C O 1) occ urs at e xact l y 5 7 % of t he 
[ADDRESS_643073] ic al  si g nifica nce f or O S will be declare d if t he n ull h y p ot hesis f or P F S is 
r ej ecte d a n d t he o bser v e d p -val ue f or O S is p < 0. 0 0 3, w hic h e q uates t o a H R ≤ 0. 4 9.  T he 
si g nifica nce l e vel at t he fi nal f or mal O S a nal ysis ( D C O 2) will be deter mi ne d base d o n t he 
e xact n u m ber of e ve nts at t he ti me of t he i nteri m O S a nal yses ( D C O 1) a n d fi nal f or mal O S 
a nal yses ( D C O 2).  If t he i nteri m a nal ysis f or O S occ urs at e xactl y  5 7 % of  e ve nts a n d t he 
n u m ber of O S e ve nts at t he fi nal f or mal O S a nal ysis is a p pr o xi matel y 1 0 6 t he n t he 1 -si de d 
si g nifica nce l e vel t o be a p plie d f or t he fi nal f or mal O S a nal ysis will be 2. 4 %.  Statist ical 
si g nifica nce f or O S will be declare d if t he o bser ve d p -val ue f or O S is p < 0. 0 2 4, w hic h e q uates 
t o a H R ≤ 0. 6 8. 
All pla n ne d a nal yses will be perf or me d, re gar dless of t he o utc o me of t he M T P. 
8. 8. 2 A n al ysis of t he pri m ar y v ari a ble (s) 
T he pri m ar y P F S a nal ysis w ill be perf or me d w he n a p pr o xi matel y 8 7 pr o gressi o n e ve nts ha ve 
occ urre d ( 6 0 % mat urit y)  base d o n t he BI C R.  N o f urt her a nal yses of P F S are pla n ne d be y o n d 
t hi s p oi nt u nl ess re q ueste d b y  Heal t h  A ut h ori ti es 
P F S will be a nal yse d usi n g a l o g ra n k test.  T he haza r d rati o ( H R) a n d c o nfi de nce i nter val will 
be est i mate d fr o m t h e U a n d V statistics o btai ne d direct l y fr o m t h e LI F E T E S T m o d el  (a n d 
usi n g t he Bresl o w a p pr oac h f or ha n dli n g ties). 
T he H R a n d its c o nfi de nce i nter val will be est i mate d fr o m t h e l o g -ra n k as f oll o ws ( Berr y  et al  
1 9 9 9 a n d Sell ke et al 1 9 8 3 )
T he H R ( Ol a pari b vs. pl ace b o) t o get her wit h its c orres p o n di n g 9 5 % c o nfi de nce i nter val ( CI) 
a n d p -v al ue will  b e p rese nte d (a H R less t ha n 1 will fa v o ur Ola pari b).  C CI 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643074] 2 0 1 9 
1 1 4( 1 3 3) A Ka pla n -Meier ( K M) pl ot of  P F S will be prese nte d b y  tr e at m e nt gr o u p. S u m maries of t he 
n u m ber a n d perce nta ge of patie nts e x perie nci n g a P F S e ve nt, a n d t he t y pe o f e ve nt ( R E CI S T 
or deat h) will be pr o vi de d al o n g wi t h  m e dia n P F S f or eac h treat me nt ar m. 
T he ass u m pt i o n of pr o p orti o nalit y will  b e assesse d. N ote t hat i n t he prese nce of n o n -
pr o p orti o nali t y , t he H R will be i nter prete d as a n a vera ge H R o ver t he o bser ve d e xte nt of 
f o ll o w-u p.  Pr o p orti o nalit y will  b e teste d fi rstl y b y  pr o d uci n g pl ots of  c o m ple me n t ar y  l o g -l o g 
(e ve nt ti mes) vers us l o g (ti me) a n d, if t hese raise c o ncer ns, a ti me de pe n de nt c o variate w o ul d 
be fit te d t o assess t he e xte nt t o w hic h t his re prese nts ra n d o m variat i o n. 
T he pri mar y  a nal ysis will be base d o n t he pr o gra m mat icall y deri ve d P F S ba se d o n BI C R 
o verall visit assess me nts (ie I n di vi d ual t u m o ur meas ure me nts will n ot be use d) a n d usi n g all 
sca ns re gar dless o f w het her t he y  were sc he d ule d or n ot. 
T he est i mate d P F S rates at 6 m o nt hs a n d 1 2 m o nt hs will be s u m marise d ( usi n g t he K M c ur ve) 
a n d prese nte d b y  tr e at m e nt gr o u p. 
T he n u m ber of pat ie nt s pre mat urel y ce ns ore d will be s u m marise d b y treat me nt ar m t o get her 
wi t h  baseli ne pr o g n osti c f act ors of t he pre mat urel y ce ns ore d patie nts.  A patie nt is defi ne d as 
pr e m at urel y  ce ns ore d if t he y ha d n ot pr o g resse d a n d t he latest sca n pri or t o D C O was m ore 
t h a n o ne sc he d ule d t u m o ur assess me nt i nter val ( + 2 wee ks) pri or t o t he D C O date. 
S u b gr o u p a nal yses will be c o n d ucte d c o m pari n g P F S bet wee n treat me nts. T he p ur p ose of t he 
s u b gr o u p a nal yses is t o assess t he c o nsiste nc y of treat me nt effect acr oss p ote ntial or e x pecte d 
pr o g n osti c f act ors.  If t here are t o o fe w e ve nts a vaila ble f or a mea ni n gf ul a nal ysis of a 
parti c ular s u b gr o u p (it is n ot c o nsi dere d a p pr o priate t o prese nt a nal yses w here t here are less 
t h a n 2 0 e ve n ts i n a s u b gr o u p), t he relati o ns hi p bet wee n t hat s u b gr o u p a n d P F S will n ot be 
f o r m all y a nal yse d.  I n t his case, o nl y  descri pti ve s u m maries will be pr o vi de d 
C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643075] 2 0 1 9 
1 1 5( 1 3 3)   
 
Ot her baseli ne varia bles ma y  als o be assesse d if t here is cli nical j ust ificat i o n. 
F or eac h s u b gr o u p, t he H Rs ( Ola pari b: place b o) a n d ass ociate d CIs will be calc ulate d fr o m a 
C o x pr o p orti o nal hazar ds m o del (t ies = Efr o n) t hat c o ntai ns t he treat me nt ter m, f act or a n d 
treat m e nt -b y- fact or i nteracti o n ter m.  T he treat me nt effect H Rs f or eac h treat me nt c o m paris o n 
al o n g wi t h  t heir c o nfi de nce i nter vals will be o btai ne d f or eac h le vel o f t h e s u b gr o u p fr o m t hi s 
si n gle m o del.  T he H Rs a n d 9 5 % CIs will be prese nte d o n a f orest pl ot i ncl u di n g t he H R a n d 
9 5 % CI fr o m t he o verall p o p ulat i o n ( usi n g t he pri mar y  a nal ysis).  
 
 
A f urt her a nal ysis of P F S ( usi n g I n vest i gat or assesse d R E CI S T) ma y be perf or me d at t he ti me 
of  t he O S a nal yses, if re q ueste d b y  H e al t h  a ut h ori ti es. 
8. 8. [ADDRESS_643076].  T he sa me met h o d ol o g y  a n d m o d el  will  b e use d as f or t he pri mar y  a nal ysis of P F S a n d 
t h e H R a n d ass ociate d 9 5 % CI will be re p orte d. 
Se nsit i vit y a nal yses will be perf or me d t o assess t he p ossi ble prese nce of ti me -assess me nt bias 
(i e, differe nt ial assess me nt ti mes bet wee n treat me nt gr o u ps). 
S u m mar y  statistics f or t he n u m ber of wee ks bet we e n t he ti me of pr o gressi o n a n d t he last 
e val ua ble R E CI S T assess me nt pri or t o pr o gressi o n will be prese nte d f or eac h treat me nt gr o u p. 
8. 8. 3. [ADDRESS_643077] 2019
116(133)approach has been shown to be robust to even highly asymmetric assessment schedules ( Sun 
and Chen 2010). Thi s approach will use the BICR RECIST assessments.
[IP_ADDRESS] Attrition bias
Attrition bias will be assessed by  [CONTACT_499497], rather than the censored times, of subjects who progressed or died in the 
absence of progression immediately fo llowing two, or more , non -evaluable tumour 
assessments will be included. In addit ion, subjects who take subsequent therapy  prior to thei r 
last evaluable RECIST assessment or progression or death will be censored at their last 
evaluable assessment prior to taking the subsequen t therapy .
Addit ionally  a Kaplan -Meier pl ot of the time to censoring where the censoring indicator of the 
primary  PFS analysis is reversed will be presented.
[IP_ADDRESS] Ascertainment bias
A log-rank test will be repeated using the programmat ically derived RECIST usi ng 
Invest igator assessed PFS.  The HR and 95% Confidence Interval will be presented.  
If there is an important discrepancy between the primary analysis using BICR assessments and 
this sensi tivity analysis using Invest igator assessments, then the proportio n of patients with 
site but no central  confirmati on of  progressi on will be summarised.  The approach of imput ing 
an event at the next visit in the central review analysis may help inform the most likely HR 
value, but only  if an important di screpancy exists .  
Disagreements between invest igator and central reviews of RECIST progression will be 
presented for each treatment group.  The summary  will include the early discrepancy  rate 
which is the frequency o f central  review declared progressions before the Inve stigator review 
as a proportion of all central review progressions and the late discrepancy rate which is the 
frequency  of central  review declared progressions after the Invest igator review as a proportion 
of all discrepancies.
[IP_ADDRESS] Deviation bias (if meaningfu l to do)
As a sensit ivity analysis to the primary  endpoint of PFS, an analysis excluding pat ients with 
deviat ions that may  affect the efficacy  of the tri al therapy will be performed if > 10% of 
patients:
 did not have the intended disease or indicat ion or
 did not receive any rando mised therapy
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643078] 2 0 1 9 
1 1 7 (1 3 3 )A l o g- ra n k test will be re peate d usi n g t he BI C R R E CI S T data, usi n g t he sa me ties as 
descri be d f or t he pri mar y a nal ysis of P F S. T he H R a n d 9 5 % CI will be prese nte d. 
8. 8. 4 A n al ysis of t he sec o n d ar y v ari a ble(s) 
8. 8. 4. 1 A n al ysis of O S e n d p oi nt 
I nteri m O S data will be a nal yse d at t he ti me of t he fi nal a nal ysis of P F S ( D C O 1) a n d will use 
t h e sa m e met h o d ol o g y  a n d m o d el  ( pr o vi de d t here are s ufficie nt e ve nts a vaila ble f or a 
mea ni n gf ul a nal ysis [ > 2 0 deat hs], if n ot descri pti ve s u m maries will be pr o vi de d).  A fi nal 
f o r m al a nal ysis o f O S will  b e perf or m e d w he n a p pr o xi matel y  1 0 6 deat hs ha ve occ urre d 
( D C O 2).  t o ta ke place 1 2 m o nt hs after t he a nal ysis base d o n 
1 0 6 deat hs, will be a descri pt i ve o nl y a nal ysis ( D C O 3) a n d will  use t he sa me m et h o d ol o g y  as 
t h e fi nal f or mal O S a nal ysis. 
T he se nsit i vit y a nal ysis o utli ne d i n Secti o n 8. 8. [ADDRESS_643079] ice a n d ma y i n v o l ve a n y  o f; o bject i ve ra di o l o gi cal or s y m pt o mat ic 
pr o gressi o n or deat h. R E CI S T meas ure me nts will n ot be c ollecte d f or assess me nt of P F S 2. 
T he date of t he P F S [ADDRESS_643080] i gat or o pi [INVESTIGATOR_9384] o n of pr o gressi o n stat us ( pr o gresse d or 
n o n -pr o gresse d) at eac h assess me nt  will be rec or de d i n t he e C R F. Sec o n d pr o gressi o n stat us C CI 
C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643081] 2019
118(133)will be reviewed every  8 weeks foll owing the progressio n event used for the primary variable 
PFS (the first progression) and status recorded. Patients alive and for whom a second disease 
progressi on has not been observed should be censored at the last time known to be alive and 
without a second disease progression, ie censored at the last progression assessment date if the 
patient has not had a second progression or death) 
As a key  sensi tivity, the analysis o f PFS2 will be repeated in those patients whose gBRCAm
status is confirmed by [CONTACT_499498]. A KM plot of PFS2 in this subset of patients will be 
presented by [CONTACT_1570].
A KM plot of the time to censoring where the censoring indicator of the primary PFS2 is 
reversed will be produced.
Time fro m second progression to previous assessment will be summarised by  [CONTACT_3219] .
[IP_ADDRESS] Analysis of TDT endpoint
Time to study  treatm ent discont inuat ion or death (TDT) will be analysed using the same 
metho dology and m odel as the primary  analysis of PFS. The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by [CONTACT_2939].  No 
multiplicit y adjust ment will be applied as this is viewed as a supportive endpoint.
As a key  sensi tivity, the analyses of TDT will be repeated in those patients whose gBRCAm
status is confirmed by [CONTACT_499498]. A KM plot of TDT in this subset of patients will be 
presented by [CONTACT_1570].
[IP_ADDRESS] Analysis of TFST endpoint
Time to first subsequent therapy  or death (TFST) will be analysed using the same 
methodol ogy and m odel as the primary  analysis of PFS. The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by [CONTACT_2939].  In 
addition, the time between progression and starting subsequent therapy  will be assessed.  
As a key  sensi tivity, the analyses of TFST will be repeated in those patients whose gBRCAm
status is confirmed by [CONTACT_499498]. A KM plot of TFST in this subs et of patients will be 
presented by [CONTACT_1570].
[IP_ADDRESS] Analysis of TSST endpoint
Time to first second subsequent therapy  or death (TSST) will be analysed analysed using the 
same m ethodol ogy and m odel as the primary  analysis of PFS.  The HR for the treatment effect 
together with 95% CIs will be presented.  A KM plot will be presented by [CONTACT_2939].  
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643082] 2 0 1 9 
1 1 9( 1 3 3) S u m mar y  ta bles of fi rst a n d sec o n d s u bse q ue nt t hera pi[INVESTIGATOR_014] b y  tr e at m e nt ar m  will  b e pr o vi de d, as 
well as res p o nse t o first s u bse q ue nt t hera p y  b y  tr e at m e nt ar m .
As a ke y  se nsi ti vit y,  t he a nal yses of T S S T will be re peate d i n t h ose patie nts w h ose g B R C A m 
stat us is c o nfir me d b y t he M y ri a d test. A K M pl ot of T S S T i n t his s u bset of pat ie nt s will be 
prese nte d b y treat me nt gr o u p. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643083] 2 0 1 9 
1 2 0( 1 3 3)  
 
 
8. 8. 4. [ADDRESS_643084] o ver all R E CI S T Res p o nse ( B o R) a n d O R R 
F or eac h treat me nt ar m, best o verall res p o nse ( B o R) will be s u m marise d b y  n  ( %) f or eac h 
cate g or y  ( C R, P R, S D, N E D, P D, N E).  N o f or mal statist ical a nal yses are pla n ne d.  
T he o bj ect i ve res p o nse rate ( O R R) will be s u m marise d (ie, n u m ber of patie nts ( %) ) b y 
treat m e nt gr o u p i n pat ie nt s i n t he F A S (I T T p o p ulati o n) wit h meas ura ble disease at baseli ne.  
A n y pat ie nt s w h o e x perie nce d C R or P R w hic h was first o bser ve d w hilst recei vi n g s u bse q ue nt 
t h era p y  af ter disc o nt i n uat i o n of Ola pari b/ place b o will be i de nt ifi e d. T he de n o mi nat or f or t he 
res p o nse rate will be meas ura ble disease as defi ne d b y  t he BI C R data 
O R R a n d B O R will be prese nte d base d o n t he BI C R data a n d als o s u m marise d i n a si milar 
w a y  usi n g t he i n vesti gat or rec or de d data. 
8. 8. 4. 8 S u m m ar y of D C R   
T he disease c o nt r ol  rate ( D C R) will be s u m marise d (ie, n u m ber of pat ie nt s ( %)) b y  treat m e nt 
gr o u p i n patie nts i n t he F A S (I T T p o p ulati o n). 
D C R will be prese nte d base d o n t he BI C R data a n d als o t he i n vesti gat or rec or de d data. 
8. 8. [ADDRESS_643085] 2 0 1 9 
1 2 1( 1 3 3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 C CI 
C CI C CI 
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643086] 2 0 1 9 
1 2 2( 1 3 3)  
 
 
 
 
 
8. [ADDRESS_643087] u d y  i s P F S.   A p pr o xi matel y 1 4 5 pat ie nt s will be ra n d o mise d 
( 3: 2 rati o of  Ol a pari b: place b o) a n d t he pri mar y P F S a nal ysis will occ ur o nce a p pr o xi matel y 8 7 
P F S e ve nts (c o nfir me d via a ce ntral re vie w) ha ve occ urre d.  A si n gle i nteri m P F S a nal ysis f or 
f utilit y will be per f o r m e d w he n 5 0 % of t he fi nal n u m ber of pr o gressi o n e ve nts re q uire d f or t he 
pri mar y  P F S a nal ysis has bee n reac he d (a p pr o xi matel y 4 4 P F S e ve nts) base d o n BI C R. 
T he st u d y  i s size d ass u mi n g a tr ue treat me nt effect is a P F S Hazar d Rati o ( H R) of 0. 5 4, 
ass u mi n g 8 0 % p o wer a n d 2. 5 % al p ha ( 1 -si de d), wi t h  3: 2 ra n d o misat i o n ( Ol a pari b: place b o). 
Ass u mi n g P F S is e x p o ne nt ia ll y distri b ute d, a P F S H R of 0. [ADDRESS_643088] u d y  has 8 0 % 
p o wer t o s h o w a statist icall y si g nifica nt differe nce i n O S at t he 1 -si de d 2. 5 % l e vel if t he 
ass u me d tr ue treat me nt effect is a H R 0. 5 7; t his tra nslates t o a n a p pr o xi mate [ADDRESS_643089] 2019
123(133)rando mised in the study. It is estimated that 44PFS events will occur approximately [ADDRESS_643090] patient in.
8.9.1 Interim analysis
A single interim PFS analysis for futility will be perform ed when 50% of the final number of 
progression events requi red for the primary  PFS analysis has been reached (approximately  44
PFS events) based on BICR.  The interim analysis will be performed by [CONTACT_499499] (IDMC) and full details will be provided in the IDMC charter.  
Safety data including death rates will also be reviewed at this time.
The fut ility assessment will be based on the probabilit y of eventually showing statistical 
significance for the prima ry endpoint when the number of PFS events (n=87) is reached 
(Lachin 2005).  The determinat ion of this probability  will be condit ional on the observed data 
at the time of the interim analysis and on the assumed hazard ratio for the alternat ive 
hypothesis (P FS HR=0.54).  If the probabilit y is less than 20%, the IDMC will consider the 
option of  declaring futilit y.
The exact figure used for the fut ility boundary  will be calculated by  [CONTACT_499500], based on the num ber of events which have occurred at that 
time.  As an example, if exact ly 50% of the PFS events required for the primary PFS analysis 
have occurred at the time of the interim analysis (44 events), then the HR that corresponds to 
20% condit ional power for the interim analysis will be 1.02.  Therefore, if the observed HR 
for PFS at the interim is more than 1.02, the IDMC will consider the option of declaring 
futilit y.
An interim analys is of OS will be performed at the time of the primary  analysis of PFS 
(approximately 87 events) with the final formal OS analysis when approximately [ADDRESS_643091] patient is entered into the study , an [COMPANY_008] representative will review and 
discuss the requirements of the Clinical Study  Protocol  and rel ated do cuments with the 
investigat ional staff and also train them in any study  specific procedures and the WBDC
system (s) utilised.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643092] 2019
124(133)The Principal Invest igator will ensure that appropriate training relevant to the study is given to 
all of these staff, and that any new information relevant to the performance of this study  is 
forwarded to the staff invo lved.
The Principal Invest igator will maintain a record of all individuals invo lved in the study  
(medical, nursing and other staff).
9.[ADDRESS_643093] regular contacts with the study  site, 
including visits to:
Provi de inform ation and support to the Invest igator(s)
Confirm that facilit ies remain acceptable
Confirm that the invest igational team  is adhering to the protocol , that data are 
being accurately and timely recorded in the CRFs, that bio logical sam ples are 
handled in accordance with the Laboratory  Manual and that study  drug 
accountabilit y checks are being performed
Perform  source data verification (a co mparison of the data in the CRFs wit h the 
patient’s medical records at the hospi[INVESTIGATOR_7117], and other records relevant 
to the study ) incl uding verificat ion of informed consent of participat ing 
patients. Thi s will  require di rect access to all original records for each patient 
(eg, clinic charts)
Ensure withdrawal of informed consent to the use of the patient’s bio logical 
samples is reported and bio logical samples are i dentified and disposed 
of/destroy ed accordingly, and the action is documented, and reported to the 
patient.
The [COMPANY_008] representative will be available between visit s if the Invest igator(s) or other 
staff at the centre needs information and advice about the study  conduct.
9.2.[ADDRESS_643094] igator at each/the centre should comply wit h all the terms, condit ions, and 
obligat ions of the Clinical Study  Agreement, or equivalent, for this study .  In the event of any 
inconsistency between this Clinical Study  Protocol and the Clinical Study  Agreement, the 
terms of Clinical Study  Protocol  shall  prevail wi th respect to the conduct of the study  and the 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643095] 2019
125(133)treatm ent of patients and in all other respects, not relat ing to study conduct or treatment of 
patients, the term s of the Clinical Study  Agreement shall prevail.
Agreements between [COMPANY_008] and the Principal Investigator [INVESTIGATOR_153210] -related procedures can take place, or patients are enrolled.
9.2.3 Archiving of study documents
The Investigator foll ows the principles outlined in the Clinical Study  Agreement (CSA). 
9.3 Study timetable and end of study
The end o f the study  is defined as ‘the last visit of the last patient undergoing the study’.
The study  is expected to start in Q2 [ADDRESS_643096] study  
data.
Adverse events and medical/sur gical history  will be cl assified according to the termino logy of 
the latest version the Medical Dict ionary for Regulatory  Activit ies (MedDRA).  Medicat ions 
will be classified according to the [COMPANY_008] Drug Dictionary .  All  coding will be 
perform ed by [CONTACT_427400].
Data queri es will be raised for inconsistent, impossible or missing data.  All entries to the 
study  database will be available in an audit trail.
The data will be validated as defined in the Data Management Plan. Qualit y control  
procedures will be applied to each stage of data handling to ensure that all data are reliable 
and have been processed correctly .
When all data have been coded, validated, and locked, clean file will be declared.  Any 
treatm ent revealing data may  thereafter be added and the final database will be locked.
Re vise d Cli nic al St u d y Pr ot oc ol _ Gl o b al 
Dr u g S u bsta nce Ola pari b   
St u d y C o de D [ADDRESS_643097] 2 0 1 9 
1 2 6( 1 3 3) Data ass ociate d wit h bi o l o gical sa m ples will be tra nsferre d fr o m la b orat ories i nter nal or 
e xter nal t o Astra Ze neca.  Data fr o m e xter nal pr o vi ders (e g ce ntral la b orat orie s) will be 
vali date d as a p pr o priate t o e ns ure it is c o nsiste nt wit h t he cli nical data a n d i ncl u de d i n t he 
fi nal data base.   
 
 
 
 
 
 
Si te staff will e nter P R O b o o klet data i nt o M e di data Ra ve e xact l y as re p orte d b y  t he pati e nt. 
[ADDRESS_643098] u d y  will  be perf or m e d i n acc or da nce wit h et hical pri nci ples t hat ha ve t heir ori gi n i n t he 
Declarati o n of Helsi n ki a n d are c o nsiste nt wit h I C H/ G o o d Cli nical Pract ice, a p plica ble 
re g ul at or y  r e q ui re me nts a n d t he Astra Ze neca p olic y  o n Bi oet hics a n d H u m a n Bi ol o gi c al  
S a m ples. 
1 0. 2 P atie nt d at a pr otecti o n 
T he I nf or me d C o nse nt F or m will i nc or p orate ( or, i n s o me cases, be acc o m pa nie d b y a 
se parate d oc u m e nt i nc or p orati n g) w or di n g t hat c o m plies wit h rel e va nt data pr otecti o n a n d 
pri vac y  l e gislat i o n. 
Astra Ze neca will n ot pr o vi de i n di vi d ual ge n ot y pe res ul ts t o patie nts, a n y  i ns ura nce c o m pa n y, 
a n y e m pl o yer, t heir fa mil y me m bers, ge neral p h ysicia n or a n y  ot her t hi r d part y , u nless 
re q ui re d t o d o s o b y  l a w .
T he e xce pt i o n t o t he a b o ve is t he res ult of t he M y ri a d B R C A test. T hi s will  b e ma de a vaila ble 
t o t he I n vest i gat or a n d patie nt. C CI 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643099] 2019
127(133)Extra precautions are taken to preserve confident iality and prevent genetic data being linked to 
the identi ty of the patient. In except ional circumstances, however, certain individuals might 
see both the genetic data and the personal ident ifiers of a pati ent. For example, in the case of a 
medical emergency, an [COMPANY_008] Physician or an invest igator might know a patient’s 
ident ity and also have access to his or her genet ic data. Also Regulatory  authori ties may 
requi re access to the relevant files, though the patient’s medical information and the genetic 
files woul d rem ain physically  separate.
10.[ADDRESS_643100] (IRB)/Ethics Co mmittee should approve the final study  
protocol , including the final versio n of the Informed Consent Form and any other written 
inform ation and/or m aterials to be provided to the pati ents.  The invest igator will ensure the 
distribut ion of these documents to the applicable Ethics Co mmittee, and to the study  site staff.
The opi[INVESTIGATOR_3078] n of the Ethics Co mmittee should be given in writ ing. The invest igator should 
submit the written app roval to [COMPANY_008] before enro lment of any pat ient into the study . 
The Ethi cs Co mmittee should approve all advertising used to recruit patients for the study.
[COMPANY_008] should approve any  modificati ons to the Informed Consent Form that are needed 
to meet local requi rements.
If required by  [CONTACT_24550], the protocol should be re -approved by [CONTACT_309577].
Before enrolment of any patient into the study , the final  study  protocol , incl uding the final 
versio n of the Informed Consent Fo rm is approved by  [CONTACT_24551] a 
notification to the nat ional regulatory  authori ty is done, according to local regulations.
[COMPANY_008] will handle the distribut ion of any of these documents to the national regulatory  
authori ties.
[COMPANY_008] will provide Regulatory  Authori ties, Ethics Co mmit tees and Principal 
Invest igators with safety updates/reports according to local requirements, including S[LOCATION_003]Rs 
(Suspected Unexpected Serious Adverse Reactions), where relevant.
Each Principal Inv estigator i s responsible for providing the Ethics Co mmit tees/IRB wi th 
reports of any  serious and unexpected adverse drug reactions from any other study  conducted 
with the invest igational product.  [COMPANY_008] will provide this information to the Principal 
Invest igator so that he/she can meet these reporting requirements.
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643101] 2019
128(133)10.[ADDRESS_643102] igator(s) at each centre will:
 Ensure each patient is given full and adequate oral and written informat ion about 
the nature, purpose, possible risk and benefit of the study
 Ensure each patient is notified that they  are f ree to di scontinue fro m the study  at any  
time
 Ensure that each patient is given the opportunit y to ask questions and allowed time 
to consi der the inform ation provi ded
 Ensure each patient p rovides signed and dated info rmed consent before conducting 
any procedure specifically for the study
 Ensure the original, signed Informed Consent Form(s) is/are stored in the 
Invest igator’s Study  File
 Ensure a copy  of the signed Informed Consent Form is gi ven to the pati ent
 Ensure that any  incentives for patients who participate in the study  as well  as any  
provi sions for pati ents harmed as a consequence of study  parti cipat ion are described 
in the informed consent form that is approved by [CONTACT_427401] .
10.[ADDRESS_643103] igator, National Co -ordinat ing Investigator, and the Principal Investigator 
[INVESTIGATOR_255684].
If there are any substant ial changes to the study  protocol , then these changes will be 
docum ented in a study  protocol  amendment and where required in a new versio n of the study  
protocol  (Revised Clinical Study  Protocol ).
The am endment i s to be approved by  [CONTACT_291474], also the 
national regulatory  authori ty approval , before implem entati on.  Local  requi rements are to be 
followed for revi sed protocol s.
[COMPANY_008] will distribute any subsequent amendments and new versio ns of the protocol  to 
each Principal Invest igator (s). F or distribut ion to Ethics Co mmittee see Section 10.3.
If a protocol amendment requires a change to a c entre’s Informed Consent Form, [COMPANY_008] 
and the centre’s Ethics Co mmit tee are to approve the revised Informed Consent Form before 
the revised form is used. 
Revised Clinical Study Protocol_Global
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643104] 2019
129(133)If local regulat ions requi re, any  administrative change will be communicated to or approved 
by [CONTACT_427402].
10.[ADDRESS_643105] ivities were conducted, and 
data were recorded, analysed, and accurately reported according to the protocol, Good Clinical 
Practi ce (GCP), gui delines of the International Conference on Harmonisat ion (ICH), and any  
applicable regulatory  requi rements.  The invest igator will contact [CONTACT_309580]  a regul atory  agency  about an inspect ion at the centre.
11. LIST OF REFE RENCES
Alexandrov et al 2013 
Alexandrov et al. Signatures of mutational processes in human cancer Nature 
2013;500;7463;415-21
American Cancer Society 2013
American Cancer Societ y. Cancer Facts and Figures 2013. Atlanta, Georgia: American Cancer 
Society, 2013. http://www.cancer.org
Audeh et al 2010
Audeh, M.W., Carmichael, J, Penson R.T. et al., Oral poly(ADP -ribose) polymerase inhibitor 
Olaparib in pat ients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof -
of-concept tri al. Lancet, 2010. 376(9737): p. 245- 51.PMID: 20609468
Bang et al 2013 
Bang et al . Olaparib plus paclitaxel in pat ients with recurrent or m etastati c gastri c cancer: A 
rando mized, double -blind phase II study . J Clin Oncol  31, 2013 (suppl; abstr 4013)
Bergfeldt et al 1995
Bergfeldt K, Einhorn S, Rosendahl I & Hall P. Increased risk of second primary  malignancies 
in patients with gyneco logical cancer. A Swedish record- linkage study. Acta Onco l. 
1995;34(6):771 -7.
Berry et al 1999
Berry  G, Ki tchin RM & Mock PA.  A comparison of two simple hazard ratio estimators based 
on the l ogrank test.  Statist ics in Medicine 1991; 10:749-[ADDRESS_643106] 2019
130(133)Bryant et al 2005
Bryant HE, Schul tz N, Thom as HD, Parker KM, Flower D, Lopez E, et al. Specific killing of 
BRCA2 -deficient tumours with inhibitors of po ly(ADP -ribose) polymerase. Nature, 2005. 
434(7035): p. 913 -7. PMID: [ADDRESS_643107] for Accelerated Approval of Onco logy Drugs. Statistics in 
Biopharmaceuti cal Research 2011, Vol . 3, No. 3DOI: 10.1198/sbr.2011.[ZIP_CODE]
Cole and Strair 2010
Cole M, & Strai r R.  Acute myelogenous leukemia and myelodysplasia secondary  to breast 
cancer treatment: case studies and literature review. Am J Med Sci 2010;339(1):36 -40.
Conroy et al 2011 
Conroy  T. FOLFIRINOX versus Gemcitabine fo r Metastati c Pancreat ic Cancer, 2011 NEngl J 
Med 364; 1817-25
Cowley et al 2013
Cowley  et al  Understanding pancreas cancer genomes. J Hepatobiliary Pancreat Sci (2013) 
20:549 –556
Fayers et al 1999
Fayers P, Aaronson N, Bjordal K & Sullivan M (1999). EORTC QLQC30, Scoring Manual. 
Belgium: EORTC Data Center.
Fayers et al 2001
Fayers et al. EORTC QLQ -C30 Scoring Manual (Third Edit ion). Bel gium : EORTC Qualit y of 
Life Group, 2001.
Ferrone CR et al 2009
Ferrone CR. et al.BRCA Germline Mutations in Jewish Pat ients Wit h Pancreat ic 
Adenocarcino ma. Journal o f Clinical Onco logy, Vol  27, No 3 (January  20), 2009: pp. 433 -
438.
Fitzsimmons D et al 1999
Fitzsimm ons D, Johnson CD, George S, et al. Development of a disease specific qualit y of life 
(QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the 
QLQ -C30 in pat ients with pancreat ic cancer. Eur. J. Cancer 35: 939 -941, 1999.
Fong et al 2009
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui -Roelvink M, et al. Inhibit ion of 
poly(ADP -ribose) polymerase in tumors from BRCA mutation carri ers. N Engl  J Med. 
2009;361(2):[ADDRESS_643108] 2019
131(133)Fowble et al [ADDRESS_643109] cancer : ident ifying a subset of women 
at increased risk. Int J Radiat Onco l, Biol, Phys. 2001; 51 (3);679 -690.
Gaymes et al 2008
Gaymes TJ, Shall S, MacPherson LJ, Twine NA, Lea NC, Farzaneh F, and Muft i GJ. 
Inhibitors of poly ADP -ribose polymerase (PARP) induce apoptosis of myelo id leukemic 
cells: potential for therapy  of myel oid leukemia and myelodysplast ic syndro mes. 
Haematologica 2009; 94:638 -646. doi :10.3324/haematol.2008.[ZIP_CODE]
Ginsburg et al 2010
Ginsburg et al BRCA1 and BRCA2 families a nd the risk of skin cancer Springer 
Science+Business Media B.V. 2010
Goggins M. et al 1996
Germline M et al BRCA2 gene mutations in pat ients wi th apparently sporadic pancreat ic 
carcino mas. Cancer Res. 1996 Dec 1;56(23):5360 -4
Hay et al 2009
Hay T, Matthews JR, Pi[INVESTIGATOR_48816] L, Lau A, Cranston A, Ny gren AO, et al . Poly(ADP -ribose) 
polymerase -1 inhibitor treatm ent regresses autochthonous Brca2/p53 -mutant mammary 
tumors in vivo and delays tumor relapse in combination with carboplat in. Cancer Res. 
2009;69(9):[ADDRESS_643110]. 
2003 Feb 5;95(3):214-21.
Helleday 2011
Helleday T. The underlying mechanism for the PARP and BRCA synthet ic lethalit y: Clearing 
up the misunderstandi ngs. Molecular Onco logy 2011; 5: 387 -393.
Jemal A et al 2011
Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011 Mar -Apr;61(2):69 -90
Kaufman B et al 2013
Kaufman B, Shapi[INVESTIGATOR_20116] -Frommer R Schmutzler RK, Audeh MW, et al. Olaparib mo notherapy  in 
patients with advanced cancer and a germline BRCA1/2 mutation: An open label phase II 
study . J Clin Oncol  31, 2013 (suppl; abstr [ZIP_CODE])
Revised Clinical Study Protocol_Gl obal
Drug Substance Olaparib   
Study Code D081FC00001
Edition Number [ADDRESS_643111] 2019
132(133)Kim et al [ADDRESS_643112]. 
Med. (2005) 24: 2747–2764.
Lan and DeMets 1983
Lan KKG, DeMets DL. Discrete sequent ial boundari es for clinical trials. Bio metrika 1983; 70: 
659-63.
Ledermann et al 2013
Ledermann, J Clin Onco l 31, 2013. Ol aparib maint enance therapy  in pat ients with platinum 
sensit ive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm )
Lowery M et al 2011
Lowery  M et al .An Em erging Ent ity: Pancreat ic Adenocarcino ma Associ ated wi th a Known 
BRCA Mutation: Clinical Descriptors, Treatment Implicat ions, and Future Direct ions The 
Onco logist 2011, 16:1397 -1402.
Murai et al 2012
Murai  J, Huang SN, Das BB, Renaud A, Zhnag, Y, Doroshow, JH, et al. Trappi[INVESTIGATOR_48817]1 
and PARP2 by [CONTACT_48883]. AACR; 72(21); 5588 –99.
Murphy KM et al 2002
Evaluat ion of Candidate Genes MAP2K4, MADH4, ACVR1B, and Mutations in 17% 
BRCA2 in Fam ilial Pancreat ic Cancer: Deleterious BRCA2. Cancer Res 2002;62:3789 -3793.
Osoba D et al 1998
Osoba D, Rodrigues G, Myles J, Zee B and Pater J. Interpreting the significance of changes in 
healt h-related qualit y-of-life scores. JCO January 1998 vol. 16 no. 1 139-144
Ozcelik et al 1997
Ozcelik et al Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreat ic cancer 
patients Nature Geneti cs  16, 17 -18 (1997) 
Rahma et al 2013
Rahma et al Second -line treatment in advanced pancreat ic cancer: a comprehensiv e analysis 
of published clinical trials. Annals of Onco logy 2013 Aug;24(8):[ADDRESS_643113] 2019
133(133)Robins et al 1991
Robins JM, Tsiat is AA. Correcting for noncompliance in rando mized trials using rank 
preserving structural failure t ime models. Communicat ions in Stati stics -Theory  and Methods 
1991; 20:[ADDRESS_643114] ment in proportional hazards regressio n 
analysis of randomized trials using surrogate markers. Proceedings of the Biopharmaceut ical 
Secti on, American Statis tical Associ ation 1993; 24-33.
Rottenberg et al 2008
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Ny gren AO, Zander SA, et al. High 
sensit ivity of BRCA 1-deficient mammary tumors to the PARP inhibitor AZD2281 alo ne and 
in combinat ion with platinum drugs. Proc Natl  Acad Sci . 2008;105(44):[ZIP_CODE]-84.
Roy et al 2012
Roy, R., J. Chun, and S.N. Powell, BRCA1 and BRCA2: different roles in a co mmo n pathway  
of geno me protection. Nat Rev Cancer, 2012. 12(1): p. 68 -78. PMID: 22193408
Sadler ZK. 2012
Sadler ZK . 2012. BRCA and Pancreat ic Cancer: Select ion of Chemotherapy Journal o f the 
Pancreas JOP. J Pancreas (Online) 2012 Mar 10; 13(2):180 -181
Sellke et al 1983
Sellke, T. and Siegmund, D. Sequential analysis o f the proportional hazards model. 
Biometrika 70: [ADDRESS_643115] ics 5 (2010) 151-161
Sun and Chen 2010
Sun X, Chen C: Comparison of Finkelstein’s Method With the Convent ional Approach for 
Interval -Censored Data Analysis.  Stat Biopharm Research 2:97- 108, [ADDRESS_643116] Cancer Linkage Consortium: 1999 J Natl  Cancer 91:1310-16
Tutt A et al 2010
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel J et al,. Oral po ly(ADP -
ribose) polymerase inhibitor Olaparib in pat ients wit h BRCA1 or BRCA2 mutations and 
advanced breast cancer: a proof -of-concept tri al.  Lancet 2 010; 376: 235–[ADDRESS_643117] 2019
134(134)Von Hoff et al 2013 
Daniel D. Von Hoff, M.D. et al. Increased Survival in Pancreat ic Cancer with nab -Pacli taxel  
plus Gemcitabine N Engl J Med 2013; 369:[ADDRESS_643118] cancer. J Clin 
Onco l, 2007;ASCO Annual Meet ing Proceedings Part I. Vol (25);No. 18S (June [ADDRESS_643119] ement):[ZIP_CODE].
Clinical Study Protocol Appendix B
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
Appendix B
Additional Safety Information
Clinical Study Protocol Appendix B
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
2(3)FURTHER GUIDANCE ON THE DEFINITION OF A SERIOUS 
ADVERSE EVENT (SAE )
Life threatening
‘Life -threatening’ means that the subject was at immediate risk of death from the AEas it 
occurred or it is suspected that use or continued use of the product would result in the 
subject ’s death.  ‘Life -threatening’ does not mean that h ad an AEoccurred in a more severe 
form it might have caused death (eg, hepatit is that resolved wit hout hepatic failure).
Hospi[INVESTIGATOR_72917] a serious AE , although the reasons 
for it may be (eg, bronc hospasm, laryngeal oedema).  Hospi[INVESTIGATOR_33094]/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way  during the study .
Important medical event or medical intervention
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important m edical events may  not be immediately life threatening or result in 
death, hospi [INVESTIGATOR_72913], disabili ty or incapaci ty but may jeopardize the subject or may require 
medical intervention to prevent one or more outcomes listed in the definit ion of serious.  
These should usually be considered as serious.
Simply sto ppi[INVESTIGATOR_33095]; medical 
judgement must be used.
Examples of such events are:
 Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatm ent
 Hepatotoxicit y caused by [CONTACT_499501] (acetaminophen) overdose requiring 
treatm ent wi th N-acetylcysteine
 Intensive treatment in an emergency room or at home for allergic bronchospasm
 Blood dy scrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or 
convulsio ns that d o not result in hospi[INVESTIGATOR_72913]
 Development of drug dependency or drug abuse.
Clinical Study Protocol Appendix B
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
3(3)A GUIDE TO INTERPRETING THE CA[LOCATION_003]LITY QUESTION
The fo llowing factors should be considered when deciding if there is a “reasonable 
possibilit y” that an AE may have been caused by [CONTACT_33641].
 Time Course.  Exposure to suspect drug.  Has the subject actually received the 
suspect drug?  Did the AE occur in a reasonable temporal relat ionship to the 
administration of the suspect drug?
 Consistency wit h known drug profile.  Was the AE consi stent wi th the previ ous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? OR coul d the AE be anticipated from its pharmaco logical 
properties?
 Dechallenge experience.  Did the AE reso lve or improve on st oppi[INVESTIGATOR_96699]?
 No al ternative cause.  The AE cannot be reasonably  explained by [CONTACT_309581], other drugs, other host or environmental factors.
 Rechallenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? [COMPANY_008] would not normally  recommend or support 
a rechallenge.
 Laboratory  tests.  A specific laboratory  invest igation (if performed) has confirmed 
the relationship?
A “reasonable possib ility” coul d be considered to exist for an AE where one or more of these 
factors exi st.
In contrast, there would not be a “reasonable possibilit y” of causalit y if none of the above 
criteria apply or where there is evidence of exposure and a reasonable t imecourse but any  
dechallenge (if performed) is negat ive or ambiguous or there is another more likely cause of 
the AE.
In difficult cases, other factors could be considered such as:
 Is this a recognised feature of overdose of the drug?
 Is there a known mecha nism?
Ambiguous cases should be considered as being a “reasonable possibilit y” of a causal 
relationship unless further evidence beco mes available to refute this.  Causal relat ionship in 
cases where the disease under study  has deteri orated due to l ack of ef fect shoul d be cl assified 
as no reasonable possibilit y.
Clinical Study Protocol Appendix C
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
Appendix C
International Airline Transportation Association (IATA) 6.[ADDRESS_643120] u d y C o de D 0 8 1 F C 0 0 0 0 1 
E diti o n N u m ber 1
Date 3 1 M ar c h 2 0 1 4 
2( 2) L A B E L LI N G A N D S HI P M E N T O F BI O H A Z A R D S A M P L E S 
I nter nati o nal Airli ne Tra ns p ortati o n Ass ociat i o n (I A T A) classifies bi o hazar d o us a ge nts i nt o 3 
cate g ori es ( htt p:// w w w.i at a. or g/ w h at we d o/c ar g o/ d gr/ P a ges/i nfecti o us _s u bst a nces. as p x) . 
F or tra ns p ort p ur p oses t he classificat i o n of i nfect i o us s u bsta nces acc or di n g t o ris k gr o u ps was 
r e m o ve d fr o m  t he Da n ger o us G o o ds Re g ulat i o ns ( D G R) i n t he 4 6t h e dit i o n ( 2 0 0 5).  I nfect i o us 
s u bsta nces are n o w classifie d eit her as Cate g or y  A, Cate g or y  B or E xe m pt.  T here i s n o di rect 
r el at i o ns hi p bet wee n Ris k Gr o u ps a n d cate g ories A a n d B. 
C ate g or y A I nfecti o us S u bst a nces are i nfect i o us s u bsta nces i n a f or m t hat, w he n e x p os ure t o 
it  occ urs, i s ca pa ble of ca usi n g per ma ne nt disa bilit y,  life -t h reate ni n g or fatal  di sease i n 
ot her wi se healt h y h u ma ns or a ni mal s.  Cate g or y  A pat h o ge ns are e g, E b ol a, Lassa fe ver vir us: 
 are t o be pac ke d a n d s hi p pe d i n acc or da nce wit h I A T A I nstr ucti o n [ADDRESS_643121] i o us S u bsta nces t hat d o n ot meet t he criteria f or 
i ncl usi o n i n Cate g or y  A .  Cate g or y B pat h o ge ns are e g, He patit is A, B, C, D, a n d E vir uses, 
H u m a n i m m u n o deficie nc y vir us ( HI V) t y pes 1 a n d 2.  T he y  are assi g ne d t he f oll o wi n g U N 
n u m ber a n d pr o per s hi p pi n g na me: 

E xe m pt -all ot her materials wit h mi ni mal ris k of c o ntai ni n g pat h o ge ns 
 Cli nical trial sa m ples will fall i nt o Cate g or y  B or e xe m pt u n der I A T A re g ulati o ns 
 Cli nical trial sa m ples will r o uti nel y be pac ke d a n d tra ns p orte d at a m bie nt 
t e m perat ure i n I A T A 6 5 0 c o m plia nt pac ka gi n g 
( htt p:// w w w.i at a. or g/ w h at we d o/c ar g o/ d gr/ P a ges/i nfecti o us _s u bst a nces. as p x) 
 Bi ol o gic al s a m ples tr a ns p orte d i n dr y ice re q uire a d diti o n al d a n ger o us g o o ds 
s pecific ati o n f or t he dr y -ice c o nte nt 
 I A T A c o m p lia nt c o urier a n d pac k a gi n g materi als s h o ul d be use d f or pac ki n g a n d 
tra ns p ortati o n a n d pac ki n g s h o ul d be d o ne b y a n I A T A certifie d pers o n, as 
a p plica ble 
 S a m ples r o uti nel y tra ns p orte d b y  r oa d or rail are s u bject t o l ocal re g ulati o ns w hic h 
re q ui re t hat t he y  are al s o pac ke d a n d t ra ns p orte d i n a safe a n d a p pr o priate wa y  t o 
c o ntai n a n y  ris k of i nfect i o n or c o nta mi nat i o n b y usi n g a p pr o ve d c o uriers a n d 
pac ka gi n g / c o ntai n me nt materials at all ti mes.  T he I A T A 6 5 0 bi o l o gical  sa m ple 
c o ntai n me nt sta n dar ds are e nc o ura ge d w here ver p ossi ble w he n r oa d or rail tra ns p ort 
is use d. C CI 
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 2019
Appendix D
Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 2019
2(8)TABL E OF CONTENTS PAGE
TABLE OF CONTENTS ................................
..................................................... 2
1. INTRODUCTION ............................................................................................... 3
2. DEFINITIONS .................................................................................................... 3
3. IDENTIFICATION OF PO TENTIAL HY’S LAW CAS ES................................. 4
4. FOLLOW -UP...................................................................................................... 4
4.1 Potenti al Hy’s Law Cri teria not m et..................................................................... 4
4.2 Potenti al Hy’s Law Cri teria met ........................................................................... 4
5. REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW CASES .............. 5
6. ACTIONS REQUIRED WHE N POTENTIAL HY’S LAW CRITERIA 
ARE MET BEFORE AND A FTER STARTING STUDY TREATMENT ........... 7
7. ACTIONS REQUI RED FOR REPEAT EPI[INVESTIGATOR_499464]’S LAW .......................................................................................................... 7
8. REFERENCES .................................................................................................... 8
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 2019
3(8)1. INTRODUCTION
This Appendix describes the process to be fo llowed in order to ident ify and appropriately 
report Potential Hy’s Law (PH L) cases and Hy’s Law (HL) cases.  It is not intended to be a 
comprehensive gui de to the m anagement of el evated liver biochemistries.
During the course of the study  the Invest igator will remain vigilant for increases in liver 
biochemistry .The Investigator is responsible for determining whether a subject meets 
potenti al PHL cri teria at any  point duri ng the study.
All sources of l aboratory  data are appropri ate for the determinat ion of PHL and HL events; 
this includes samples taken at scheduled study  visits a nd other visits including central and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL 
criteria coul d be m et by  [CONTACT_96724]  a central  laboratory  and/or elevated TBL fro m 
a local laboratory . 
The Inv estigator will also review Adverse Event data (for example, for AEs that may indicate 
elevations in liver biochemistry ) for possible PHL events.
The Investigator participates, together with [COMPANY_008] clinical project representatives, in 
review and assess ment of cases meet ing PHL criteria to agree whether Hy’s Law (HL) criteria 
are met.  HL criteria are met if there is no alternat ive explanat ion for the el evations in liver 
biochemistry  other than Drug Induced Liver Injury (DILI) caused by  [CONTACT_309582] (IMP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Serious Adverse Events (SAEs) and Adverse Events (AEs) according to the 
outcom e of the review and assessment in line wit h standard safet y reporting processes.
2. DEFINITIONS
Potential Hy’s Law (PHL)
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upper Limit of 
Norm al (ULN) together with Total Bilirubin (TBL) ≥ 2xULN at any po int during the study  
following the start of study  medicat ion, irrespect ive of an increase in Alkaline P hosphatase 
(ALP).
Hy’s Law (HL)
AST or ALT ≥ 3x ULN together with TBL ≥ 2xULN, where no other reason ,other than the 
IMP, can be found to explain the combinat ion of increases, e.g., elevated ALP indicating 
cholestasis, viral hepat itis, another drug.
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 2019
4(8)For PH L and HL the elevat ion in transaminases must precede or be coincident with (ie, on the 
same day ) the el evati on in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
3. IDENTIFICATION OF PO TENTIAL HY’S LAW CASES
In order to i dentify  cases of PHL i t is important to perform a comprehensive review of 
laboratory  data for any  patient who m eets any  of the fo llowing i dentificat ion criteria in 
isolation or in combinat ion:
 ALT ≥ 3xULN
 AST ≥ 3xULN
 TBL ≥ 2xULN
The Investigator will wit hout delay review each new laboratory  report and if the ident ificat ion 
criteria are met will:
 Notify  the [COMPANY_008] representative 
 Determine whether the patient meets PHL criteria (see Section 2of this Appendix 
for definit ion) by [CONTACT_309583]
 Prom ptly enter the laboratory  data into the l aboratory  CRF.
4. FOLLOW -UP
4.1 Potential Hy’s Law Criteria not met
If the patien t does not meet PHL criteria the Investigator will:
 Perform  follow-up on subsequent laboratory  resul ts according to the guidance 
provi ded in the Clinical Study  Protocol .
4.2 Potential Hy’s Law Criteria met
If the patient does meet PHL criteria the Investigator will:
 Determine whether PHL criteria were met at any  study  visit prior to starting study  
treatm ent (See Secti on 6)
 Notify  the [COMPANY_008] representative who will then inform the central Study  Team .
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 2019
5(8) Within [ADDRESS_643122] igator will report the case as an 
SAE of Potential Hy’s Law; serious criteria ‘Important medical event’ and causalit y 
assessment ‘y es/related’ according to CSP process for SAE reporting.
 For subjects that met PHL crit eria prior to starti ng IMP, the invest igator is not 
requi red to submit a PHL SAE unless there is a significant change#in the subject’s 
condi tion
 The Study  Physician contacts the Invest igator, to provide guidance, discuss and 
agree an approach for the stud y patient’s fo llow-up (including any further 
laboratory testing) and the continuous review of data.  
 Subsequent to this contact [CONTACT_73016]:
 Moni tor the pati ent until liver biochemistry  parameters and appropriate 
clinical symptoms and signs retu rn to normal or baseline levels, or as long as 
medically indicated . Completes fo llow-up SAE Form  as requi red.
 Invest igate the etio logy of the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician .
 Com plete the 3 Liver CRF Modul es as information beco mes available
5. REVIEW AND ASSESSMEN T OF POTENTIAL HY’S LAW 
CASES
The instructions in this sect ion shoul d be fo llowed for all  cases where PHL cri teria were met.
As soon as possible after the bi ochemistry  abnormalit y was ini tially detect ed, the Study  
Physician contacts the Invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL criteria other than DILI caused by [CONTACT_86184], to ensure timely analysis and reporting to healt h autho rities wi thin [ADDRESS_643123] igator will fo llow the 
instructi ons bel ow.
                                               
#A ‘significant’ change in the subject’s condition refers to a clinically relevant change in any of the individual 
liver biochemistry parameters (AL T, AST or total bilirubin) in isolation or in combination, or a clinically 
relevant change in associated symptoms.  The determination of whether there has been a significant change will 
be at the discretion of the Investigator, this may be in consultation with the Study Physician if there is any 
uncertainty .
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 2019
6(8)Where there is an agreed alternative explanation for the ALT or AST and TBL elevations, 
a determination of whether the alternat ive explanatio n is an AE will be made a nd 
subsequent ly whether the AE meets the criteria for a SAE:
 If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate CRF
 If the alternat ive explanat ion is an AE/SAE :update the previously submitted 
Potenti al Hy’s Law SAE and AE CRFs accordingly  with the new inform ation 
(reassessing event term; causalit y and seri ousness cri teria) fo llowing the AZ 
standard processes .
If it is agreed that there is no explanat ion that would explain the ALT or AST and TBL 
elevations oth er than the I MP:
 Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes. 
The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious 
criteria apply
As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If there is an unavo idable delay o f over 15 cal endar days in obtaining the informat ion 
necessary  to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alterna tive explanation unt il such time as an informed decisio n can be made:
 Provi des any  further update to the previously submitted SAE of Potential Hy’s Law, 
(report term now ‘Hy’s Law case’) ensuring causalit y assessment i s related to IMP 
and seriousness crite ria is medically  important, according to CSP process for SAE 
reporting.
 Continue fo llow-up and review according to agreed plan.  Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to 
determine whether HL criteria are still met.  Update the previously submitted PHL
SAE report following CSP process for SAE reporting, according to the outcome of 
the review and amending the reported term if an alternative explanat ion for the liver 
biochemistry  elevat ions is determined .
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 2019
7(8)6. AC
TIONS REQUIRED WHEN POTENTIAL HY’S LAW 
CRITERIA ARE MET BEF ORE AND AFTER STARTI NG 
STUDY TREATMENT
This sect ion is applicable to patients who meet PHL criteria on study  treatm ent having 
previously met PHL criteria at a study  visit pri or to starti ng study  treatm ent. 
At the first on study  treatm ent occurrence of PHL cri teria being met (including the 30 -day 
follow-up period) the Invest igator will determine if there has been a significant change in the 
patients’ condit ion#compared with the last visit where PHL criteria were m et
If there is no significant change no action is required
If there is a significant change, notify the [COMPANY_008] representative, who will 
inform  the central  Study  Team , then foll ow the subsequent process described is 
Secti on 4.2 of this Appendix.
# A ‘significant’ change in the patient’s condit ion refers to a subsequent clinically relevant 
change in any  of the individual liver biochemistry  param eters (ALT, AST or total bilirubin) in 
isolation or in combinat ion, or a clinically  relevant ch ange in associated symptoms such as 
fatigue, vo miting, rash, right upper quadrant pain, jaundice, eosinophilia.  The determinat ion 
of whether there has been a significant change will be at the discretion o f the Invest igator; this 
may be in consultat ion with the Study  Physician if there is any uncertaint y.
7. ACTIONS REQUIRED FOR REPEAT EPI[INVESTIGATOR_291429]’S LAW
This sect ion is applicable when a patient meets PHL criteria on study treatment (including the 
30-day follow - up peri od) and has already  met PHL cr iteria at a previous on study  treatm ent 
visit.
The requi rement to conduct fo llow-up, revi ew and assessment of a repeat occurrence(s) of 
PHL i s based on the nature of the alternat ive cause identified for the previous occurrence.
The invest igator should dete rmine the cause for the previous occurrence of PHL criteria being 
met and answer the fo llowing quest ion:
                                               
#A ‘significant’ change in the subject’s condition refers to a clinically relevant change in any of the individual 
liver biochemistry parameters (ALT, AST or total bilirubin) in isolation or in combina tion, or a clinically 
relevant change in associated symptoms.  The determination of whether there has been a significant change will 
be at the discretion of the Investigator, this may be in consultation with the Study Physician if there is any 
uncertainty .
Clinical Study Protocol Appendix D
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 2
Date 30 Aug 20 19
8(8) Was the alternat ive cause for the previous occurrence o f PHL cri teria being met 
found to be the di sease under study  e.g. chronic or progressing maligna nt disease or 
did the pati ent meet PHL cri teria pri or to starting study  treatm ent and at thei r first 
on study  treatm ent visi t as described in Sect ion 6?
If No: follow the process described in Sect ion 4.2 of this Appendix
If Yes:Determine if there has been a significant change in the pat ient’s condit ion#compared 
with when PHL cri teria were previously  met:
 If there is no significant change no action is required
 If there is a significant change fo llow the process described in Section 4.2 of this 
Appendix for reporting PHL as an SAE .
8. REFERENCES
Aithal et al 2011, Clinical Pharmaco logy and Therapeutics 89(6):806 -815.
FDA Guidance for Industry  (issued July  2009) ‘Drug -induced liver injury: Premarket ing 
clinical evalua tion’:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf
                                               
#A ‘significant’ change in the patient’s condition refers to a subsequent clinically relevant change in any of the 
individual liver biochemistry parameters (ALT, AST or total bilirubin) in isolation or in combination, or a 
clinically relevant change in a ssociated symptoms, such as fatigue, vomiting, rash, right upper quadrant pain, 
jaundice, eosinophilia.  The determination of whether there has been a significant change will be at the discretion 
of the Investigator; this may be in consultation with the St udy Ph ysician if there is any uncertainty.
Clinical Study Protocol Appendix E
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
Appendix E
Acceptable Birth Control Methods
Clinical Study Protocol Appendix E
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
2(2)1. ACCEPTABLE BIRTH CONTROL METHODS
Olaparib is regarded as a compound with medium/high foetal risk.
Patients of childbearing potential and their partners, who are sexually act ive, must agree to the 
use of two highly  effect ive forms of contraception in combinat ion while they  are receiving 
study  treatm ent and for [ADDRESS_643124] dose of study  drug.
Acceptable Non -hormonal birth control methods include
 Total /True abst inence: when the subject refrains from any form of sexual 
intercourse and this is in line wit h their usual and/or preferred lifest yle; this must 
continue for the total  durati on of  the study  treatm ent and for [ADDRESS_643125] 
dose of study  drug.  [Peri odic abstinence (eg, cal endar, ovul ation, symptothermal, 
post-ovulation methods), and withdrawal are not acceptable methods of 
contraception]
 Vasectomised sexual partner plus male condom. Wit h parti cipant assurance that 
partner received post -vasectomy confirmat ion of azoospermia
 Tubal occlusio n plus m ale condom
 IUD pl us m ale condom . Provi ded coils are copper -banded
Acceptable hormonal methods  
 Etono gestrel implants (eg, Implanon, Norplan) + male condo m
 Norm al and l ow dose combined oral  pi[INVESTIGATOR_3353] + male condom
 Norel gestromin / EE transdermal system + male condom
 Intravaginal device + male condom (eg, EE and etonogestrel)
 Cerazette (desogestrel) + male con dom. Cerazette i s currently the only highly  
efficacious progesterone based pi[INVESTIGATOR_499465] F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number [ADDRESS_643126] 1.1 Criteria (Respon se Evaluation Criteria in Solid Tumours)
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
2 (10)1. INTRODUCTION
This appendix details the implementation o f modified RECIST (Response Evaluat ion Cri teria 
in So lid Tumours) 1.1 guidelines ( Eisenhauer et al 2009 )for the study  D081FC00001 wi th 
regards to investigator assessment of tumour burden including protocol -specific requirements 
for this study .
2. DEFINITION OF MEASUR ABLE, NON -MEASURABLE , 
TARGET AND NON- TARGE T LESIONS
Patients wi th measurable disease and/or non measur able  disease or no evidence of disease 
assessed at baseline by  [CONTACT_4654] (or MRI where CT is contraindicated) will be entered in this study . 
RECIST 1.1 has been modified to allow the assessment of progression due to new lesio ns in 
patients wi th no evidence o f disease at base -line.
Measurable lesions 
A lesio n, not previously irradiated, that can be measured accurately at baseline as ≥[ADDRESS_643127] diameter (except lymph nodes which must have a short axis ≥[ADDRESS_643128] or 
MRI and which is suitable for ac curate repeated measurements.
Non-measurable lesions
 All other lesio ns, including small lesio ns (lo ngest di ameter < 10 mm or pathological 
lymph nodes with ≥10 mm  to < 15 mm  short axi s at baseline.  Nodes with < 10 mm 
short axis are considered non -patho logical and should not be recorded as non -target 
lesions (NTLs)
 Truly non -measurable lesio ns include the following: bone lesions, leptomeningeal 
disease, ascites, pleural/pericardial effusio n, inflammatory  breast di sease, 
lymphangit ic involvement of skin or l ung, abdo minal masses/abdo minal 
organom egaly  identified by  [CONTACT_499502]
 Previously  irradiated l esions. Localised post -radiatio n changes which affect lesio n 
size, m ay occur.  Therefore, l esions that have been pre viously irradiated will not be 
considered measurable and must be selected as NTLs at baseline and fo llowed up as 
part of the NTL assessment
 Skin l esions assessed by [CONTACT_198278] 
 Brain metastasis
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
3 (10)Special cases
 Lytic bone lesio ns or mixed ly tic
–blastic lesi ons, wi th identifiable so ft tissue 
components, can be considered measurable if the soft tissue component meets the 
definit ion of measurabilit y. Blast ic lesio ns are considered non -measurable.
 Cystic met astases can be considered measurable lesions if they meet the cri teria for 
measurabilit y from a radi ological  point of view, but if non -cystic lesions are present 
in the same patient; these non -cystic lesio ns should be selected as target lesio ns 
(TLs).
Target lesions
A maximum of 5 measurable lesio ns (w ith a maximum o f 2 lesions per organ), representative 
of all lesio ns involved suitable for accurate repeated measurement, should be identified as TLs 
at baseline.
Non-target lesions
All other lesio ns (or sites of disease) not recorded as TLs should be iden tified as NTLs at 
baseline.
3. METHODS OF MEASUREME NT
The same method of assessment and the same technique should be used to characterise 
each identified and reported lesion at baseline and during follow -up.
The m ethods to be used for RECIST assessment are su mmar ised in Table 1and those 
excluded for tumour assessments in this study  are di scussed below, with the rationale 
provi ded.
Table [ADDRESS_643129] (preferred)
MRICT (preferred)
MRI
X-ray, Chest x- ray
Clinical examination CT (preferred)
MRI
X-ray, Chest x- ray, Clinical 
examination
Ultrasound
Bone scan
FDG -PET
3.[ADDRESS_643130] currently  available and reproducible 
methods to measure TLs selected for response assessment and to assess NTLs and 
ident ificat ion of new lesio ns.
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
4 (10)In study  D081FC00001 i t is recommended that CT examinat ions of the chest, abdomen and 
pelvis will be used to assess tumour b urden at baseline and fo llow-up visits.  CT examinat ion 
with intravenous contrast media administration is the preferred method.  MRI should be used 
where CT is not feasible or it is medically  contra -indicated.  For assessment of brain lesio ns 
MRI i s the pr eferred m ethod.
3.[ADDRESS_643131] ic origin of any ef fusion that appears or worsens 
during treatment is required when the measurable tumour has met criteria for response or 
stable disease.  In such circumstances, the cy tology is necessary  to different iate between 
response / stable disease (an effusio n may be a side effect of the treatment) and progressive 
Clinical Study Protocol Appendix F
Drug Substance Olap arib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
5 (10)disease (if the neoplast ic origin o f the fluid is confirm ed).  Where cy tology findings are not 
available, any  effusi on that si gnificant ly worsens (fro m trace to l arge) or the appearance of a 
clinically signi ficant effusio n (requi ring change in drug therapy ) during the study  treatm ent 
will be considered to be progression of NTLs or disease progression due to new lesio ns.
3.[ADDRESS_643132], MRI and X -
ray is recommended where bone scan findings are equivocal.
3.9 FDG -PET scan 
In the D081FC00001 study  FDG-PET (fl uorodeoxyglucose posi tron emissio n tom ography ) 
scans may  be used as a m ethod for i dentifying new lesio ns, according wit h the following 
algorithm: New lesi ons will  be recorded where there is positive FDG uptake (defined as when 
an uptake greater t han twice that of the surrounding tissue is observed) not present on baseline 
FDG -PET scan or i n a locati on corresponding to a new lesio n on CT/MRI at the same fo llow-
up visit.  If there is no baseline FDG -PET scan available, and no evidence of new lesio nson 
CT/MRI scans then fo llow-up CT/MRI assessments should be continued, scheduled as per 
protocol  or clinical indicated, in order to confirm new lesio ns.
4. TUMOUR RESPONSE EVAL UATION 
4.[ADDRESS_643133] igate areas that may be invo lved 
based on signs and symptoms of individual pat ients and should be performed no more than 28 
days before the start of stud y treatm ent.  F ollow -up assessments should be performed every  8 
weeks (±1 week) for 40 weeks and then every  12 weeks ± [ADDRESS_643134] 1.1.  See 
Table 1: Study  Sche dule from  Study  Protocol  for further inform ation. Any other sites at which 
new disease is suspected should also be adequately imaged at follow -up.
If an unscheduled assessment was performed and the pat ient has not progressed, every  attem pt 
shoul d be made to perform  the subsequent assessments at their scheduled visit s. This schedule 
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
6 (10)is to be followed in order to minimise any  unintenti onal bias caused by  [CONTACT_122606] e patients being 
assessed at a different frequency  than other pati ents.
All patients will cont inue to b e assessed for radio logical tumour assessments according to the 
study  schedule, until object ive radio logical disease progression, irrespect ive of reasons for 
discontinuat ion of treatm ent.
4.2 Target lesions 
4.2.1 Documentation of target lesions
A maximum of 5 measurable lesi ons, wi th a maximum o f 2 lesions per organ (including 
lymph nodes), representative of all lesions invo lved, should be identified as TLs at baseline.  
Target l esions shoul d be selected on the basis of their size (longest diameter for non -nodal  
lesions or short axis for nodal lesio ns) but in addit ion should be those that lend themselves to 
reproducible repeated measurements.  It may be the case that, on occasion, the largest lesio n 
does not l end itself to reproducible measurement in which ci rcumstan ce the next l argest lesi on, 
which can be measured reproducibly , shoul d be selected.
The site and locat ion of each TL should be documented as well as the longest diameter for 
non-nodal  lesions (or short axis for lymph nodes).  All measurements should be rec orded in 
millimetres.  At baseline, the sum o f the diameters for all TLs will be calculated and reported 
as the baseline sum of diameters.  At fo llow-up visits the sum o f diameters for all TLs will be 
calculated and reported as the follow -up sum  of diam eters.
Special cases:
 For TLs m easurable in [ADDRESS_643135] diameter.  For 
pathol ogical lymph nodes measurable in 2 or 3 dimensions, always report the short 
axis. 
 If the CT/MRI slice thickness used is > 5mm, the minimum size of m easurable 
disease at baseline should be twice the slice thickness of the baseline scan.
 If a lesio n has co mpletely disappeared, the longest diameter should be recorded as 0 
mm.
 If a TL split s into two or more parts, then record the sum of the diameters of those 
parts.
 If two or more TLs merge then the sum o f the diameters of the combined lesio n 
shoul d be recorded for one of the lesions and 0 mm recorded for the other lesio n(s).
 If a TL i s believed to be present and is faint ly seen but too sm all to measure, a 
defaul t value of 5 mm  shoul d be assi gned.  If an accurate m easure can be given, this 
shoul d be recorded, even if it is below 5 mm.
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
7 (10) If a TL cannot be measured accurately due to it being too large, provide an est imate 
of the si ze of  the l esion.
 When a TL h as had any intervent ion eg, radi otherapy , embo lisation, surgery  etc, 
during the study , the si ze of the TL should st ill be provi ded where possible.
4.2.2 Evaluation of target lesions
Table 2provides the definit ions of th e criteria used to determine objective tumour visit 
response for TLs.
Table 2 Overall Visit Response for Target Lesions
Complete Response (CR) Disappearance of all TLs since baseline. Any pathological lymph 
nodes selected as TLs mus t have a reduction in short axis to < 10 
mm.
Partial Response (PR) At least a 30% decrease in the sum of diameters of TLs, taking as 
reference the baseline sum of diameters.
Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficien t 
increase to qualify for PD
Progressive Disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as 
reference the smallest sum on study (this includes the baseline 
sum if that is the smallest on study).  In addition to the relative 
increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5mm.
Not Evaluable (NE) Only relevant if any of the TLs were not assessed or not evaluable 
or had a lesion intervention at this visit.
Note: If the sum of diameters meets the pro gressive disease 
criteria, progressive disease overrides not evaluable (NE) as a TL 
response
4.3 Non-Target lesions 
4.3.1 Evaluation of non -target lesions
All other lesio ns (or sites of disease) not recorded as TLs should be ident ified as NTLs at 
baseline.  Measur ements are not requi red for these lesions but their status should be fo llowed 
at subsequent visits.  At each visit, an overall assessment of the NTL response should be 
recorded by  [CONTACT_3170].  This sect ion provi des the definit ions of the criteria use d to 
determine and record overall response for NTLs at the investigational site at each visit.
Table 3 Overall Visit Response for Non -Target Lesions 
Complete Response (CR) Disappearance of all NTLs since baseline.  All lymph nodes must 
be non-pathological in size (< 10 mm short axis).
Non-CR/Non PD Persistence of one or more NTLs.
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
8 (10)Progressive Disease (PD) Unequivocal progression of existing NTLs.  Unequivocal 
progr ession may be due to an important progression in one lesion 
only or in several lesions.  In all cases the progression MUST 
clinically significant for the physician to consider changing or 
stoppi[INVESTIGATOR_499466] (NE) Only relevant when one or some of the NTLs were not assessed 
and in the investigator’s opi[INVESTIGATOR_499467] y are not able to provide an 
evaluable overall NTL assessment at this visit.
Note: For patients without TLs at baseline, this is relevant if any 
of the NTLs were not assessed at this visit and the progression 
criteria have not been met.
To achieve ‘unequi vocal progressi on’ on the basis of NTLs, there must be an overall level of 
substant ial worsening in non -target disease such that, even in presence of SD or PR in TLs, 
the overall tumour burden has increased sufficient ly to merit discont inuat ion of therapy .  A 
modest ‘increase’ in the size of one or more NTLs is usually not sufficient to qualify for 
unequivocal progression status.
4.4 New Lesions
Details o f any new lesio ns will also be recorded with the date of assessment.  The presence of 
one or m ore new l esions is assessed as progression.
A lesio n identified at a follow up assessment in an anatomical locat ion that was not scanned at 
baseline is considered a new lesio n and will indicate disease progression.
The finding of a new lesio n shoul d be unequivocal: ie, not attributable to differences in 
scanning technique, change in imaging modalit y or findings thought to represent something 
other than tumour.
If a new lesio n is equivocal, for example because of its small size, the treatment and tumour 
assessments should be cont inued unt il the new lesion has been confirmed.  If repeat scans 
confirm there is a new lesio n, then the progression date should be declared using the date of 
the init ial scan.
4.[ADDRESS_643136] ive response: it is a reason for 
stoppi[INVESTIGATOR_45806] .
Patients wi th ‘symptom atic deterioration’ requiring discont inuat ion of treatment without 
objective evidence of disease progression at that time should continue to undergo tumour 
assessmen ts where possible unt il objective disease progression is observed.
4.[ADDRESS_643137] Overall Response 
The overall visit response will be derived using the algorithm shown in Table 4
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
9 (10)Table 4 Overall Visit Response
Target lesions Non-Target lesions New Lesions Overall response
CR CR No CR
CR NA No CR
NA CR No CR
CR Non-CR/Non PD No PR
CR NE No PR
PR Non PD or NE No PR
SD Non PD or NE No SD
NA Non CR/Non PD No SD (Non CR/no n PD)
NE Non-PD or NE No NE
NA NE No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
NA NA No NED
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease
IR = incomplete response, NE = not evaluable, NE D = no evidence of disease, NA = not applicable (relevant 
when no TLs/NTLs at baseline)
5. CENTRAL REVIEW 
All CT/MRI scans will be sent to an [COMPANY_008] appointed Clinical Research Organisat ion 
(CRO) for blinded independent central review. Aft er the final P rogressi on Free Survival (PFS) 
analysis, central review of scans will no longer be required.  Patients should cont inue to 
receive study  treatm ent unt il object ive radio logical disease progressi on as per modified 
RECIST 1.[ADDRESS_643138] igator’s opi[INVESTIGATOR_3078] n they  
are benefit ing fro m treatm ent and they  do not m eet any  other discont inuat ion criteria.  The 
CRO appointed by [CONTACT_499503].
6. REFERENCES
Eisenhauer et al [ADDRESS_643139] R, Dancey  J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dod d L, Kaplan R, Laco mbe D, Verweij J.  
Clinical Study Protocol Appendix F
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
10 (10)New response evaluat ion criteria in so lid tumours: Revised RECIST guideline (versio n 1.1).  
European Journal of Cancer.  45 (2009) [ADDRESS_643140] u d y C o de D 0 8 1 F C 0 0 0 0 1 
E diti o n N u m ber 1
Date 3 1 M ar c h 2 0 1 4 
2 ( 2)  
 
 
 
 
 C
CI 
Clinical Study Protocol Appendix H
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
Appendix H
CYP3A4/5 Restrictions
Clinical Study Protocol Appendix H
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
2(4)TABLE OF CONTENTS PAGE
TABLE OF CONTENTS ................................
..................................................... 2
GUIDANCE REGARDING P OTENTIAL INTERACTION S WITH 
CONCOMITANT MEDICATI ONS ..................................................................... 3
1. POTENT INHIBITORS OF CYP3A4/5 ............................................................... 3
2. INDUCERS OF CYP ........................................................................................... 3
3. NATURAL / HERBAL PRO DUCTS ................................................................... [ADDRESS_643141] OF TABLES
Table 1 Com petitive inhibitors of CYP3A4/5 ....................................................... 3
Table 2 Time dependent inhibitors of CYP3A4/5 ................................................. 3
Table 3 Inducers of CYP ...................................................................................... 3
Clinical Study Protocol Appendix H
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
3(4)GUIDANCE REGARDING P OTENTIAL INTERACTION S WITH 
CONCOMITANT MEDICATI ONS
NB. While this is not an exhaustive list, it covers the known potent inhibitors and inducers, 
which have most often previously  been reported to be associated with clinically significant 
drug interactions.  Please contact [CONTACT_499504].
1. POTENT INHIBITORS OF CYP3A4/5
In vitro data has shown that the principal enzyme responsible for the format ion of the 3 m ain 
metabo lites of olaparib is CYP3A4/5 and consequent ly, to ensure patient safet y, the following 
inhib itors of CYP3A4/[ADDRESS_643142] not be used during this study.
Table 1 Competitive inhibitors of CYP3A4/5
Drug Minimum  washout period prior to starting olaparib
Ketoconazole 1 Week
Itraconazole
Indinavir
Saquinavir
Telithromycin
Nelfinavir
Table 2 Time dependent inhibitors of CYP3A4/[ADDRESS_643143] ions in exposure due to dru g interacti ons, the following 
CYP3 inducers should be avoided:
Table 3 Inducers of CYP
Drug Minimum  washout period prior to starting olaparib
Carbamazepi[INVESTIGATOR_050] 3 Weeks
Clinical Study Protocol Appendix H
Drug Substance Olaparib
Study Code D081FC00001
Edition Number 1
Date 31 March 2014
4(4)Table [ADDRESS_643144] John’s Wort (Hypericum perforatum)
Phenobarbitone 5 Weeks
After rando misat ion if the use of any potent CYP inducers or inhibitors of CYP3A4/5 are 
considered necessary  for the pati ent’s safet y and welfare, the invest igator must contact [CONTACT_499490]. A decisio n to allow the patient to continue in the study will be 
made on a case -by-case basis.
3. NATURAL / HERBAL PRO DUCTS
The use of any  natural /herbal  products or other “folk remedies” should be discouraged but use 
of these pro ducts, as well as use of all vitamins, nutritional supplements and all other 
concomitant medicat ions must be recorded in the appropriate eCRF.
4. INTERACTIONS WITH P4 [ADDRESS_643145] u d y C o de D 0 8 1 F C 0 0 0 0 1 
E diti o n N u m ber 1
Date 3 1 Marc h 2 0 1 4 
A p pe n di x I 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 
C CI 